WO2024121711A1 - Méthodes de traitement au moyen d'antagonistes d'antigène de maturation des lymphocytes b - Google Patents
Méthodes de traitement au moyen d'antagonistes d'antigène de maturation des lymphocytes b Download PDFInfo
- Publication number
- WO2024121711A1 WO2024121711A1 PCT/IB2023/062182 IB2023062182W WO2024121711A1 WO 2024121711 A1 WO2024121711 A1 WO 2024121711A1 IB 2023062182 W IB2023062182 W IB 2023062182W WO 2024121711 A1 WO2024121711 A1 WO 2024121711A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bcma
- belantamab
- antagonist
- patient
- antibody
- Prior art date
Links
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 title claims abstract description 593
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 title claims abstract description 593
- 239000005557 antagonist Substances 0.000 title claims abstract description 464
- 238000000034 method Methods 0.000 title claims abstract description 268
- 238000011282 treatment Methods 0.000 title claims description 348
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 205
- 201000010099 disease Diseases 0.000 claims abstract description 109
- 208000035475 disorder Diseases 0.000 claims abstract description 96
- 230000000903 blocking effect Effects 0.000 claims abstract description 58
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 56
- 229940018964 belantamab mafodotin Drugs 0.000 claims description 331
- 229940018963 belantamab Drugs 0.000 claims description 309
- 206010028980 Neoplasm Diseases 0.000 claims description 211
- 201000011510 cancer Diseases 0.000 claims description 181
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 160
- 229960003957 dexamethasone Drugs 0.000 claims description 140
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical group C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 114
- 229960004942 lenalidomide Drugs 0.000 claims description 109
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 94
- 239000000611 antibody drug conjugate Substances 0.000 claims description 93
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 87
- 239000000427 antigen Substances 0.000 claims description 75
- 108091007433 antigens Proteins 0.000 claims description 75
- 102000036639 antigens Human genes 0.000 claims description 75
- 239000012634 fragment Substances 0.000 claims description 74
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 65
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 59
- 239000003795 chemical substances by application Substances 0.000 claims description 58
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims description 51
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 47
- 230000002519 immonomodulatory effect Effects 0.000 claims description 47
- 229960000688 pomalidomide Drugs 0.000 claims description 46
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 45
- 239000003207 proteasome inhibitor Substances 0.000 claims description 45
- 229960001467 bortezomib Drugs 0.000 claims description 42
- 230000001988 toxicity Effects 0.000 claims description 32
- 231100000419 toxicity Toxicity 0.000 claims description 32
- 229940124295 CD38 monoclonal antibody Drugs 0.000 claims description 28
- 208000034578 Multiple myelomas Diseases 0.000 claims description 28
- 238000002659 cell therapy Methods 0.000 claims description 28
- 229960002204 daratumumab Drugs 0.000 claims description 26
- 229950007752 isatuximab Drugs 0.000 claims description 25
- 206010067484 Adverse reaction Diseases 0.000 claims description 17
- 230000006838 adverse reaction Effects 0.000 claims description 17
- 208000037914 B-cell disorder Diseases 0.000 claims description 7
- 208000021161 Plasma cell disease Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 description 57
- -1 6- maleimidocaproyl Chemical group 0.000 description 45
- 230000003442 weekly effect Effects 0.000 description 44
- 229940079593 drug Drugs 0.000 description 38
- 208000037821 progressive disease Diseases 0.000 description 37
- 102000025171 antigen binding proteins Human genes 0.000 description 29
- 108091000831 antigen binding proteins Proteins 0.000 description 29
- 238000001802 infusion Methods 0.000 description 27
- 238000002560 therapeutic procedure Methods 0.000 description 27
- 229960000106 biosimilars Drugs 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- 229940121623 teclistamab Drugs 0.000 description 19
- 229940054315 ciltacabtagene autoleucel Drugs 0.000 description 18
- 229940121453 idecabtagene vicleucel Drugs 0.000 description 18
- 108700004894 idecabtagene vicleucel Proteins 0.000 description 18
- 230000004083 survival effect Effects 0.000 description 18
- 229940127121 immunoconjugate Drugs 0.000 description 17
- 230000004044 response Effects 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- 229940062813 alnuctamab Drugs 0.000 description 16
- 125000003275 alpha amino acid group Chemical group 0.000 description 16
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 15
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 239000003053 toxin Substances 0.000 description 14
- 231100000765 toxin Toxicity 0.000 description 14
- 108700012359 toxins Proteins 0.000 description 14
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 13
- 108010059074 monomethylauristatin F Proteins 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 238000001990 intravenous administration Methods 0.000 description 12
- 239000003246 corticosteroid Substances 0.000 description 11
- 229960001334 corticosteroids Drugs 0.000 description 11
- 229940127089 cytotoxic agent Drugs 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 230000000259 anti-tumor effect Effects 0.000 description 10
- 108010021331 carfilzomib Proteins 0.000 description 10
- 229960002438 carfilzomib Drugs 0.000 description 10
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 10
- 229940094732 darzalex Drugs 0.000 description 10
- 229960003648 ixazomib Drugs 0.000 description 10
- 229960003433 thalidomide Drugs 0.000 description 10
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 9
- 239000003540 gamma secretase inhibitor Substances 0.000 description 9
- 229940126601 medicinal product Drugs 0.000 description 9
- 108010093470 monomethyl auristatin E Proteins 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- VFCRKLWBYMDAED-REWPJTCUSA-N (2s)-2-[[(2s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-n-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide Chemical compound O=C([C@@H](N[C@@H]1CC2=C(F)C=C(F)C=C2CC1)CCC)NC1=CN(C(C)(C)CNCC(C)(C)C)C=N1 VFCRKLWBYMDAED-REWPJTCUSA-N 0.000 description 8
- YCBAQKQAINQRFW-UGSOOPFHSA-N 4,4,4-trifluoro-n-[(2s)-1-[[(7s)-5-(2-hydroxyethyl)-6-oxo-7h-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-oxopropan-2-yl]butanamide Chemical compound OCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)CCC(F)(F)F)C)C2=CC=CC=C2C2=CC=CN=C21 YCBAQKQAINQRFW-UGSOOPFHSA-N 0.000 description 8
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 8
- 231100000599 cytotoxic agent Toxicity 0.000 description 8
- 229940121432 dostarlimab Drugs 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 229950001637 nirogacestat Drugs 0.000 description 8
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 230000004614 tumor growth Effects 0.000 description 8
- 206010061137 Ocular toxicity Diseases 0.000 description 7
- 206010044245 Toxic optic neuropathy Diseases 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 239000002254 cytotoxic agent Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 231100000327 ocular toxicity Toxicity 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 6
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 6
- 102000023732 binding proteins Human genes 0.000 description 6
- 108091008324 binding proteins Proteins 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 150000003949 imides Chemical class 0.000 description 6
- 206010023365 keratopathy Diseases 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 238000000846 Bartlett's test Methods 0.000 description 5
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 description 5
- 108010064641 ONX 0912 Proteins 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 229950001466 delanzomib Drugs 0.000 description 5
- SJFBTAPEPRWNKH-CCKFTAQKSA-N delanzomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(C=2C=CC=CC=2)=N1 SJFBTAPEPRWNKH-CCKFTAQKSA-N 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 229940000764 kyprolis Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- SWZXEVABPLUDIO-WSZYKNRRSA-N n-[(2s)-3-methoxy-1-[[(2s)-3-methoxy-1-[[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound N([C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)C(=O)C1=CN=C(C)S1 SWZXEVABPLUDIO-WSZYKNRRSA-N 0.000 description 5
- 229940030115 ninlaro Drugs 0.000 description 5
- 229950005750 oprozomib Drugs 0.000 description 5
- 230000003285 pharmacodynamic effect Effects 0.000 description 5
- 229940008606 pomalyst Drugs 0.000 description 5
- 229940120975 revlimid Drugs 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 5
- 229940034915 thalomid Drugs 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 229940099039 velcade Drugs 0.000 description 5
- PKXWXXPNHIWQHW-RCBQFDQVSA-N (2S)-2-hydroxy-3-methyl-N-[(2S)-1-[[(5S)-3-methyl-4-oxo-2,5-dihydro-1H-3-benzazepin-5-yl]amino]-1-oxopropan-2-yl]butanamide Chemical compound C1CN(C)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](O)C(C)C)C2=CC=CC=C21 PKXWXXPNHIWQHW-RCBQFDQVSA-N 0.000 description 4
- AYOUDDAETNMCBW-GSHUGGBRSA-N (2S,3R)-N'-[(3S)-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)butanediamide Chemical compound O=C([C@@H](NC(=O)[C@H](CCC(F)(F)F)[C@H](CCC(F)(F)F)C(N)=O)N=1)N(C)C2=CC=CC=C2C=1C1=CC=CC=C1 AYOUDDAETNMCBW-GSHUGGBRSA-N 0.000 description 4
- SYTBZMRGLBWNTM-SNVBAGLBSA-N (R)-flurbiprofen Chemical compound FC1=CC([C@H](C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-SNVBAGLBSA-N 0.000 description 4
- XCGJIFAKUZNNOR-UHFFFAOYSA-N 3-[4-(4-chlorophenyl)sulfonyl-4-(2,5-difluorophenyl)cyclohexyl]propanoic acid Chemical compound C1CC(CCC(=O)O)CCC1(S(=O)(=O)C=1C=CC(Cl)=CC=1)C1=CC(F)=CC=C1F XCGJIFAKUZNNOR-UHFFFAOYSA-N 0.000 description 4
- WHIWGRCYMQLLAO-UHFFFAOYSA-N 6-(4-tert-butylphenoxy)pyridin-3-amine Chemical compound C1=CC(C(C)(C)C)=CC=C1OC1=CC=C(N)C=N1 WHIWGRCYMQLLAO-UHFFFAOYSA-N 0.000 description 4
- XEAOPVUAMONVLA-QGZVFWFLSA-N Avagacestat Chemical compound C=1C=C(Cl)C=CC=1S(=O)(=O)N([C@H](CCC(F)(F)F)C(=O)N)CC(C(=C1)F)=CC=C1C=1N=CON=1 XEAOPVUAMONVLA-QGZVFWFLSA-N 0.000 description 4
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- OJPLJFIFUQPSJR-INIZCTEOSA-N RO4929097 Chemical compound N1C(=O)[C@@H](NC(=O)C(C)(C(=O)NCC(F)(F)C(F)(F)F)C)C2=CC=CC=C2C2=CC=CC=C21 OJPLJFIFUQPSJR-INIZCTEOSA-N 0.000 description 4
- 229960005565 RO4929097 Drugs 0.000 description 4
- 108020004459 Small interfering RNA Proteins 0.000 description 4
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 4
- 230000001446 anti-myeloma Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 4
- 229950008567 avagacestat Drugs 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000004087 cornea Anatomy 0.000 description 4
- 229950009663 crenigacestat Drugs 0.000 description 4
- 229940026692 decadron Drugs 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 229940027008 deltasone Drugs 0.000 description 4
- 229940087410 dexasone Drugs 0.000 description 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 4
- 201000003444 follicular lymphoma Diseases 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 230000036210 malignancy Effects 0.000 description 4
- 229940087412 maxidex Drugs 0.000 description 4
- 229940064748 medrol Drugs 0.000 description 4
- 229960004584 methylprednisolone Drugs 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 229960004618 prednisone Drugs 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000004055 small Interfering RNA Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 4
- 229950005628 tarenflurbil Drugs 0.000 description 4
- 230000004304 visual acuity Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 208000004736 B-Cell Leukemia Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 240000000560 Citrus x paradisi Species 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 206010053869 POEMS syndrome Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 229960000455 brentuximab vedotin Drugs 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000001934 delay Effects 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 3
- 229930188854 dolastatin Natural products 0.000 description 3
- 229950004930 enfortumab vedotin Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 3
- 102000046935 human TNFRSF17 Human genes 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229950004101 inotuzumab ozogamicin Drugs 0.000 description 3
- 239000002050 international nonproprietary name Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000009092 lines of therapy Methods 0.000 description 3
- 229950009758 loncastuximab tesirine Drugs 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 229950000720 moxetumomab pasudotox Drugs 0.000 description 3
- 229950009416 polatuzumab vedotin Drugs 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 229950004269 tisotumab vedotin Drugs 0.000 description 3
- 229940049679 trastuzumab deruxtecan Drugs 0.000 description 3
- 229960001612 trastuzumab emtansine Drugs 0.000 description 3
- 231100000402 unacceptable toxicity Toxicity 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
- BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 2
- VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
- UURVHRGPGCBHIC-UHFFFAOYSA-N 3-(ethenoxycarbonylamino)propanoic acid 4-[[[[[[[[[[[[[[[[[[[[[[[[[[[4-ethenoxycarbonyloxybutyl(dimethyl)silyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]butyl ethenyl carbonate 1-ethenylpyrrolidin-2-one ethenyl N-[3-tris(trimethylsilyloxy)silylpropyl]carbamate Chemical compound C=CN1CCCC1=O.OC(=O)CCNC(=O)OC=C.C[Si](C)(C)O[Si](CCCNC(=O)OC=C)(O[Si](C)(C)C)O[Si](C)(C)C.C[Si](C)(CCCCOC(=O)OC=C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)CCCCOC(=O)OC=C UURVHRGPGCBHIC-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 208000023761 AL amyloidosis Diseases 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000000624 Esophageal and Gastric Varices Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 description 2
- 238000012313 Kruskal-Wallis test Methods 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 101710085938 Matrix protein Proteins 0.000 description 2
- 229930126263 Maytansine Natural products 0.000 description 2
- 101710127721 Membrane protein Proteins 0.000 description 2
- 102100032965 Myomesin-2 Human genes 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 208000007452 Plasmacytoma Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108010039491 Ricin Proteins 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 229940123237 Taxane Drugs 0.000 description 2
- 229940122803 Vinca alkaloid Drugs 0.000 description 2
- 238000001790 Welch's t-test Methods 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 108010044540 auristatin Proteins 0.000 description 2
- 238000013475 authorization Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229930195731 calicheamicin Natural products 0.000 description 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960002173 citrulline Drugs 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000005917 in vivo anti-tumor Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 229940124590 live attenuated vaccine Drugs 0.000 description 2
- 229940023012 live-attenuated vaccine Drugs 0.000 description 2
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 description 2
- IDBIFFKSXLYUOT-UHFFFAOYSA-N netropsin Chemical compound C1=C(C(=O)NCCC(N)=N)N(C)C=C1NC(=O)C1=CC(NC(=O)CN=C(N)N)=CN1C IDBIFFKSXLYUOT-UHFFFAOYSA-N 0.000 description 2
- 229960002715 nicotine Drugs 0.000 description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 210000004789 organ system Anatomy 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 238000011375 palliative radiation therapy Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 208000031223 plasma cell leukemia Diseases 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 231100000654 protein toxin Toxicity 0.000 description 2
- 239000001990 protein-drug conjugate Substances 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 229950000143 sacituzumab govitecan Drugs 0.000 description 2
- ULRUOUDIQPERIJ-PQURJYPBSA-N sacituzumab govitecan Chemical compound N([C@@H](CCCCN)C(=O)NC1=CC=C(C=C1)COC(=O)O[C@]1(CC)C(=O)OCC2=C1C=C1N(C2=O)CC2=C(C3=CC(O)=CC=C3N=C21)CC)C(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN(N=N1)C=C1CNC(=O)C(CC1)CCC1CN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O ULRUOUDIQPERIJ-PQURJYPBSA-N 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- 229960004355 vindesine Drugs 0.000 description 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 2
- JFCFGYGEYRIEBE-YVLHJLIDSA-N wob38vs2ni Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)S)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 JFCFGYGEYRIEBE-YVLHJLIDSA-N 0.000 description 2
- AADVCYNFEREWOS-UHFFFAOYSA-N (+)-DDM Natural products C=CC=CC(C)C(OC(N)=O)C(C)C(O)C(C)CC(C)=CC(C)C(O)C(C)C=CC(O)CC1OC(=O)C(C)C(O)C1C AADVCYNFEREWOS-UHFFFAOYSA-N 0.000 description 1
- ORFNVPGICPYLJV-YTVPMEHESA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]amino]-3-phenylpropan Chemical compound C([C@H](NC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(C=CC1=O)=O)C(C)C)OC)C(O)=O)C1=CC=CC=C1 ORFNVPGICPYLJV-YTVPMEHESA-N 0.000 description 1
- WOWDZACBATWTAU-FEFUEGSOSA-N (2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 WOWDZACBATWTAU-FEFUEGSOSA-N 0.000 description 1
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 description 1
- XSAKVDNHFRWJKS-IIZANFQQSA-N (2s)-n-benzyl-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC=2C=CC=CC=2)CCC1 XSAKVDNHFRWJKS-IIZANFQQSA-N 0.000 description 1
- INAUWOVKEZHHDM-PEDBPRJASA-N (7s,9s)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7-[(2r,4s,5s,6s)-5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1 INAUWOVKEZHHDM-PEDBPRJASA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- FBUTXZSKZCQABC-UHFFFAOYSA-N 2-amino-1-methyl-7h-purine-6-thione Chemical compound S=C1N(C)C(N)=NC2=C1NC=N2 FBUTXZSKZCQABC-UHFFFAOYSA-N 0.000 description 1
- YIMDLWDNDGKDTJ-QLKYHASDSA-N 3'-deamino-3'-(3-cyanomorpholin-4-yl)doxorubicin Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1C#N YIMDLWDNDGKDTJ-QLKYHASDSA-N 0.000 description 1
- QUHGSDZVAPFNLV-UHFFFAOYSA-N 4-[(5-acetamidofuran-2-carbonyl)amino]-n-[3-(dimethylamino)propyl]-1-propylpyrrole-2-carboxamide Chemical compound C1=C(C(=O)NCCCN(C)C)N(CCC)C=C1NC(=O)C1=CC=C(NC(C)=O)O1 QUHGSDZVAPFNLV-UHFFFAOYSA-N 0.000 description 1
- AFZIRBOYYNKYFJ-UHFFFAOYSA-N 4-pyridin-2-ylsulfanylpentanoic acid Chemical compound OC(=O)CCC(C)SC1=CC=CC=N1 AFZIRBOYYNKYFJ-UHFFFAOYSA-N 0.000 description 1
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010060921 Abdominal abscess Diseases 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- OMNVYXHOSHNURL-WPRPVWTQSA-N Ala-Phe Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OMNVYXHOSHNURL-WPRPVWTQSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 1
- 206010003671 Atrioventricular Block Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 229930190007 Baccatin Natural products 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 229940022962 COVID-19 vaccine Drugs 0.000 description 1
- AUJXLBOHYWTPFV-BLWRDSOESA-N CS[C@H]1SC[C@H]2N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H]1N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C2=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1 Chemical compound CS[C@H]1SC[C@H]2N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H]1N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C2=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1 AUJXLBOHYWTPFV-BLWRDSOESA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 101710158575 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 244000183685 Citrus aurantium Species 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 235000005976 Citrus sinensis Nutrition 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 108700032819 Croton tiglium crotin II Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 description 1
- OFDNQWIFNXBECV-UHFFFAOYSA-N Dolastatin 10 Natural products CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)CC)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-UHFFFAOYSA-N 0.000 description 1
- LQKSHSFQQRCAFW-UHFFFAOYSA-N Dolastatin 15 Natural products COC1=CC(=O)N(C(=O)C(OC(=O)C2N(CCC2)C(=O)C2N(CCC2)C(=O)C(C(C)C)N(C)C(=O)C(NC(=O)C(C(C)C)N(C)C)C(C)C)C(C)C)C1CC1=CC=CC=C1 LQKSHSFQQRCAFW-UHFFFAOYSA-N 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010009858 Echinomycin Proteins 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229940124895 FluMist Drugs 0.000 description 1
- 241001069765 Fridericia <angiosperm> Species 0.000 description 1
- 206010051012 Gastric varices Diseases 0.000 description 1
- 206010061974 Gastrointestinal obstruction Diseases 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 208000009139 Gilbert Disease Diseases 0.000 description 1
- 208000022412 Gilbert syndrome Diseases 0.000 description 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 208000012766 Growth delay Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000003623 Hypoalbuminemia Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 208000022435 Light chain deposition disease Diseases 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 244000302512 Momordica charantia Species 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 108010042309 Netropsin Proteins 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- 208000023715 Ocular surface disease Diseases 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 101100413173 Phytolacca americana PAP2 gene Proteins 0.000 description 1
- 231100000742 Plant toxin Toxicity 0.000 description 1
- 206010036673 Primary amyloidosis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037508 Punctate keratitis Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 206010037765 Radiation pneumonitis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- OWPCHSCAPHNHAV-UHFFFAOYSA-N Rhizoxin Natural products C1C(O)C2(C)OC2C=CC(C)C(OC(=O)C2)CC2CC2OC2C(=O)OC1C(C)C(OC)C(C)=CC=CC(C)=CC1=COC(C)=N1 OWPCHSCAPHNHAV-UHFFFAOYSA-N 0.000 description 1
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000031091 Synodontis clarias Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229940127323 Thrombopoietin Receptor Agonists Drugs 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 206010056091 Varices oesophageal Diseases 0.000 description 1
- 240000001866 Vernicia fordii Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 231100000851 acute glomerulonephritis Toxicity 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010011559 alanylphenylalanine Proteins 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 108010001818 alpha-sarcin Proteins 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 238000012443 analytical study Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960003008 blinatumomab Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 108010046713 cemadotin Proteins 0.000 description 1
- 229950009017 cemadotin Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229930191339 dianthin Natural products 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 description 1
- 108010045524 dolastatin 10 Proteins 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 229960005501 duocarmycin Drugs 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- 229930184221 duocarmycin Natural products 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000002283 elective surgery Methods 0.000 description 1
- XOPYFXBZMVTEJF-PDACKIITSA-N eleutherobin Chemical compound C(/[C@H]1[C@H](C(=CC[C@@H]1C(C)C)C)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O XOPYFXBZMVTEJF-PDACKIITSA-N 0.000 description 1
- XOPYFXBZMVTEJF-UHFFFAOYSA-N eleutherobin Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(=CCC1C(C)C)C)C1C=C2COC1OCC(O)C(O)C1OC(C)=O XOPYFXBZMVTEJF-UHFFFAOYSA-N 0.000 description 1
- 229940125183 elranatamab Drugs 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 108010028531 enomycin Proteins 0.000 description 1
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 208000024170 esophageal varices Diseases 0.000 description 1
- 201000010120 esophageal varix Diseases 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- APWPAIPBHUQYOV-UHFFFAOYSA-N ethenylcarbamic acid 1-silylbutan-1-ol Chemical compound CCCC(O)[SiH3].OC(=O)NC=C.OC(=O)NC=C APWPAIPBHUQYOV-UHFFFAOYSA-N 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229920002457 flexible plastic Polymers 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000015201 grapefruit juice Nutrition 0.000 description 1
- 208000025750 heavy chain disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940124622 immune-modulator drug Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108700009084 lexitropsin Proteins 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 208000004731 long QT syndrome Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 231100001142 manageable toxicity Toxicity 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 108010010621 modeccin Proteins 0.000 description 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229950006344 nocodazole Drugs 0.000 description 1
- 208000015270 non-secretory plasma cell myeloma Diseases 0.000 description 1
- 231100001035 ocular change Toxicity 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 201000009234 osteosclerotic myeloma Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 108010076042 phenomycin Proteins 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000003123 plant toxin Substances 0.000 description 1
- 210000003720 plasmablast Anatomy 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- AUJXLBOHYWTPFV-UHFFFAOYSA-N quinomycin A Natural products CN1C(=O)C(C)NC(=O)C(NC(=O)C=2N=C3C=CC=CC3=NC=2)COC(=O)C(C(C)C)N(C)C(=O)C2N(C)C(=O)C(C)NC(=O)C(NC(=O)C=3N=C4C=CC=CC4=NC=3)COC(=O)C(C(C)C)N(C)C(=O)C1CSC2SC AUJXLBOHYWTPFV-UHFFFAOYSA-N 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 238000003044 randomized block design Methods 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 235000020095 red wine Nutrition 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- OWPCHSCAPHNHAV-LMONGJCWSA-N rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000019505 tobacco product Nutrition 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 230000007888 toxin activity Effects 0.000 description 1
- LZAJKCZTKKKZNT-PMNGPLLRSA-N trichothecene Chemical compound C12([C@@]3(CC[C@H]2OC2C=C(CCC23C)C)C)CO1 LZAJKCZTKKKZNT-PMNGPLLRSA-N 0.000 description 1
- 229930013292 trichothecene Natural products 0.000 description 1
- 230000036326 tumor accumulation Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- LVLANIHJQRZTPY-UHFFFAOYSA-N vinyl carbamate Chemical compound NC(=O)OC=C LVLANIHJQRZTPY-UHFFFAOYSA-N 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Definitions
- the present disclosure generally relates to methods of treating a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) by the administration of one or more BCMA antagonists.
- BCMA B-cell maturation antigen
- B-cell maturation antigen is a cell surface receptor expressed in the plasmablast lineage and upregulated on various disease cell types including multiple myeloma (MM) cells.
- MM is an incurable malignant clonal plasma cell disorder and accounts for 1% of all cancers and for 10% of all hematologic malignancies globally.
- NDMM multiple myeloma
- Belantamab mafodotin is a BCMA-directed antibody-drug conjugate (ADC) that is conjugated to a microtubule disrupting agent, monomethyl auristatin-F (MMAF) and has demonstrated antitumor activity in MM cells.
- ADC BCMA-directed antibody-drug conjugate
- MMAF monomethyl auristatin-F
- Belantamab mafodotin is produced in an afucosylated form, which enhances interaction with the FcyRIIIa receptor. This enhanced interaction increases antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) activities, including against MM cells.
- ADCC antibody-dependent cellular cytotoxicity
- ADCP antibody-dependent cellular phagocytosis
- belantamab mafodotin possesses a dual anti-tumor activity via delivery of the MMAF cytotoxin, as well as through ADCC/ADCP.
- Ocular toxicity has been reported for belantamab mafodotin, as well as in other MMAF containing ADCs, leading to dose delays and dose reductions. Therefore, there is a need for additional therapies for treatment of MM and other diseases associated with abnormal BCMA expression with manageable toxicity.
- the disclosure provides a method of treating a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) in a patient, the method comprising administering to the patient belantamab at a dose of about 300 mg to about 2000 mg.
- BCMA B-cell maturation antigen
- the disclosure provides the use of belantamab in the treatment of a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) by administration of belantamab at a dose of about 300 mg to about 2000 mg.
- BCMA B-cell maturation antigen
- the disclosure provides use of belantamab in the manufacture of a medicament for use in the treatment of a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) by administration of belantamab at a dose of about 300 mg to about 2000 mg.
- BCMA B-cell maturation antigen
- the dose is about 300 mg, about 900 mg, or about 2000 mg.
- the dose is administered at a regular interval for a period of time.
- the dose is administered once every week ⁇ 3 days to once every four weeks ⁇ 3 days.
- the dose is administered once every two weeks ⁇ 3 days.
- the dose is administered once every three weeks ⁇ 3 days.
- the dose is administered once every four weeks ⁇ 3 days.
- the dose is administered on days 1 and 15 of a 28 day cycle.
- the dose is administered on day 1 of a 21 day cycle.
- the patient has been treated with at least one prior line of cancer treatment.
- the patient has been treated with one, two, three, or four prior lines of cancer treatments.
- the prior lines of cancer treatments include an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
- belantamab is administered through an intravenous infusion or a subcutaneous injection.
- the patient is further receiving at least one additional cancer treatment, such as an anti-CD38 monoclonal antibody, a proteasome inhibitor, an immunomodulatory agent, or an anti-PD-1 monoclonal antibody.
- the additional cancer treatment is selected from lenalidomide, dexamethasone, daratumumab, isatuximab, pomalidomide, bortezomib, or a combination thereof, such as lenalidomide and dexamethasone.
- the additional cancer treatment is lenalidomide at a dose of 10 mg to 25 mg once daily for a period of time.
- the patient is receiving lenalidomide on days 1-21 of a 28 day cycle.
- the additional cancer treatment is dexamethasone. In an embodiment, the additional cancer treatment is dexamethasone at a dose of 20 mg to 40 mg once weekly. In an embodiment, the patient is receiving dexamethasone on days 1, 8, 15, and 22 of a 28 day cycle. In an embodiment, (i) the patient is less than 75 years old and is receiving dexamethasone at a dose of 40 mg once weekly; or (ii) the patient is at least 75 years old and is receiving dexamethasone at a dose of 20 mg once weekly.
- the patient has a BMI of at least 18.5 and is receiving dexamethasone at a dose of 40 mg once weekly; or (ii) the patient has a BMI less than 18.5 and is receiving dexamethasone at a dose of 20 mg once weekly.
- the method or use further comprises discontinuing administration of belantamab and subsequently administering belantamab mafodotin. In an embodiment, the method or use further comprises administering belantamab mafodotin and subsequently discontinuing administration of belantamab. In an embodiment, belantamab mafodotin is administered at a dose of 2.5 mg/kg once every three weeks ⁇ 3 days.
- the method or use further comprises administering a lead-in dose of belantamab mafodotin prior to beginning administration of belantamab, wherein the lead-in dose of belantamab mafodotin is about 1.4 mg/kg to about 3.4 mg/kg once during a lead-in period.
- the lead-in dose of belantamab mafodotin is about 1.4 mg/kg to about 1.9 mg/kg once during a lead-in period.
- the lead-in dose of belantamab mafodotin is about 1.4 mg/kg, about 1.9 mg/kg, about 2.5 mg/kg, or about 3.4 mg/kg once during a lead-in period.
- the lead-in dose of belantamab mafodotin is about 1.4 mg/kg once during a lead- in period.
- the lead-in period is four weeks ⁇ 3 days and belantamab mafodotin is administered on day 1 of the lead-in period.
- the method or use further comprises administering at least one additional cancer treatment to the patient during the lead-in period, such as an anti-CD38 monoclonal antibody, a proteasome inhibitor, an immunomodulatory agent, or an anti-PD-1 monoclonal antibody.
- the additional cancer treatment is selected from lenalidomide, dexamethasone, daratumumab, isatuximab, pomalidomide, bortezomib, or a combination thereof, such as lenalidomide and dexamethasone.
- the additional cancer treatment is lenalidomide at a dose of 10 mg to 25 mg once daily for a period of time.
- lenalidomide is administered to the patient on days 1-21 of the lead-in period. In an embodiment, lenalidomide is administered to the patient on days 1-21 of the lead-in period and the lead-in period is four weeks ⁇ 3 days. In an embodiment, lenalidomide is administered to the patient on days 1-21 of the lead-in period and the lead-in period is 28 days.
- the additional cancer treatment is dexamethasone. In an embodiment, the additional cancer treatment is dexamethasone at a dose of 20 mg to 40 mg once weekly. In an embodiment, dexamethasone is administered to the patient on days 1, 8, 15, and 22 of the lead-in period.
- dexamethasone is administered to the patient on days 1, 8, 15, and 22 of the lead-in period and the lead-in period is four weeks ⁇ 3 days. In an embodiment, dexamethasone is administered to the patient on days 1, 8, 15, and 22 of the lead-in period and the lead-in period is 28 days. In an embodiment, (i) the patient is less than 75 years old and dexamethasone is administered to the patient at a dose of 40 mg once weekly; or (ii) the patient is at least 75 years old and dexamethasone is administered to the patient at a dose of 20 mg once weekly.
- the patient has a BMI of at least 18.5 and dexamethasone is administered to the patient at a dose of 40 mg once weekly; or (ii) the patient has a BMI less than 18.5 and dexamethasone is administered to the patient at a dose of 20 mg once weekly.
- the disclosure provides a method of treating a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) in a patient, the method comprising administering to a patient belantamab mafodotin at a dose of about 1.4 mg/kg to about 3.4 mg/kg once every eight weeks ⁇ 3 days, such as about 1.4 mg/kg to about 1.9 mg/kg once every eight weeks ⁇ 3 days.
- BCMA B-cell maturation antigen
- the disclosure provides the use of belantamab mafodotin in the treatment of a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) by administration of belantamab mafodotin at a dose of about 1.4 mg/kg to about 3.4 mg/kg once every eight weeks ⁇ 3 days, such as about 1.4 mg/kg to about 1.9 mg/kg once every eight weeks ⁇ 3 days.
- BCMA B-cell maturation antigen
- the disclosure provides use of belantamab mafodotin in the manufacture of a medicament for use in the treatment of a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) by administration of belantamab mafodotin at a dose of about 1.4 mg/kg to about 3.4 mg/kg once every eight weeks ⁇ 3 days, such as about 1.4 mg/kg to about 1.9 mg/kg once every eight weeks ⁇ 3 days.
- BCMA B-cell maturation antigen
- the dose is about 1.4 mg/kg, about 1.9 mg/kg, about 2.5 mg/kg, or about 3.4 mg/kg once every eight weeks ⁇ 3 days.
- the disclosure provides a method of treating a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) in a patient, the method comprising administering a therapeutically effective amount of a combination comprising a first BCMA antagonist and a second BCMA antagonist to the patient.
- the disclosure provides the use of a combination comprising a first BCMA antagonist and a second BCMA antagonist to the patient in the treatment of a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA).
- the disclosure provides use of a combination comprising a first BCMA antagonist and a second BCMA antagonist in the manufacture of a medicament for use in the treatment of a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA).
- BCMA B-cell maturation antigen
- the first and second BCMA antagonists are independently selected from the group consisting of an anti-BCMA antibody or antigen binding fragment thereof, an anti- BCMA antibody-drug conjugate, a bispecific anti-BCMA antibody or antigen binding fragment thereof, and a BCMA-targeted chimeric antigen receptor T (CAR T)-cell therapy.
- the first and second BCMA antagonists are independently selected from the group consisting of idecabtagene vicleucel, ciltacabtagene autoleucel, teclistamab, REGN5458, belantamab mafodotin, belantamab, SEA-BCMA, ABBV-383, elrantamab, pavurutumab, alnuctamab, MEDI2228, and CC99712.
- the first BCMA antagonist is belantamab mafodotin.
- the first BCMA antagonist is belantamab.
- the first BCMA antagonist is an anti-BCMA antibody-drug conjugate and the second BCMA antagonist is the corresponding unconjugated anti-BCMA antibody.
- the anti-BCMA antibody-drug conjugate is selected from the group consisting of belantamab mafodotin, MEDI2228, and CC99712.
- the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is belantamab.
- the disclosure provides a method of treating a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) in a patient, the method comprising administering a therapeutically effective amount of a combination comprising belantamab mafodotin and belantamab to the patient.
- BCMA B-cell maturation antigen
- the disclosure provides the use of a combination comprising belantamab mafodotin and belantamab in the treatment of a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA).
- BCMA B-cell maturation antigen
- the disclosure provides use of a combination comprising belantamab mafodotin and belantamab in the manufacture of a medicament for use in the treatment of a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA).
- BCMA B-cell maturation antigen
- the method or use further comprises administering at least one additional cancer treatment to the patient, such as an anti-CD38 monoclonal antibody, a proteasome inhibitor, an immunomodulatory agent, or an anti-PD-1 monoclonal antibody.
- the additional cancer treatment is selected from lenalidomide, dexamethasone, daratumumab, isatuximab, pomalidomide, bortezomib, or a combination thereof, such as lenalidomide and dexamethasone.
- the disclosure provides a kit comprising: (i) a first B-cell maturation antigen (BCMA) antagonist; and (ii) instructions for use in treating a disease or disorder responsive to inhibiting or blocking BCMA when combined with a second BCMA antagonist.
- BCMA B-cell maturation antigen
- the disclosure provides a kit comprising: (i) belantamab mafodotin; and (ii) instructions for use in treating a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) when combined with belantamab.
- BCMA B-cell maturation antigen
- the disclosure provides a kit comprising: (i) belantamab; and (ii) instructions for use in treating a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) when combined with belantamab mafodotin.
- BCMA B-cell maturation antigen
- the disclosure provides a method of treating a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) in a patient previously treated with a first BCMA antagonist, the method comprising administering a therapeutically effective amount of a second BCMA antagonist to the patient, wherein the patient discontinued administration of the first BCMA antagonist prior to beginning administration of the second BCMA antagonist and the second BCMA antagonist is not the same as the first BCMA antagonist.
- BCMA B-cell maturation antigen
- the disclosure provides the use of a second BCMA antagonist in the treatment of a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) in a patient previously treated with a first BCMA antagonist wherein administration of the first BCMA antagonist is discontinued prior to beginning administration of the second BCMA antagonist and the second BCMA antagonist is not the same as the first BCMA antagonist.
- BCMA B-cell maturation antigen
- the disclosure provides use of a second BCMA antagonist in the manufacture of a medicament for the treatment of a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) in a patient previously treated with a first BCMA antagonist wherein administration of the first BCMA antagonist is discontinued prior to beginning administration of the second BCMA antagonist and the second BCMA antagonist is not the same as the first BCMA antagonist.
- BCMA B-cell maturation antigen
- the first and second BCMA antagonists are independently selected from the group consisting of an anti-BCMA antibody or antigen binding fragment thereof, an anti- BCMA antibody-drug conjugate, a bispecific anti-BCMA antibody or antigen binding fragment thereof, and a BCMA-targeted chimeric antigen receptor T (CAR T)-cell therapy.
- the first and second BCMA antagonists are independently selected from the group consisting of idecabtagene vicleucel, ciltacabtagene autoleucel, teclistamab, REGN5458, belantamab mafodotin, belantamab, SEA-BCMA, ABBV-383, elrantamab, pavurutumab, alnuctamab, MEDI2228, and CC99712.
- the first BCMA antagonist is belantamab mafodotin.
- the first BCMA antagonist is belantamab.
- the second BCMA antagonist is belantamab mafodotin.
- the second BCMA antagonist is belantamab.
- the first BCMA antagonist is an anti- BCMA antibody-drug conjugate and the second BCMA antagonist is the corresponding unconjugated anti-BCMA antibody.
- the anti-BCMA antibody-drug conjugate is selected from the group consisting of belantamab mafodotin, MEDI2228, and CC99712.
- the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is belantamab.
- the second BCMA antagonist is an anti-BCMA antibody-drug conjugate and the first BCMA antagonist is the corresponding unconjugated anti- BCMA antibody.
- the anti-BCMA antibody-drug conjugate is selected from the group consisting of belantamab mafodotin, MEDI2228, and CC99712.
- the second BCMA antagonist is belantamab mafodotin and the first BCMA antagonist is belantamab.
- the disclosure provides a method of treating a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) in a patient previously treated with belantamab mafodotin, the method comprising administering a therapeutically effective amount of belantamab to the patient, wherein the patient discontinued administration of belantamab mafodotin prior to beginning administration of belantamab.
- BCMA B-cell maturation antigen
- the disclosure provides the use of belantamab in the treatment of a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) in a patient previously treated with belantamab mafodotin, wherein administration of belantamab mafodotin is discontinued prior to beginning administration of belantamab.
- BCMA B-cell maturation antigen
- the disclosure provides use of belantamab for use in the manufacture of a medicament for use in the treatment of a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) in a patient previously treated with belantamab mafodotin, wherein administration of belantamab mafodotin is discontinued prior to beginning administration of belantamab.
- BCMA B-cell maturation antigen
- the disclosure provides a method of treating a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) in a patient previously treated with belantamab, the method comprising administering a therapeutically effective amount of belantamab mafodotin to the patient, wherein the patient discontinued administration of belantamab prior to beginning administration of belantamab mafodotin.
- BCMA B-cell maturation antigen
- the disclosure provides the use of belantamab mafodotin in the treatment of a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) in a patient previously treated with belantamab wherein administration of belantamab is discontinued prior to beginning administration of belantamab mafodotin.
- BCMA B-cell maturation antigen
- the disclosure provides use of belantamab mafodotin in the manufacture of a medicament for use in the treatment of a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) in a patient previously treated with belantamab wherein administration of belantamab is discontinued prior to beginning administration of belantamab mafodotin.
- BCMA B-cell maturation antigen
- the methods or uses further comprise administering at least one additional cancer treatment to the patient, such as an anti-CD38 monoclonal antibody, a proteasome inhibitor, an immunomodulatory agent, or an anti-PD-1 monoclonal antibody.
- the additional cancer treatment is selected from lenalidomide, dexamethasone, daratumumab, isatuximab, pomalidomide, bortezomib, or a combination thereof, such as lenalidomide and dexamethasone.
- the disclosure provides a method of reducing corneal toxicity in a patient previously treated with a first B-cell maturation antigen (BCMA) antagonist, the method comprising administering a therapeutically effective amount of a second BCMA antagonist to the patient, wherein the patient discontinued administration of the first BCMA antagonist prior to beginning administration of the second BCMA antagonist and the second BCMA antagonist is not the same as the first BCMA antagonist.
- BCMA B-cell maturation antigen
- the disclosure provides the use of a second BCMA antagonist for the reduction of corneal toxicity in a patient previously treated with a first B-cell maturation antigen (BCMA) antagonist, wherein administration of the first BCMA antagonist is discontinued prior to beginning administration of the second BCMA antagonist and the second BCMA antagonist is not the same as the first BCMA antagonist.
- BCMA B-cell maturation antigen
- the disclosure provides use of a second BCMA antagonist in the manufacture of a medicament for use in the reduction of corneal toxicity in a patient previously treated with a first B-cell maturation antigen (BCMA) antagonist, wherein administration of the first BCMA antagonist is discontinued prior to beginning administration of the second BCMA antagonist and the second BCMA antagonist is not the same as the first BCMA antagonist.
- BCMA B-cell maturation antigen
- the first and second BCMA antagonists are independently selected from the group consisting of an anti-BCMA antibody or antigen binding fragment thereof, an anti- BCMA antibody-drug conjugate, a bispecific anti-BCMA antibody or antigen binding fragment thereof, and a BCMA-targeted chimeric antigen receptor T (CAR T)-cell therapy.
- the first and second BCMA antagonists are independently selected from the group consisting of idecabtagene vicleucel, ciltacabtagene autoleucel, teclistamab, REGN5458, belantamab mafodotin, belantamab, SEA-BCMA, ABBV-383, elrantamab, pavurutumab, alnuctamab, MEDI2228, and CC99712.
- the first BCMA antagonist is belantamab mafodotin.
- the first BCMA antagonist is belantamab.
- the second BCMA antagonist is belantamab mafodotin.
- the second BCMA antagonist is belantamab.
- the first BCMA antagonist is an anti- BCMA antibody-drug conjugate and the second BCMA antagonist is the corresponding unconjugated anti-BCMA antibody.
- the anti-BCMA antibody-drug conjugate is selected from the group consisting of belantamab mafodotin, MEDI2228, and CC99712.
- the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is belantamab.
- the second BCMA antagonist is an anti-BCMA antibody-drug conjugate and the first BCMA antagonist is the corresponding unconjugated anti- BCMA antibody.
- the anti-BCMA antibody-drug conjugate is selected from the group consisting of belantamab mafodotin, MEDI2228, and CC99712.
- the second BCMA antagonist is belantamab mafodotin and the first BCMA antagonist is belantamab.
- the disclosure provides the use of belantamab for the reduction of corneal toxicity in a patient previously treated with belantamab mafodotin, wherein the patient discontinued administration of belantamab mafodotin prior to beginning administration of belantamab.
- the disclosure provides use of belantamab in the manufacture of a medicament for use in the reduction of corneal toxicity in a patient previously treated with belantamab mafodotin, wherein the patient discontinued administration of belantamab mafodotin prior to beginning administration of belantamab.
- the disclosure provides a method of reducing corneal toxicity in a patient previously treated with belantamab, the method comprising administering a therapeutically effective amount of belantamab mafodotin to the patient, wherein the patient discontinued administration of belantamab prior to beginning administration of belantamab mafodotin.
- the disclosure provides the use of belantamab mafodotin for the reduction of corneal toxicity in a patient previously treated with belantamab, wherein the patient discontinued administration of belantamab prior to beginning administration of belantamab mafodotin.
- the disclosure provides use of belantamab mafodotin in the manufacture of a medicament for use in the reduction of corneal toxicity in a patient previously treated with belantamab, wherein the patient discontinued administration of belantamab prior to beginning administration of belantamab mafodotin.
- the methods and uses further comprise administering at least one additional cancer treatment to the patient, such as an anti-CD38 monoclonal antibody, a proteasome inhibitor, an immunomodulatory agent, or an anti-PD-1 monoclonal antibody.
- the additional cancer treatment is selected from lenalidomide, dexamethasone, daratumumab, isatuximab, pomalidomide, bortezomib, or a combination thereof, such as lenalidomide and dexamethasone.
- the disclosure provides a method of treating a disease or disorder in a patient, the method comprising administering a therapeutically effective amount of a combination comprising an antibody-drug conjugate and the corresponding unconjugated antibody.
- the disclosure provides the use of a combination comprising an antibodydrug conjugate and the corresponding unconjugated antibody in the treatment of a disease or disorder.
- the disclosure provides use of a combination comprising an antibodydrug conjugate and the corresponding unconjugated antibody for use in the manufacture of a medicament for the treatment of a disease or disorder.
- the disclosure provides a method of treating a disease or disorder in a patient previously treated with an antibody-drug conjugate, the method comprising administering a therapeutically effective amount of the corresponding unconjugated antibody to the patient, wherein the patient discontinued administration of the antibody-drug conjugate prior to beginning administration of the corresponding unconjugated antibody.
- the disclosure provides the use of an antibody in the treatment of a disease or disorder in a patient previously treated with an antibody-drug conjugate, wherein the antibody is the corresponding unconjugated antibody and the patient discontinued administration of the antibody-drug conjugate prior to beginning administration of the corresponding unconjugated antibody.
- the disclosure provides use of an antibody in the manufacture of a medicament for use in the treatment of a disease or disorder in a patient previously treated with an antibody-drug conjugate, wherein the antibody is the corresponding unconjugated antibody and the patient discontinued administration of the antibody-drug conjugate prior to beginning administration of the corresponding unconjugated antibody.
- the antibody-drug conjugate is selected from gemtuzumab ozogamicin, brentuximab vedotin, ado-trastuzumab emtansine, inotuzumab ozogamicin, polatuzumab vedotin, enfortumab vedotin, fam-trastuzumab deruxtecan, sacituzumab govitecan, belantamab mafodotin, loncastuximab tesirine, tisotumab vedotin, moxetumomab pasudotox, MEDI2228, or CC99712.
- the disease or disorder is a plasma cell disorder or a B-cell disorder. In an embodiment, the disease or disorder is a BCMA-expressing cancer. In an embodiment, the disease or disorder is multiple myeloma (MM). In an embodiment, the MM is relapsed and/or refractory MM, newly-diagnosed MM, transplant-ineligible MM, or transplant-ineligible newly- diagnosed MM. In an embodiment, the MM is relapsed and/or refractory MM, newly-diagnosed MM, transplant-ineligible MM, or transplant-ineligible newly-diagnosed MM.
- MM is relapsed and/or refractory MM, newly-diagnosed MM, transplant-ineligible MM, or transplant-ineligible newly-diagnosed MM.
- the disclosure provides a method of treating cancer in a patient, wherein the patient has a Grade 1 corneal adverse reaction resulting from belantamab mafadotin administration, the method comprising temporarily discontinuing administration of belantamab mafadotin; administering to the patient a therapeutically effective amount of belantamab for a lead- in period; and resuming administration of belantamab mafadotin after the lead-in period.
- the disclosure provides the use of belantamab in the treatment of cancer in a patient, wherein the patient has a Grade 1 corneal adverse reaction resulting from belantamab mafadotin administration, wherein belantamab mafadotin is temporarily discontinued for a lead- in period during which belantamab is administered, followed by resuming administration of belantamab mafadotin after the lead-in period.
- the disclosure provides use of belantamab in the manufacture of a medicament for use in the treatment of cancer in a patient, wherein the patient has a Grade 1 corneal adverse reaction resulting from belantamab mafadotin administration, wherein belantamab mafadotin is temporarily discontinued for a lead-in period during which belantamab is administered, followed by resuming administration of belantamab mafadotin after the lead-in period.
- the disclosure provides a method of treating cancer in a patient, wherein the patient has a Grade 2 or above corneal adverse reaction resulting from belantamab mafodotin administration, the method comprising temporarily discontinuing administration of belantamab mafadotin; administering to the patient a therapeutically effective amount of belantamab for a lead- in period; and resuming administration of belantamab mafadotin after the lead-in period.
- the disclosure provides the use of belantamab in the treatment of cancer in a patient, wherein the patient has a Grade 2 or above corneal adverse reaction resulting from belantamab mafadotin administration, wherein belantamab mafadotin is temporarily discontinued for a lead-in period during which belantamab is administered, followed by resuming administration of belantamab mafadotin after the lead-in period.
- the disclosure provides use of belantamab in the manufacture of a medicament for use in the treatment of cancer in a patient, wherein the patient has a Grade 2 or above corneal adverse reaction resulting from belantamab mafadotin administration, wherein belantamab mafadotin is temporarily discontinued for a lead-in period during which belantamab is administered, followed by resuming administration of belantamab mafadotin after the lead-in period.
- FIG. 1 is a graph depicting tumor volume growth curves for all treatment groups as a function of study day, as described in Example 1.
- FIG. 2 is a graph depicting Kaplan-Meier survival curves for all treatment groups as a function of study day, as described in Example 1.
- FIG. 3 is a graph depicting tumor volume growth with different drug to antibody ratios (DARs) as a function of study day, as described in Example 3.
- DARs drug to antibody ratios
- FIG. 4 are graphs depicting progression free survival of patients grouped according to sBCMA levels for the belantamab mafodotin treatment arm (left) and pom/dex treatment arm (right), as described in Example 4.
- FIG. 5 is a graph depicting the level of reduction of sBCMA from pre-dosing with belantamab mafodotin to end of infusion (EOI) for cycle 1, day 1 of belantamab mafodotin treatment, as described in Example 4.
- ETI end of infusion
- FIG. 6 is a graph depicting level of sBCMA 24 hours post-end of infusion (EOI) of belantamab mafodotin, as described in Example 4.
- FIGs. 7A and 7B are graphs depicting sBCMA levels in patients grouped according to response to treatment with belantamab mafodotin, as described in Example 4.
- FIG. 7A shows baseline sBCMA levels prior to administration of belantamab mafodotin; and
- FIG. 7B shows sBCMA levels 24 hours post-EOI of belantamab mafodotin.
- CR complete response;
- MR /SD minimal response/stable disease ;
- PD/NE progressive disease/non-evaluable.
- FIG. 8 is a graph depicting the mean tumor volume curves of vehicle control and treatment groups between randomization and study termination of the in vivo efficacy study of belantamab and belantamab mafodotin in human multiple myeloma xenograft NOG mice, as described in Example 5.
- FIG. 9 is a graph showing the Kaplan-Meier survival curves for all treatment groups as a function of study day of the in vivo efficacy study of belantamab and belantamab mafodotin in human multiple myeloma xenograft NOG mice, as described in Example 5.
- composition “comprising” encompasses “including” or “consisting,” e.g., a composition “comprising” X may consist exclusively of X or may include something additional, e.g., X + Y.
- Ranges provided herein include all values within a particular range described and values about an endpoint for a particular range.
- the figures and tables of the disclosure also describe ranges, and discrete values, which may constitute an element of any of the methods and uses disclosed herein.
- Concentrations described herein are determined at ambient temperature and pressure. This may be, for example, the temperature and pressure at room temperature or within a particular portion of a process stream. Preferably, concentrations are determined at a standard state of 25 °C and 1 bar of pressure.
- antigen binding protein refers to antibodies and other protein constructs, such as domains, which are capable of binding to the antigen.
- antibody is used herein in the broadest sense to refer to molecules with an immunoglobulin-like domain (for example IgG, IgM, IgA, IgD or IgE) and includes monoclonal, recombinant, polyclonal, chimeric, human, humanised, multispecific antibodies, including bispecific antibodies, and heteroconjugate antibodies; a single variable domain (e.g., a domain antibody (DAB)), antigen binding antibody fragments, Fab, F(ab’)2, Fv, disulphide linked Fv, single chain Fv, disulphide-linked scFv, diabodies, TANDABS, etc. and modified versions of any of the foregoing (for a summary of alternative “antibody” formats see Holliger and Hudson, Nature Biotechnology, 2005, Vol 23, No. 9, 1126-1136).
- DAB domain antibody
- the term, full, whole or intact antibody refers to a heterotetrameric glycoprotein with an approximate molecular weight of 150,000 daltons.
- An intact antibody is composed of two identical heavy chains (HCs) and two identical light chains (LCs) linked by covalent disulphide bonds. This H2L2 structure folds to form three functional domains comprising two antigen-binding fragments, known as ‘Fab’ fragments, and a ‘Fc’ crystallisable fragment.
- the Fab fragment is composed of the variable domain at the amino-terminus, variable heavy (VH) or variable light (VL), and the constant domain at the carboxyl terminus, CHI (heavy) and CL (light).
- the Fc fragment is composed of two domains formed by dimerization of paired CH2 and CH3 regions.
- the Fc may elicit effector functions by binding to receptors on immune cells or by binding Clq, the first component of the classical complement pathway.
- the five classes of antibodies IgM, IgA, IgG, IgE and IgD are defined by distinct heavy chain amino acid sequences, which are called p, a, y, s and 5 respectively, each heavy chain can pair with either a K or X light chain.
- the majority of antibodies in the serum belong to the IgG class, there are four isotypes of human IgG (IgGl, IgG2, IgG3 and IgG4), the sequences of which differ mainly in their hinge region.
- Fully human antibodies can be obtained using a variety of methods, for example using yeast-based libraries or transgenic animals (e.g. mice) that are capable of producing repertoires of human antibodies.
- yeast-based libraries or transgenic animals e.g. mice
- Yeast presenting human antibodies on their surface that bind to an antigen of interest can be selected using FACS (Fluorescence-Activated Cell Sorting) based methods or by capture on beads using labelled antigens.
- Transgenic animals that have been modified to express human immunoglobulin genes can be immunized with an antigen of interest and antigen-specific human antibodies isolated using B-cell sorting techniques. Human antibodies produced using these techniques can then be characterized for desired properties such as affinity, developability and selectivity.
- Alternative antibody formats include alternative scaffolds in which the one or more CDRs of the antigen binding protein can be arranged onto a suitable non-immunoglobulin protein scaffold or skeleton, such as an affibody, a SpA scaffold, an LDL receptor class A domain, an avimer (see, e.g., U.S. Patent Application Publication Nos. 2005/0053973, 2005/0089932, 2005/0164301) or an EGF domain.
- a suitable non-immunoglobulin protein scaffold or skeleton such as an affibody, a SpA scaffold, an LDL receptor class A domain, an avimer (see, e.g., U.S. Patent Application Publication Nos. 2005/0053973, 2005/0089932, 2005/0164301) or an EGF domain.
- anti-BCMA antigen binding protein refers to antibodies and other protein constructs, such as domains, which are capable of binding to BCMA.
- BCMA binding protein and “anti-BCMA antigen binding protein” are used interchangeably herein.
- the anti-BCMA antigen binding proteins described herein may bind to human BCMA having, including, for example, human BCMA containing the amino acid sequence of GenBank Accession Number Q02223.2, or genes encoding human BCMA having at least 90 percent homology or at least 90 percent identity thereto.
- Exemplary anti-BCMA antigen binding proteins and methods of making the same are disclosed in International Publication No. WO2012/163805 which is incorporated by reference herein in its entirety. Additional exemplary anti-BCMA antigen binding proteins include those described in WO2016/014789, WO2016/090320, WO2016/090327, W02016/020332, WO2016/079177, WO2014/122143, WO2014/122144, WO2017/021450, WO2016/014565, WO20 14/068079, WO2015/166649, WO2015/158671, WO2015/052536, WO2014/140248, WO2013/072415, WO2013/072406, WO2014/089335, US2017/165373, WO2013/154760, W02018/201051 and W02017/051068, each of which is incorporated by reference herein in its entirety.
- a BCMA binding protein disclosed herein may be derived from rat, mouse, primate (e.g., cynomolgus, Old World monkey or Great Ape) or human.
- the BCMA binding protein may be a human, humanized or chimeric antibody.
- the BCMA binding protein may comprise a constant region, which may be of any isotype or subclass.
- the constant region may be of the IgG isotype, for example IgGl, IgG2, IgG3, IgG4 or variants thereof.
- the BCMA binding protein constant region may be IgGl .
- a BCMA binding protein which can comprise any one or a combination of the following CDRs: CDRH1 of SEQ ID NO: 5, CDRH2 of SEQ ID NO: 6, CDRH3 of SEQ ID NO: 7, CDRL1 of SEQ ID NO: 8, CDRL2 of SEQ ID NO: 9, CDRL3 of SEQ ID NO: 10.
- CDRs may be modified by at least one amino acid substitution, deletion or addition, wherein the variant antigen binding protein substantially retains the biological characteristics of the unmodified protein, such as binding to the antigen.
- the anti-BCMA antigen binding protein comprises CDRH1 according to SEQ ID NO: 5, CDRH2 according to SEQ ID NO: 6, CDRH3 according to SEQ ID NO: 7, CDRL1 according to SEQ ID NO: 8, CDRL2 according to SEQ ID NO: 9, and CDRL3 according to SEQ ID NO: 10.
- the anti-BCMA antigen binding protein comprises a heavy chain variable region (VH) according to SEQ ID NO: 3 and a light chain variable region (VL) according to SEQ ID NO: 4.
- the anti-BCMA antigen binding protein comprises a heavy chain (H) according to SEQ ID NO: 1 and a light chain (L) according to SEQ ID NO: 2.
- the anti-BCMA antigen binding protein is a T-cell redirecting antibody (BiTE) with dual inhibition of BCMA and CD3 receptors, such as teclistamab (Pillarisetti et al., Blood Advances 4, 4538-49, 2020) and blinatumomab, AMG 424, GBR 1342, BFR4350A, AMG 420, AMG 701, elranatamab (PF-06863135), REGN5458, TNB-383B (Alhallak et al., Cancers 13, 2853, 2021).
- teclistamab Pillarisetti et al., Blood Advances 4, 4538-49, 2020
- blinatumomab AMG 424, GBR 1342, BFR4350A, AMG 420, AMG 701, elranatamab (PF-06863135), REGN5458, TNB-383B (Alhallak et al., Cancers 13, 2853, 202
- the anti-BCMA antigen binding protein is a non- fucosylated BCMA-directed antibody, such as SEA-BCMA (Van Epps et al., Cancer Res 2018;78(13 Suppl) Abstract nr 3833).
- the anti-BCMA antigen binding protein is a CAR-T cell Therapeutic.
- the anti-BCMA antigen binding protein is used in an immunoconjugate.
- An “immunoconjugate” (interchangeably referred to as an “antibody-drug conjugate,” “ADC,” or “antigen binding protein-drug conjugate) comprises an anti-BCMA antigen binding protein conjugated to one or more drugs, such as a cytotoxic agent, such as a chemotherapeutic agent, an immunotherapeutic agent, a growth inhibitory agent, a toxin (e.g., a protein toxin, such as an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), an antiviral agent, a radioactive isotope (i.e., a radioconjugate), an antibiotic, or a small interfering RNA (siRNA).
- drugs such as a cytotoxic agent, such as a chemotherapeutic agent, an immunotherapeutic agent, a growth inhibitory agent, a toxin (e.g.,
- the anti-BCMA antigen binding protein can be an immunoconjugate having the following general structure:
- ABP is an antigen binding protein
- Linker is either absent or any a cleavable or non-cleavable linker
- Ctx is any cytotoxic agent described herein n is 0, 1 , 2, or 3 and m is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
- Exemplary linkers may include 6- maleimidocaproyl (MC), maleimidopropanoyl (MP), valine-citrulline (val-cit), alanine- phenylalanine (ala-phe), p-aminobenzyloxycarbonyl (PAB), N-Succinimidyl 4-(2- pyridylthio)pentanoate (SPP), N-succinimidyl 4-(N- maleimidomethyl)cyclohexane-l carboxylate (SMCC), and N-succinimidyl (4-iodo-acetyl) aminobenzoate (SIAB).
- MC 6- maleimidocaproyl
- MP maleimidopropanoyl
- val-cit valine-citrulline
- ala-phe p-aminobenzyloxycarbonyl
- PAB p-aminobenzyloxycarbonyl
- SPP N-Succ
- the anti-BCMA antigen binding protein can be an immunoconjugate containing a monoclonal antibody linked to MMAE or MMAF.
- the anti- BCMA antigen binding protein can be an immunoconjugate containing a monoclonal antibody linked to MMAE or MMAF by an MC linker as depicted in the following structures:
- the anti-BCMA antigen binding protein can be the antibody belantamab. In another embodiment, the anti-BCMA antigen binding protein can be the immunoconjugate belantamab mafodotin.
- a BCMA antagonist is a BCMA-targeted chimeric antigen receptor (CAR)-T cell therapy.
- CAR chimeric antigen receptor
- CAR refers to an engineered receptor that consists of an extracellular antigen binding domain (usually derived from a monoclonal antibody, or antigen binding fragment thereof, e.g. a VH domain and a VL domain in the form of a scFv), optionally a spacer region, a transmembrane region, and one or more intracellular effector domains.
- CARs have also been referred to as chimeric T cell receptors or chimeric immunoreceptors (CIRs).
- CARs are genetically introduced into hematopoietic cells, such as T cells, to redirect T cell specificity for a desired cell-surface antigen, resulting in a CAR-T therapeutic.
- spacer region refers to an oligo- or polypeptide that functions to link the transmembrane domain to the target binding domain. This region may also be referred to as a “hinge region” or “stalk region”. The size of the spacer can be varied depending on the position of the target epitope in order to maintain a set distance (e.g. 14 nm) upon CAR: target binding.
- transmembrane domain refers to the part of the CAR molecule that traverses the cell membrane.
- intracellular effector domain refers to the domain in the CAR that is responsible for intracellular signalling following the binding of the antigen binding domain to the target.
- the intracellular effector domain is responsible for the activation of at least one of the normal effector functions of the immune cell in which the CAR is expressed.
- the effector function of a T cell can be a cytolytic activity or helper activity including the secretion of cytokines.
- VH and/or VL domains disclosed herein may be incorporated, e.g. in the form of a scFv, into CAR-T therapeutics.
- CDRs are defined as the complementarity determining region amino acid sequences of an antigen binding protein. These are the hypervariable regions of immunoglobulin heavy and light chains. There are three heavy chain and three light chain CDRs (or CDR regions) in the variable portion of an immunoglobulin. Thus, “CDRs” as used herein refers to all three heavy chain CDRs, all three light chain CDRs, all heavy and light chain CDRs, or at least two CDRs.
- variable domain sequences and variable domain regions within full-length antigen binding sequences are numbered according to the Kabat numbering convention.
- CDR Kabat et al., Sequences of Proteins of Immunological Interest, 4 th Ed., U.S. Department of Health and Human Services, National Institutes of Health (1987).
- Table 1 represents one definition using each numbering convention for each CDR or binding unit. It should be noted that some of the CDR definitions may vary depending on the individual publication used. Table 1
- An immunoconjugate (interchangeably referred to as an “antibody-drug conjugate,” “ADC” or “antigen binding protein-drug conjugate”) comprises an antigen binding protein (e.g., an antibody or antigen binding fragment thereof) conjugated to one or more drugs, such as a cytotoxic agent, such as a chemotherapeutic agent, an immunotherapeutic agent, a growth inhibitory agent, a toxin (e.g., a protein toxin, such as an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), an antiviral agent, a radioactive isotope (i.e., a radioconjugate), an antibiotic, or a small interfering RNA (siRNA).
- drugs such as a cytotoxic agent, such as a chemotherapeutic agent, an immunotherapeutic agent, a growth inhibitory agent, a toxin (e.g., a protein toxin, such as an enzymatic
- Immunoconjugates have been used for the local delivery of cytotoxic agents, i.e., drugs that kill or inhibit the growth or proliferation of cells, in the treatment of cancer (Lambert, J. (2005) Curr. Opinion in Pharmacology 5:543-549; Wu et al. (2005) Nature Biotechnology 23(9): 1137- 1146; Payne, G. (2003) Cancer Cell 3:207-212; Syrigos andEpenetos (1999) Anticancer Research 19:605-614; Niculescu-Duvaz and Springer (1997) Adv. Drug Deliv. Rev. 26:151-172; U.S. Pat. No. 4,975,278).
- cytotoxic agents i.e., drugs that kill or inhibit the growth or proliferation of cells
- Immunoconjugates allow for, inter alia, the targeted delivery of a drug moiety to a tumor, and intracellular accumulation therein, where systemic administration of unconjugated drugs may result in unacceptable levels of toxicity to normal cells (Tsuchikama and An, Protein and Cell, (2016) 9: 33-46).
- Immunoconjugates can enable selective delivery of a potent cytotoxic payload to target cancer cells, resulting in improved efficacy, reduced systemic toxicity, and preferable pharmacokinetics (PK)/pharmacodynamics (PD) and biodistribution compared to traditional chemotherapy (Tsuchikama and An 2018); Beck A. et al (2017) Nature Rev. Drug Disc. 16: 315-337).
- an immunoconjugate comprises an antigen binding protein, such as an antibody, and a drug, such as toxin, such as a chemotherapeutic agent.
- the drug can be modified (e.g., via standard synthetic chemistry) to allow its chemical attachment (e.g., to contain a reaction handle to allow its chemical attachment) to a reactive end of a linker that joins the drug to the antigen binding protein.
- Drugs such as chemotherapeutic agents, useful in the generation of immunoconjugates are described herein.
- Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. See, e.g., WO 93/21232 published Oct. 28, 1993.
- a radioactive material such as a radionucleotide
- a radionucleotide may be used as the drug in an ADC.
- a variety of radionucleotides are available for the production of radioconjugated antibodies. Examples include 212Bi, 1311, 131In, 90Y, and 186Re.
- Antigen binding proteins may also be conjugated to one or more toxins, including, but not limited to, a calicheamicin, a maytansinoid, a dolastatin, an aurostatin, a trichothecene, and CC1065, and a derivative of these toxins that have toxin activity.
- toxins including, but not limited to, a calicheamicin, a maytansinoid, a dolastatin, an aurostatin, a trichothecene, and CC1065, and a derivative of these toxins that have toxin activity.
- Suitable cytotoxic agents include, but are not limited to, an auristatin including dovaline-valine- dolaisoleunine-dolaproine-phenylalanine (MMAF) and monomethyl auristatin E (MMAE) as well as an ester form of MMAE, a DNA minor groove binding agent, a DNA minor groove alkylating agent, an enediyne, a lexitropsin, a duocarmycin, a taxane (such as paclitaxel and docetaxel), a puromycin, a dolastatin, a maytansinoid, and a vinca alkaloid.
- an auristatin including dovaline-valine- dolaisoleunine-dolaproine-phenylalanine (MMAF) and monomethyl auristatin E (MMAE) as well as an ester form of MMAE
- a DNA minor groove binding agent e.g., a DNA minor groove alkylating
- cytotoxic agents include topotecan, morpholino-doxorubicin, rhizoxin, cyanomorpholino-doxorubicin, dolastatin- 10, 1 echinomycin, combretatstatin, chalicheamicin, maytansine, DM-1, DM-4, and netropsin.
- Other suitable cytotoxic agents include anti-tubulin agents, such as an auristatin, a vinca alkaloid, a podophyllotoxin, a taxane, a baccatin derivative, a cryptophysin, a maytansinoid, a combretastatin, or a dolastatin.
- Antitubulin agents include dimethylvaline-valine-dolaisoleuine-dolaproine- phenylalanine-p-phenylenediamine (AFP), MMAF, MMAE, auristatin E, vincristine, vinblastine, vindesine, vinorelbine, VP- 16, camptothecin, paclitaxel, docetaxel, epothilone A, epothilone B, nocodazole, colchicines, colcimid, estramustine, cemadotin, discodermolide, maytansine, DM-1, DM-4, and eleutherobin.
- AFP dimethylvaline-valine-dolaisoleuine-dolaproine- phenylalanine-p-phenylenediamine
- MMAF methylvaline-valine-dolaisoleuine-dolaproine- phenylalanine-p-phenylenediamine
- Antibody drug conjugates can be produced by conjugating the anti-tubulin agent monomethylauristatin E (MMAE) or monomethylauristatin F (MMAF) to an antigen binding protein (such as an antibody).
- the linker can consist of a thiol-reactive maleimide, a caproyl spacer, the dipeptide valine-citrulline, or p-aminobenzyloxy carbonyl, a self- immolative fragmenting group.
- MMAF a protease-resistant maleimidocaproyl linker can be used.
- the conjugation process leads to heterogeneity in drug-antibody attachment, varying in both the number of drugs bound to each antibody molecule (drug-antibody ratio [DAR]) and the site of attachment.
- DAR drug-antibody ratio
- the overall average drug-to-antibody ratio (DAR) is approximately 4.
- progression of tumor growth or a “progressive disease” (“PD”) as used herein in reference to cancer status indicates an increase in the sum of the diameters of the target lesions (tumors).
- progressive disease is measured and defined as per International Myeloma Working Group (IMWG) criteria (see, e.g., Kumar S, Paiva B, Anderson KC., et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328-46.).
- IMWG International Myeloma Working Group
- progression of tumor growth refers to at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).
- the sum of diameters of target lesions in addition to a relative increase of 20%, must also demonstrate an absolute increase of at least 5 mm. An appearance of one or more new lesions may also be factored into the determination of progression of tumor growth.
- “Treating” as used herein refers to alleviating one or more symptoms or effects associated with a disorder and/or slowing the progression of the disorder.
- the disclosed therapies reduce ocular toxicity.
- “Ocular toxicity” refers to any unintended exposure of a therapeutic agent to ocular tissue, and includes changes in corneal epithelium, dry eyes, irritation, redness, blurred vision, dry eyes, photophobia, and/or changes in visual acuity. Detection of ocular toxicity may be determined by ophthalmic examination by an ophthalmologist or optometrist, before, during, and/or after treatment.
- An ophthalmic examination may include one or more of the following:
- Anterior segment (slit lamp) examination including fluorescein staining of the cornea and lens examination,
- OSDI ocular surface disease index
- the disclosure provides methods of treating a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) in a patient, the method comprising administering belantamab to the patient.
- BCMA B-cell maturation antigen
- belantamab is administered at a dose of about 300 mg to about 2000 mg. In an embodiment, belantamab is administered at a dose of about 300 mg to about 900 mg. In an embodiment, belantamab is administered at a dose of about 900 mg to about 2000 mg. In an embodiment, belantamab is administered at a dose of about 300 mg. In an embodiment, belantamab is administered at a dose of about 900 mg. In an embodiment, belantamab is administered at a dose of about 2000 mg.
- the dose of belantamab is administered at a regular interval for a period of time. In an embodiment, the dose of belantamab is administered on day 1 of the regular interval. In an embodiment, the regular interval is at least once every 8 weeks ⁇ 3 days, at least once every 6 weeks ⁇ 3 days, at least once every 4 weeks ⁇ 3 days, at least once every 3 weeks ⁇ 3 days, at least once every 2 weeks ⁇ 3 days, at least once every week ⁇ 3 days, once every week ⁇ 3 days to once every 8 weeks ⁇ 3 days, once every week ⁇ 3 days to once every 6 weeks ⁇ 3 days, once every week ⁇ 3 days to once every 4 weeks ⁇ 3 days, once every week ⁇ 3 days to once every 3 weeks ⁇ 3 days, once every week ⁇ 3 days to once every 2 weeks ⁇ 3 days, once every 2 weeks ⁇ 3 days to once every 3 weeks ⁇ 3 days, once every 3 weeks ⁇ 3 days to once every 4 weeks ⁇ 3 days, once every 4 weeks ⁇ 3 days to once every 3 days to once every every 3
- the dose of belantamab is administered at least once every 8 weeks ⁇ 3 days, at least once every 6 weeks ⁇ 3 days, at least once every 4 weeks ⁇ 3 days, at least once every 3 weeks ⁇ 3 days, at least once every 2 weeks ⁇ 3 days, at least once every week ⁇ 3 days, once every week ⁇ 3 days to once every 8 weeks ⁇ 3 days, once every week ⁇ 3 days to once every 6 weeks ⁇ 3 days, once every week ⁇ 3 days to once every 4 weeks ⁇ 3 days, once every week ⁇ 3 days to once every 3 weeks ⁇ 3 days, once every week ⁇ 3 days to once every 2 weeks ⁇ 3 days, once every 2 weeks ⁇ 3 days to once every 3 weeks ⁇ 3 days, once every 3 weeks ⁇ 3 days to once every 4 weeks ⁇ 3 days, once every 4 weeks ⁇ 3 days to once every 5 weeks ⁇ 3 days, once every 5 weeks ⁇ 3 days to once every 6 weeks ⁇ 3 days, once every 6 weeks ⁇ 3 days to once every 7 weeks ⁇ 3
- the dose of belantamab is administered once every week ⁇ 3 days to once every 4 weeks ⁇ 3 days. In an embodiment, the dose of belantamab is administered once every 2 weeks ⁇ 3 days to once every 4 weeks ⁇ 3 days. In an embodiment, the dose of belantamab is administered once every 2 weeks ⁇ 3 days. In an embodiment, the dose of belantamab is administered once every 3 weeks ⁇ 3 days. In an embodiment, the dose of belantamab is administered once every 4 weeks ⁇ 3 days.
- the dose of belantamab is administered by parenteral administration, i.e., subcutaneously (s.c. or SC), intrathecally, intraperitoneally, intramuscularly (i.m. or IM) or intravenously (i.v. or IV), including by intravenous infusion.
- parenteral administration i.e., subcutaneously (s.c. or SC), intrathecally, intraperitoneally, intramuscularly (i.m. or IM) or intravenously (i.v. or IV), including by intravenous infusion.
- the dose of belantamab is administered intravenously.
- the dose of belantamab is administered through an intravenous infusion.
- the dose of belantamab is administered subcutaneously.
- belantamab is administered as a first line of treatment for the disease or disorder. In an embodiment, belantamab is administered after one or more prior lines of treatment for the disease or disorder. In an embodiment, belantamab is administered after at least 1 prior line of treatment, after at least 2 prior lines of treatment, after at least 3 prior lines of treatment, after at least 4 prior lines of treatment, after 1 to 4 prior lines of treatment, after 2 to 4 prior lines of treatment, after 1 to 2 prior lines of treatment, after 2 to 3 prior lines of treatment, after 3 to 4 prior lines of treatment, after 1 prior line of treatment, after 2 prior lines of treatment, after 3 prior lines of treatment, or after 4 prior lines of treatment for the disease or disorder.
- belantamab is administered as a first line of cancer treatment. In an embodiment, belantamab is administered after one or more prior lines of cancer treatment. In an embodiment, belantamab is administered after at least 1 prior line of cancer treatment, after at least 2 prior lines of cancer treatment, after at least 3 prior lines of cancer treatment, after at least 4 prior lines of cancer treatment, after 1 to 4 prior lines of cancer treatment, after 2 to 4 prior lines of cancer treatment, after 1 to 2 prior lines of cancer treatment, after 2 to 3 prior lines of cancer treatment, after 3 to 4 prior lines of cancer treatment, after 1 prior line of cancer treatment, after 2 prior lines of cancer treatment, after 3 prior lines of cancer treatment, or after 4 prior lines of cancer treatment.
- the patient has not been treated with a prior treatment for the disease or disorder. In an embodiment, the patient has been treated with at least one prior treatment for the disease or disorder. In an embodiment, the patient has been treated with at least 1 prior line of treatment, at least 2 prior lines of treatment, at least 3 prior lines of treatment, at least 4 prior lines of treatment, 1 to 4 prior lines of treatment, 2 to 4 prior lines of treatment, 1 to 2 prior lines of treatment, 2 to 3 prior lines of treatment, 3 to 4 prior lines of treatment, 1 prior line of treatment, 2 prior lines of treatment, 3 prior lines of treatment, or 4 prior lines of treatment for the disease or disorder. [00134] In an embodiment, the patient has relapsed or refractory multiple myeloma and had previously received at least four prior therapies to treat the multiple myeloma.
- the prior lines of cancer treatments are selected from an anti-CD38 monoclonal antibody, a proteasome inhibitor, an immunomodulatory agent, or a combination thereof.
- a patient that has had 0, 1, 2, 3, or 4 or more prior lines of treatment before being treated as described herein can have previously been treated with an immunomodulatory agent (e.g., an immunomodulatory imide drug (ImiD)), a proteasome inhibitor (PI), an anti-CD38 treatment or combinations thereof.
- an immunomodulatory agent e.g., an immunomodulatory imide drug (ImiD)
- PI proteasome inhibitor
- the prior lines of cancer treatments include an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
- anti-CD38 antibodies useful in the methods described herein include, but are not limited to, isatuximab or isatuximab-irfc (e.g., SARCLISA®) and daratumumab (e.g, DARZALEX®, DARZALEX FASPRO®).
- the anti-CD38 monoclonal antibody is selected from daratumumab or isatuximab.
- proteasome inhibitors useful in the methods described herein include, but are not limited to, bortezomib (e.g., VELCADE®), ixazomib (e.g., NINLARO®), carfilzomib (e.g., KYPROLIS®), oprozomib, and delanzomib.
- the proteasome inhibitor is selected from bortezomib, carfilzomib, or ixazomib.
- the proteasome inhibitor is bortezomib.
- immunomodulatory imide drugs useful in the methods described herein include, but are not limited to, thalidomide (e.g., THALOMID®), lenalidomide (e.g., REVLIMID®), and pomalidomide (e.g., POMALYST®).
- the immunomodulatory agent is selected from thalidomide, lenalidomide, or pomalidomide.
- the immunomodulatory agent is lenalidomide or pomalidomide.
- the immunomodulatory agent is lenalidomide.
- belantamab is administered as a monotherapy. In an embodiment, belantamab is administered in combination with at least one additional treatment. In an embodiment, belantamab is administered in combination with at least one additional cancer treatment. In an embodiment, belantamab is administered on day 1 of a treatment cycle. In an embodiment, belantamab is administered on day 1 of a 28-day treatment cycle. In an embodiment, belantamab is administered on day 1 and day 15 of a 28-day treatment cycle. In an embodiment, belantamab is administered on day 1 of a 21 -day treatment cycle.
- the additional cancer treatment is selected from an anti-CD38 monoclonal antibody, a gamma-secretase inhibitor, a proteasome inhibitor, an immunomodulatory agent, or an anti-PD-1 monoclonal antibody.
- anti-CD38 antibodies useful in the methods described herein include, but are not limited to, isatuximab or isatuximab-irfc (e.g., SARCLISA®) and daratumumab (e.g, DARZALEX®, DARZALEX FASPRO®).
- the anti-CD38 monoclonal antibody is selected from daratumumab or isatuximab.
- Examples of gamma-secretase inhibitors useful in the methods described herein include, but are not limited to, nirogacestat (PF-0308014), crenigacestat (LY3039478), CB-103, tarenflurbil, semagacestat (LY450139), RG-4733, EVP-0962, avagacestat, MK-0752, and BMS- 906024, as well as derivatives and polymorphs thereof.
- proteasome inhibitors useful in the methods described herein include, but are not limited to, bortezomib (e.g., VELCADE®), ixazomib (e.g., NINLARO®), carfilzomib (e.g., KYPROLIS®), oprozomib, and delanzomib.
- the proteasome inhibitor is selected from bortezomib, carfilzomib, or ixazomib.
- the proteasome inhibitor is bortezomib.
- immunomodulatory imide drugs useful in the methods described herein include, but are not limited to, thalidomide (e.g., THALOMID®), lenalidomide (e.g., REVLIMID®), and pomalidomide (e.g., POMALYST®).
- the immunomodulatory agent is selected from thalidomide, lenalidomide, or pomalidomide.
- the immunomodulatory agent is lenalidomide or pomalidomide.
- the immunomodulatory agent is lenalidomide.
- the immunomodulatory agent is pomalidomide.
- anti-PD-1 monoclonal antibodies useful in the methods described herein include, but are not limited to, pembroluzimab and dostarlimab.
- the anti-PD-1 monoclonal antibody is selected from pembroluzimab or dostarlimab.
- corticosteroids examples include, but are not limited to, dexamethasone (e.g., DECADRON®, DEXASONE®, DIODEX®, HEXADROL®, MAXIDEX®), prednisone (e.g., DELTASONE®), and methylprednisolone (e.g., MEDROL®).
- the additional cancer treatment is selected from lenalidomide, pomalidomide, dexamethasone, or a combination thereof.
- the additional cancer treatments are lenalidomide and dexamethasone.
- the additional cancer treatments are pomalidomide and dexamethasone. In an embodiment, the additional cancer treatments are bortezomib and dexamethasone. In an embodiment, the additional cancer treatments are pomalidomide, bortezomib, and dexamethasone. In an embodiment, the additional cancer treatments are lenalidomide, bortezomib, and dexamethasone.
- the additional cancer treatment is standard of care treatment.
- the additional cancer treatment is lenalidomide at a dose of 10 mg to 25 mg once daily for a period of time. In an embodiment, the additional cancer treatment is lenalidomide at a dose of 10 mg to 25 mg once daily administered on days 1-21 of a 28 day cycle. [00150] In an embodiment, the additional cancer treatment is dexamethasone. In an embodiment, the additional cancer treatment is dexamethasone at a dose of 20 mg to 40 mg once weekly. In an embodiment, the additional cancer treatment is dexamethasone at a dose of 40 mg once weekly if the patient is less than 75 years old.
- the additional cancer treatment is dexamethasone at a dose of 20 mg once weekly if the patient is at least 75 years old. In an embodiment, the additional cancer treatment is dexamethasone at a dose of 40 mg once weekly if the patient has a BMI of at least 18.5. In an embodiment, the additional cancer treatment is dexamethasone at a dose of 20 mg once weekly if the patient has a BMI less than 18.5. In an embodiment, the dexamethasone is administered on days 1, 8, 15, and 22 of a 28 day cycle.
- the additional cancer treatments are lenalidomide at a dose of 10 mg to 25 mg administered once daily on days 1-21 of a 28 day cycle and dexamethasone at a dose of 20 mg to 40 mg administered on days 1, 8, 15, and 22 of a 28 day cycle.
- the additional cancer treatments are lenalidomide at a dose of 10 mg to 25 mg administered once daily on days 1-21 of a 28 day cycle and dexamethasone at a dose of 40 mg administered on days 1, 8, 15, and 22 of a 28 day cycle if the patient is less than 75 years old or has a BMI of at least 18.5.
- the additional cancer treatments are lenalidomide at a dose of 10 mg to 25 mg administered once daily on days 1-21 of a 28 day cycle and dexamethasone at a dose of 20 mg administered on days 1, 8, 15, and 22 of a 28 day cycle if the patient is at least 75 years old or has a BMI of less than 18.5.
- a patient is receiving an initial therapy or combination of initial therapies, referred to as a lead-in doses, prior to administration of a subsequent therapy or combination of therapies.
- the “lead-in period” refers to a period of time in which a specified initial therapy or combination of initial therapies is administered prior to administration of a subsequent therapy or combination of therapies.
- the method further comprises administering a lead-in dose of belantamab mafodotin prior to beginning administration of belantamab.
- the lead-in dose of belantamab mafodotin is about 1.4 mg/kg to about 3.4 mg/kg once during a lead- in period.
- the lead-in dose of belantamab mafodotin is about 1.4 mg/kg to about 1.9 mg/kg once during a lead-in period.
- the lead-in dose of belantamab mafodotin is about 1.4 mg/kg, about 1.5 mg/kg, about 1.6 mg/kg, about 1.7 mg/kg, about 1.8 mg/kg, about 1.9 mg/kg, about 2.0 mg/kg, about 2.5 mg/kg, about 3.0 mg/kg, or about 3.4 mg/kg once during a lead-in period.
- the lead-in dose of belantamab mafodotin is about 1.4 mg/kg once during a lead-in period.
- the lead-in dose of belantamab mafodotin is about 1.9 mg/kg once during a lead-in period.
- the lead-in period is four weeks ⁇ 3 days and belantamab mafodotin is administered on day 1 of the lead-in period.
- the dose of belantamab mafodotin is administered by parenteral administration, i.e., subcutaneously (s.c. or SC), intrathecally, intraperitoneally, intramuscularly (i.m. or IM) or intravenously (i.v. or IV), including by intravenous infusion.
- parenteral administration i.e., subcutaneously (s.c. or SC), intrathecally, intraperitoneally, intramuscularly (i.m. or IM) or intravenously (i.v. or IV), including by intravenous infusion.
- the dose of belantamab mafodotin is administered intravenously.
- the dose of belantamab mafodotin is administered through an intravenous infusion.
- belantamab mafodotin is administered as a monotherapy during the lead-in period. In an embodiment, belantamab mafodotin is administered in combination with at least one additional treatment during the lead-in period. In an embodiment, belantamab mafodotin is administered in combination with at least one additional cancer treatment during the lead-in period.
- the additional cancer treatment for administration during the lead- in period is selected from an anti-CD38 monoclonal antibody, a gamma-secretase inhibitor, a proteasome inhibitor, an immunomodulatory agent, or an anti-PD-1 monoclonal antibody.
- anti-CD38 antibodies useful in the methods described herein include, but are not limited to, isatuximab or isatuximab-irfc (e.g., SARCLISA®) and daratumumab (e.g, DARZALEX®, DARZALEX FASPRO®).
- the anti-CD38 monoclonal antibody for administration during the lead-in period is selected from daratumumab or isatuximab.
- gamma-secretase inhibitors useful in the methods described herein include, but are not limited to, nirogacestat (PF-0308014), crenigacestat (LY3039478), CB-103, tarenflurbil, semagacestat (LY450139), RG-4733, EVP-0962, avagacestat, MK-0752, and BMS- 906024, as well as derivatives and polymorphs thereof.
- proteasome inhibitors useful in the methods described herein include, but are not limited to, bortezomib (e.g., VELCADE®), ixazomib (e.g., NINLARO®), carfilzomib (e.g., KYPROLIS®), oprozomib, and delanzomib.
- the proteasome inhibitor for administration during the lead-in period is selected from bortezomib, carfilzomib, or ixazomib.
- the proteasome inhibitor for administration during the lead-in period is bortezomib.
- immunomodulatory imide drugs useful in the methods described herein include, but are not limited to, thalidomide (e.g., THALOMID®), lenalidomide (e.g., REVLIMID®), and pomalidomide (e.g., POMALYST®).
- the immunomodulatory agent for administration during the lead-in period is selected from thalidomide, lenalidomide, or pomalidomide.
- the immunomodulatory agent for administration during the lead-in period is lenalidomide or pomalidomide.
- the immunomodulatory agent for administration during the lead-in period is lenalidomide.
- the immunomodulatory agent for administration during the lead-in period is pomalidomide.
- anti-PD-1 monoclonal antibodies useful in the methods described herein include, but are not limited to, pembroluzimab and dostarlimab.
- the anti-PD-1 monoclonal antibody is selected from pembroluzimab or dostarlimab.
- corticosteroids include corticosteroids.
- corticosteroids include, but are not limited to, dexamethasone (e.g., DECADRON®, DEXASONE®, DIODEX®, HEXADROL®, MAXIDEX®), prednisone (e.g., DELTASONE®), and methylprednisolone (e.g., MEDROL®).
- the additional cancer treatment for administration during the lead- in period is selected from lenalidomide, pomalidomide, dexamethasone, or a combination thereof.
- the additional cancer treatments for administration during the lead-in period are lenalidomide and dexamethasone.
- the additional cancer treatments for administration during the lead-in period are pomalidomide and dexamethasone. In an embodiment, the additional cancer treatments for administration during the lead-in period are lenalidomide and dexamethasone. In an embodiment, the additional cancer treatments for administration during the lead-in period are bortezomib and dexamethasone. In an embodiment, the additional cancer treatments for administration during the lead-in period are pomalidomide, bortezomib, and dexamethasone. In an embodiment, the additional cancer treatments for administration during the lead-in period are lenalidomide, bortezomib, and dexamethasone.
- the additional cancer treatment for administration during the lead- in period is standard of care treatment.
- the additional cancer treatment for administration during the lead- in period is lenalidomide at a dose of 10 mg to 25 mg once daily for a period of time. In an embodiment, the additional cancer treatment for administration during the lead-in period is lenalidomide at a dose of 10 mg to 25 mg once daily administered on days 1-21 of a 28 day lead- in period.
- the additional cancer treatment for administration during the lead- in period is dexamethasone.
- the additional cancer treatment for administration during the lead-in period is dexamethasone at a dose of 20 mg to 40 mg once weekly.
- the additional cancer treatment for administration during the lead-in period is dexamethasone at a dose of 40 mg once weekly if the patient is less than 75 years old.
- the additional cancer treatment for administration during the lead-in period is dexamethasone at a dose of 20 mg once weekly if the patient is at least 75 years old.
- the additional cancer treatment for administration during the lead-in period is dexamethasone at a dose of 40 mg once weekly if the patient has a BMI of at least 18.5. In an embodiment, the additional cancer treatment for administration during the lead-in period is dexamethasone at a dose of 20 mg once weekly if the patient has a BMI less than 18.5. In an embodiment, the dexamethasone is administered on days 1, 8, 15, and 22 of a 28 day lead-in period.
- the additional cancer treatments for administration during the lead- in period are lenalidomide at a dose of 10 mg to 25 mg administered once daily on days 1-21 of a 28 day lead-in period and dexamethasone at a dose of 20 mg to 40 mg administered on days 1, 8, 15, and 22 of a 28 day lead-in period.
- the additional cancer treatments for administration during the lead-in period are lenalidomide at a dose of 10 mg to 25 mg administered once daily on days 1-21 of a 28 day lead-in period and dexamethasone at a dose of 40 mg administered on days 1, 8, 15, and 22 of a 28 day lead-in period if the patient is less than 75 years old or has a BMI of at least 18.5.
- the additional cancer treatments for administration during the lead-in period are lenalidomide at a dose of 10 mg to 25 mg administered once daily on days 1-21 of a 28 day lead-in period and dexamethasone at a dose of 20 mg administered on days 1, 8, 15, and 22 of a 28 day lead-in period if the patient is at least 75 years old or has a BMI of less than 18.5.
- the method comprises administering a lead-in dose of belantamab mafodotin during a lead-in period, followed by administering belantamab during a subsequent treatment period.
- the method comprises administering a lead-in dose of belantamab mafodotin at a dose of about 1.4 mg/kg to about 3.4 mg/kg once during a lead-in period, followed by administering belantamab at a dose of about 300 mg to about 2000 mg during a subsequent treatment period.
- the method comprises administering a lead-in dose of belantamab mafodotin at a dose of about 1.4 mg/kg, about 1.9 mg/kg, about 2.5 mg/kg, or about 3.4 mg/kg once during a lead-in period, followed by administering belantamab at a dose of about 300 mg, 900 mg, or about 2000 mg during a subsequent treatment period.
- the method further comprises application of a bandage contact lens during the lead-in period and/or subsequent treatment period.
- a bandage contact lens is a therapeutic contact lens made of soft, flexible plastics that allow oxygen to pass through to the cornea which is worn in one or both eyes for a period of time to protect the cornea and/or treat ocular toxicities, e.g., ocular toxicities resulting from treatment with a therapeutic agent such as belantamab mafodotin.
- a bandage contact lens is comprised of N-carboxy vinyl ester (NCVE), N-vinyl pyrrolidone (NVE), poly[dimethylsiloxyl] di [silylbutanol] bis[vinyl carbamate] (PBVC) and/or tris-(trimethylsiloxysilyl) propylvinyl carbamate (TPVC).
- NVE N-carboxy vinyl ester
- NVE N-vinyl pyrrolidone
- PBVC poly[dimethylsiloxyl] di [silylbutanol] bis[vinyl carbamate]
- TPVC tris-(trimethylsiloxysilyl) propylvinyl carbamate
- a bandage contact lens of comprises of NCVE, NVE, PBVC, and TPVC.
- a bandage contact lens of comprises of NCVE, NVE, PBVC, and TPVC and has a water content of 30% to 40%, such as 30%, 3
- a bandage contact lens of comprises of NCVE, NVE, PBVC, and TPVC and has a water content of about 36%.
- a bandage contact lens is made of balafilcon A.
- Balafilcon A is a copolymer of silicone vinyl carbamate, N-vinyl-pyrrolidone, a siloxane crosslinker and a vinyl alanine wetting monomer, and is 36% water by weight when immersed in solution, e.g., saline solution.
- the method further comprises discontinuing administration of belantamab and subsequently administering belantamab mafodotin.
- belantamab mafodotin is administered at a dose of 2.5 mg/kg once every three weeks ⁇ 3 days.
- administration of belantamab is discontinued after the patient demonstrates progressive disease.
- the method further comprises administering belantamab mafodotin and subsequently discontinuing administration of belantamab.
- belantamab mafodotin is administered at a dose of 2.5 mg/kg once every three weeks ⁇ 3 days.
- administration of belantamab is discontinued after the patient demonstrates progressive disease.
- the disclosure provides methods of treating a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) in a patient, the method comprising administering belantamab mafodotin to the patient.
- BCMA B-cell maturation antigen
- belantamab mafodotin is administered at a dose of about 1.4 mg/kg to about 3.4 mg/kg. In an embodiment, belantamab mafodotin is administered at a dose of about 1.4 mg/kg to about 1.9 mg/kg. In an embodiment, belantamab mafodotin is administered at a dose of about 1.4 mg/kg, about 1.5 mg/kg, about 1.6 mg/kg, about 1.7 mg/kg, about 1.8 mg/kg, about 1.9 mg/kg, about 2.0 mg/kg, about 2.5 mg/kg, about 3.0 mg/kg, or about 3.4 mg/kg.
- belantamab mafodotin is administered at a dose of about 1.4 mg/kg. In an embodiment, belantamab mafodotin is administered at a dose of about 1.9 mg/kg. In an embodiment, belantamab is administered once every eight weeks ⁇ 3 days. [00175] In an embodiment, belantamab mafodotin is administered at a dose of about 1.4 mg/kg to about 3.4 mg/kg once every eight weeks ⁇ 3 days. In an embodiment, belantamab mafodotin is administered at a dose of about 1.4 mg/kg to about 1.9 mg/kg once every eight weeks ⁇ 3 days.
- belantamab mafodotin is administered at a dose of about 1.4 mg/kg, about 1.5 mg/kg, about 1.6 mg/kg, about 1.7 mg/kg, about 1.8 mg/kg, about 1.9 mg/kg, about 2.0 mg/kg, about 2.5 mg/kg, about 3.0 mg/kg, or about 3.4 mg/kg once every eight weeks ⁇ 3 days.
- belantamab mafodotin is administered at a dose of about 1.4 mg/kg once every eight weeks ⁇ 3 days.
- belantamab mafodotin is administered at a dose of about 1.9 mg/kg once every eight weeks ⁇ 3 days.
- the method further comprises application of a bandage contact lens.
- BCMA-inhibiting or blocking therapies are also described.
- kits comprising BCMA-inhibiting or blocking therapies and instructions for use.
- the disclosure provides methods of treating a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) in a patient, the method comprising administering a therapeutically effective amount of a combination comprising a first BCMA antagonist and a second BCMA antagonist to the patient.
- BCMA antagonist refers to a molecule that specifically binds B-cell maturation antigen (BCMA) and inhibits the binding of BAFF and/or APRIL to the BCMA receptor.
- BCMA antagonists include, but are not limited to, anti-BCMA antibodies or antigen binding fragments thereof, anti-BCMA antibody-drug conjugates, bispecific anti-BCMA antibodies or antigen binding fragments thereof, and BCMA-targeted chimeric antigen receptor T (CAR T)-cell therapy.
- CAR T BCMA-targeted chimeric antigen receptor T
- the first and second BCMA antagonists are independently selected from the group consisting of an anti-BCMA antibody or antigen binding fragment thereof, an anti- BCMA antibody-drug conjugate, a bispecific anti-BCMA antibody or antigen binding fragment thereof, and a BCMA-targeted chimeric antigen receptor T (CAR T)-cell therapy.
- the first BCMA-antagonist differs from the second BCMA-antagonist.
- the first and second BCMA-antagonists are both anti-BCMA antibodies or fragments thereof, both anti-BCMA antibody-drug conjugates, both bispecific anti-BCMA antibodies or fragments thereof, or both BCMA-targeted chimeric antigen receptor T (CAR T)-cell therapies.
- the first BCMA-antagonist is an anti-BCMA antibody or antigen binding fragment thereof and the second BCMA-antagonist is a different anti-BCMA antibody or antigen binding fragment thereof.
- the first BCMA-antagonist is an anti-BCMA antibody-drug conjugate and the second BCMA-antagonist is a different anti-BCMA antibody-drug conjugate.
- the first BCMA-antagonist is a bispecific anti-BCMA antibody or antigen binding fragment thereof and the second BCMA-antagonist is a different bispecific anti-BCMA antibody or antigen binding fragment thereof.
- the first BCMA-antagonist is a BCMA-targeted chimeric antigen receptor T (CAR T)-cell therapy and the second BCMA-antagonist is a different BCMA- targeted chimeric antigen receptor T (CAR T)-cell therapy.
- CAR T BCMA-targeted chimeric antigen receptor T
- CAR T BCMA-targeted chimeric antigen receptor T
- the bispecific anti-BCMA antibody or antigen binding fragment thereof comprises an anti-BCMA antibody or antigen binding fragment thereof and an anti-CD38 antibody or antigen binding fragment thereof. In an embodiment, the bispecific anti-BCMA antibody or antigen binding fragment thereof specifically binds both BCMA and CD3.
- the first and second BCMA antagonists are independently selected from the group consisting of idecabtagene vicleucel, ciltacabtagene autoleucel, teclistamab, REGN5458, belantamab mafodotin, belantamab, SEA-BCMA, ABBV-383, elrantamab, pavurutumab, alnuctamab, MEDI2228, and CC99712.
- the first BCMA antagonist is belantamab mafodotin. In an embodiment, the first BCMA antagonist is belantamab.
- the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is an anti-BCMA antibody or antigen binding fragment thereof.
- the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is an anti-BCMA antibody-drug conjugate.
- the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is a bispecific anti-BCMA antibody or antigen binding fragment thereof.
- the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is a BCMA-targeted chimeric antigen receptor T (CAR T)-cell therapy.
- CAR T BCMA-targeted chimeric antigen receptor T
- the first BCMA antagonist is belantamab and the second BCMA antagonist is an anti-BCMA antibody or antigen binding fragment thereof.
- the first BCMA antagonist is belantamab and the second BCMA antagonist is an anti-BCMA antibody-drug conjugate.
- the first BCMA antagonist is belantamab and the second BCMA antagonist is a bispecific anti-BCMA antibody or antigen binding fragment thereof.
- the first BCMA antagonist is belantamab and the second BCMA antagonist is a BCMA-targeted chimeric antigen receptor T (CAR T)-cell therapy.
- CAR T BCMA-targeted chimeric antigen receptor T
- the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is idecabtagene vicleucel. In an embodiment, the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is ciltacabtagene autoleucel. In an embodiment, the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is teclistamab. In an embodiment, the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is REGN5458. In an embodiment, the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is SEA-BCMA.
- the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is ABBV-383. In an embodiment, the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is elrantamab. In an embodiment, the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is pavurutumab. In an embodiment, the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is alnuctamab. In an embodiment, the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is MEDI2228. In an embodiment, the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is CC99712.
- the first BCMA antagonist is belantamab and the second BCMA antagonist is idecabtagene vicleucel. In an embodiment, the first BCMA antagonist is belantamab and the second BCMA antagonist is ciltacabtagene autoleucel. In an embodiment, the first BCMA antagonist is belantamab and the second BCMA antagonist is teclistamab. In an embodiment, the first BCMA antagonist is belantamab and the second BCMA antagonist is REGN5458. In an embodiment, the first BCMA antagonist is belantamab and the second BCMA antagonist is SEA- BCMA. In an embodiment, the first BCMA antagonist is belantamab and the second BCMA antagonist is ABBV-383.
- the first BCMA antagonist is belantamab and the second BCMA antagonist is elrantamab. In an embodiment, the first BCMA antagonist is belantamab and the second BCMA antagonist is pavurutumab. In an embodiment, the first BCMA antagonist is belantamab and the second BCMA antagonist is alnuctamab. In an embodiment, the first BCMA antagonist is belantamab and the second BCMA antagonist is MEDI2228. In an embodiment, the first BCMA antagonist is belantamab and the second BCMA antagonist is and CC99712.
- the combination further comprises a third BCMA antagonist.
- the third BCMA antagonist is selected from the group consisting of an anti-BCMA antibody or antigen binding fragment thereof, an anti-BCMA antibody-drug conjugate, a bispecific anti-BCMA antibody or antigen binding fragment thereof, and a BCMA-targeted chimeric antigen receptor T (CAR T)-cell therapy.
- the third BCMA-antagonist differs from the first and second BCMA-antagonists.
- the third BCMA antagonist is selected from the group consisting of idecabtagene vicleucel, ciltacabtagene autoleucel, teclistamab, REGN5458, belantamab mafodotin, belantamab, SEA-BCMA, ABBV-383, elrantamab, pavurutumab, alnuctamab, MEDI2228, and CC99712.
- the combination comprises belantamab mafodotin, belantamab, and an anti-BCMA antibody or antigen binding fragment thereof.
- the combination comprises belantamab mafodotin, belantamab, and an anti-BCMA antibody-drug conjugate.
- the combination comprises belantamab mafodotin, belantamab, and a bispecific anti- BCMA antibody or antigen binding fragment thereof.
- the combination comprises belantamab mafodotin, belantamab, and a BCMA-targeted chimeric antigen receptor T (CAR T)-cell therapy.
- CAR T BCMA-targeted chimeric antigen receptor T
- the combination comprises belantamab mafodotin, belantamab, and idecabtagene vicleucel. In an embodiment, the combination comprises belantamab mafodotin, belantamab, and ciltacabtagene autoleucel. In an embodiment, the combination comprises belantamab mafodotin, belantamab, and teclistamab. In an embodiment, the combination comprises belantamab mafodotin, belantamab, and REGN5458. In an embodiment, the combination comprises belantamab mafodotin, belantamab, and SEA-BCMA.
- the combination comprises belantamab mafodotin, belantamab, and ABBV-383. In an embodiment, the combination comprises belantamab mafodotin, belantamab, and elrantamab. In an embodiment, the combination comprises belantamab mafodotin, belantamab, and pavurutumab. In an embodiment, the combination comprises belantamab mafodotin, belantamab, and alnuctamab. In an embodiment, the combination comprises belantamab mafodotin, belantamab, and MEDI2228. In an embodiment, the combination comprises belantamab mafodotin, belantamab, and CC99712.
- the first BCMA antagonist is an anti-BCMA antibody-drug conjugate and the second BCMA antagonist is the corresponding unconjugated anti-BCMA antibody.
- the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is belantamab.
- the first and second BCMA antagonists, and the third BCMA antagonist, if present are administered simultaneously, such as on the same day of a treatment cycle.
- the first and second BCMA antagonists, and the third BCMA antagonist, if present are administered on the same day of a treatment cycle.
- the first and second BCMA antagonists, and the third BCMA antagonist, if present are administered during the same treatment cycle on different days of the treatment cycle.
- the first and second BCMA antagonists, and the third BCMA antagonist, if present, are independently administered at least once every 8 weeks ⁇ 3 days, at least once every 6 weeks ⁇ 3 days, at least once every 4 weeks ⁇ 3 days, at least once every 3 weeks ⁇ 3 days, at least once every 2 weeks ⁇ 3 days, at least once every week ⁇ 3 days, once every week ⁇ 3 days to once every 8 weeks ⁇ 3 days, once every week ⁇ 3 days to once every 6 weeks ⁇ 3 days, once every week ⁇ 3 days to once every 4 weeks ⁇ 3 days, once every week ⁇ 3 days to once every 3 weeks ⁇ 3 days, once every week ⁇ 3 days to once every 2 weeks ⁇ 3 days, once every 2 weeks ⁇ 3 days to once every 3 weeks ⁇ 3 days, once every 3 weeks ⁇ 3 days to once every 4 weeks ⁇ 3 days, once every 4 weeks ⁇ 3 days to once every 5 weeks ⁇ 3 days, once every 5 weeks ⁇ 3 days to once every 6 weeks ⁇ 3 days, once every 4 weeks ⁇ 3 days,
- the first and second BCMA antagonists, and the third BCMA antagonist, if present are administered in combination with application of a bandage contact lens.
- the first and second BCMA antagonists, and the third BCMA antagonist, if present are administered in combination with at least one additional treatment.
- the additional cancer treatment is selected from an anti-CD38 monoclonal antibody, a gamma-secretase inhibitor, a proteasome inhibitor, an immunomodulatory agent, or an anti-PD- 1 monoclonal antibody.
- anti-CD38 antibodies useful in the methods described herein include, but are not limited to, isatuximab or isatuximab-irfc (e.g., SARCLISA®) and daratumumab (e.g, DARZALEX®, DARZALEX FASPRO®).
- the anti-CD38 monoclonal antibody is selected from daratumumab or isatuximab.
- Examples of gamma-secretase inhibitors useful in the methods described herein include, but are not limited to, nirogacestat (PF-0308014), crenigacestat (LY3039478), CB-103, tarenflurbil, semagacestat (LY450139), RG-4733, EVP-0962, avagacestat, MK-0752, and BMS- 906024, as well as derivatives and polymorphs thereof.
- proteasome inhibitors useful in the methods described herein include, but are not limited to, bortezomib (e.g., VELCADE®), ixazomib (e.g., NINLARO®), carfilzomib (e.g., KYPROLIS®), oprozomib, and delanzomib.
- the proteasome inhibitor is selected from bortezomib, carfilzomib, or ixazomib.
- the proteasome inhibitor is bortezomib.
- immunomodulatory imide drugs useful in the methods described herein include, but are not limited to, thalidomide (e.g., THALOMID®), lenalidomide (e.g., REVLIMID®), and pomalidomide (e.g., POMALYST®).
- the immunomodulatory agent is selected from thalidomide, lenalidomide, or pomalidomide.
- the immunomodulatory agent is lenalidomide or pomalidomide.
- the immunomodulatory agent is lenalidomide.
- anti-PD-1 monoclonal antibodies useful in the methods described herein include, but are not limited to, pembroluzimab and dostarlimab.
- the anti-PD-1 monoclonal antibody is selected from pembroluzimab or dostarlimab.
- corticosteroids include, but are not limited to, dexamethasone (e.g., DECADRON®, DEXASONE®, DIODEX®, HEXADROL®, MAXIDEX®), prednisone (e.g., DELTASONE®), and methylprednisolone (e.g., MEDROL®).
- dexamethasone e.g., DECADRON®, DEXASONE®, DIODEX®, HEXADROL®, MAXIDEX®
- prednisone e.g., DELTASONE®
- methylprednisolone e.g., MEDROL®
- the additional cancer treatment is selected from lenalidomide, pomalidomide, dexamethasone, or a combination thereof.
- the additional cancer treatments are lenalidomide and dexamethasone.
- the additional cancer treatments are pomalidomide and dexamethasone.
- the additional cancer treatments are bortezomib and dexamethasone.
- the additional cancer treatments are pomalidomide, bortezomib, and dexamethasone.
- the additional cancer treatments are lenalidomide, bortezomib, and dexamethasone.
- the additional cancer treatment is standard of care treatment.
- the first and second BCMA antagonists, and the third BCMA antagonist, if present, are administered on day 1 of a treatment cycle. In an embodiment, the first and second BCMA antagonists, and the third BCMA antagonist, if present, are administered on day 1 of a 28-day treatment cycle.
- the additional cancer treatment is lenalidomide at a dose of 10 mg to 25 mg once daily for a period of time. In an embodiment, the additional cancer treatment is lenalidomide at a dose of 10 mg to 25 mg once daily administered on days 1-21 of a 28 day cycle.
- the additional cancer treatment is dexamethasone. In an embodiment, the additional cancer treatment is dexamethasone at a dose of 20 mg to 40 mg once weekly.
- the additional cancer treatment is dexamethasone at a dose of 40 mg once weekly if the patient is less than 75 years old. In an embodiment, the additional cancer treatment is dexamethasone at a dose of 20 mg once weekly if the patient is at least 75 years old. In an embodiment, the additional cancer treatment is dexamethasone at a dose of 40 mg once weekly if the patient has a BMI of at least 18.5. In an embodiment, the additional cancer treatment is dexamethasone at a dose of 20 mg once weekly if the patient has a BMI less than 18.5. In an embodiment, the dexamethasone is administered on days 1, 8, 15, and 22 of a 28 day cycle.
- the additional cancer treatments are lenalidomide at a dose of 10 mg to 25 mg administered once daily on days 1-21 of a 28 day cycle and dexamethasone at a dose of 20 mg to 40 mg administered on days 1, 8, 15, and 22 of a 28 day cycle.
- the additional cancer treatments are lenalidomide at a dose of 10 mg to 25 mg administered once daily on days 1-21 of a 28 day cycle and dexamethasone at a dose of 40 mg administered on days 1, 8, 15, and 22 of a 28 day cycle if the patient is less than 75 years old or has a BMI of at least 18.5.
- the additional cancer treatments are lenalidomide at a dose of 10 mg to 25 mg administered once daily on days 1-21 of a 28 day cycle and dexamethasone at a dose of 20 mg administered on days 1, 8, 15, and 22 of a 28 day cycle if the patient is at least 75 years old or has a BMI of less than 18.5.
- the disclosure provides a kit comprising: (i) a first B-cell maturation antigen (BCMA) antagonist; and (ii) instructions for use in treating a disease or disorder responsive to inhibiting or blocking BCMA when combined with a second BCMA antagonist.
- the kit further comprises a third BCMA antagonist.
- the instructions further describe use in treating a disease or disorder responsive to inhibiting or blocking BCMA when combined with second and third BCMA antagonist.
- the first, second, and third BCMA antagonists are independently selected from the group consisting of an anti-BCMA antibody or antigen binding fragment thereof, an anti-BCMA antibody-drug conjugate, a bispecific anti-BCMA antibody or antigen binding fragment thereof, and a BCMA-targeted chimeric antigen receptor T (CAR T)-cell therapy.
- an anti-BCMA antibody or antigen binding fragment thereof an anti-BCMA antibody-drug conjugate, a bispecific anti-BCMA antibody or antigen binding fragment thereof, and a BCMA-targeted chimeric antigen receptor T (CAR T)-cell therapy.
- CAR T BCMA-targeted chimeric antigen receptor T
- the first, second, and third BCMA antagonists are independently selected from the group consisting of idecabtagene vicleucel, ciltacabtagene autoleucel, teclistamab, REGN5458, belantamab mafodotin, belantamab, SEA-BCMA, ABBV-383, elrantamab, pavurutumab, alnuctamab, MEDI2228, and CC99712.
- the disclosure provides a kit comprising: (i) belantamab mafodotin; and (ii) instructions for use in treating a disease or disorder responsive to inhibiting or blocking BCMA when combined with belantamab.
- the disclosure provides a kit comprising: (i) belantamab; and (ii) instructions for use in treating a disease or disorder responsive to inhibiting or blocking BCMA when combined with belantamab mafodotin.
- BCMA-inhibiting or blocking therapies are also described.
- kits comprising BCMA-inhibiting or blocking therapies and instructions for use.
- the disclosure provides methods of treating a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) in a patient previously treated with a first BCMA antagonist, the method comprising administering a therapeutically effective amount of a second BCMA antagonist to the patient, wherein the patient discontinued administration of the first BCMA antagonist prior to beginning administration of the second BCMA antagonist and the second BCMA antagonist is not the same as the first BCMA antagonist.
- BCMA B-cell maturation antigen
- the disclosure provides methods of reducing corneal toxicity in a patient previously treated with a first B-cell maturation antigen (BCMA) antagonist, the method comprising administering a therapeutically effective amount of a second BCMA antagonist to the patient, wherein the patient discontinued administration of the first BCMA antagonist prior to beginning administration of the second BCMA antagonist and the second BCMA antagonist is not the same as the first BCMA antagonist.
- BCMA B-cell maturation antigen
- Corneal toxicity” or “corneal adverse reaction” refers to changes in the cornea, including keratopathy (e.g., mild superficial keratopathy, moderate superficial keratopathy, severe superficial keratopathy) and corneal epithelial defect, such as corneal ulcers.
- corneal toxicity or corneal adverse reaction refers to keratopathy, and the severity or grade of such corneal adverse reaction can be determined using the keratopathy visual acuity (KVA) scale for treatment-related corneal toxicities according to Table 2.
- KVA keratopathy visual acuity
- a patient has a Grade 1 corneal adverse reaction.
- a patient has a Grade 2 corneal adverse reaction.
- a patient has a Grade 3 corneal adverse reaction.
- a patient has a Grade 4 corneal adverse reaction.
- reducing ocular toxicity refers to reducing the severity of a corneal adverse reaction or the grade of a treatment related corneal toxicity as determined according to the KVA scale.
- the first and second BCMA antagonists are independently selected from the group consisting of an anti-BCMA antibody or antigen binding fragment thereof, an anti- BCMA antibody-drug conjugate, a bispecific anti-BCMA antibody or antigen binding fragment thereof, and a BCMA-targeted chimeric antigen receptor T (CAR T)-cell therapy.
- the first BCMA-antagonist differs from the second BCMA-antagonist.
- the first and second BCMA-antagonists are both anti-BCMA antibodies or fragments thereof, both anti-BCMA antibody-drug conjugates, both bispecific anti-BCMA antibodies or fragments thereof, or both BCMA-targeted chimeric antigen receptor T (CAR T)-cell therapies.
- the first BCMA-antagonist is an anti-BCMA antibody or antigen binding fragment thereof and the second BCMA-antagonist is a different anti-BCMA antibody or antigen binding fragment thereof.
- the first BCMA-antagonist is an anti-BCMA antibody-drug conjugate and the second BCMA-antagonist is a different anti-BCMA antibody-drug conjugate.
- the first BCMA-antagonist is a bispecific anti-BCMA antibody or antigen binding fragment thereof and the second BCMA-antagonist is a different bispecific anti-BCMA antibody or antigen binding fragment thereof.
- the first BCMA-antagonist is a BCMA-targeted chimeric antigen receptor T (CAR T)-cell therapy and the second BCMA-antagonist is a different BCMA- targeted chimeric antigen receptor T (CAR T)-cell therapy.
- CAR T BCMA-targeted chimeric antigen receptor T
- CAR T BCMA-targeted chimeric antigen receptor T
- the bispecific anti-BCMA antibody or antigen binding fragment thereof comprises an anti-BCMA antibody or antigen binding fragment thereof and an anti-CD38 antibody or antigen binding fragment thereof. In an embodiment, the bispecific anti-BCMA antibody or antigen binding fragment thereof comprises an anti-BCMA antibody or antigen binding fragment thereof and an anti-CD3 antibody or antigen binding fragment thereof.
- the first and second BCMA antagonists are independently selected from the group consisting of idecabtagene vicleucel, ciltacabtagene autoleucel, teclistamab, REGN5458, belantamab mafodotin, belantamab, SEA-BCMA, ABBV-383, elrantamab, pavurutumab, alnuctamab, MEDI2228, and CC99712.
- the first BCMA antagonist is belantamab mafodotin. In an embodiment, the first BCMA antagonist is belantamab. In an embodiment, the second BCMA antagonist is belantamab mafodotin. In an embodiment, the second BCMA antagonist is belantamab.
- the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is an anti-BCMA antibody or antigen binding fragment thereof.
- the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is an anti-BCMA antibody-drug conjugate.
- the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is a bispecific anti-BCMA antibody or antigen binding fragment thereof.
- the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is a BCMA-targeted chimeric antigen receptor T (CAR T)-cell therapy.
- CAR T BCMA-targeted chimeric antigen receptor T
- the first BCMA antagonist is an anti-BCMA antibody or antigen binding fragment thereof and the second BCMA antagonist is belantamab mafodotin.
- the first BCMA antagonist is an anti-BCMA antibody-drug conjugate and the second BCMA antagonist is belantamab mafodotin.
- the first BCMA antagonist is a bispecific anti-BCMA antibody or antigen binding fragment thereof and the second BCMA antagonist is belantamab mafodotin.
- the first BCMA antagonist is a BCMA-targeted chimeric antigen receptor T (CAR T)-cell therapy and the second BCMA antagonist is belantamab mafodotin.
- CAR T BCMA-targeted chimeric antigen receptor T
- the first BCMA antagonist is belantamab and the second BCMA antagonist is an anti-BCMA antibody or antigen binding fragment thereof.
- the first BCMA antagonist is belantamab and the second BCMA antagonist is an anti-BCMA antibody-drug conjugate.
- the first BCMA antagonist is belantamab and the second BCMA antagonist is a bispecific anti-BCMA antibody or antigen binding fragment thereof.
- the first BCMA antagonist is belantamab and the second BCMA antagonist is a BCMA-targeted chimeric antigen receptor T (CAR T)-cell therapy.
- the first BCMA antagonist is an anti-BCMA antibody or antigen binding fragment thereof and the second BCMA antagonist is belantamab.
- the first BCMA antagonist is an anti-BCMA antibody-drug conjugate and the second BCMA antagonist is belantamab.
- the first BCMA antagonist is a bispecific anti-BCMA antibody or antigen binding fragment thereof and the second BCMA antagonist is belantamab.
- the first BCMA antagonist is a BCMA-targeted chimeric antigen receptor T (CAR T)-cell therapy and the second BCMA antagonist is belantamab.
- the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is idecabtagene vicleucel. In an embodiment, the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is ciltacabtagene autoleucel. In an embodiment, the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is teclistamab. In an embodiment, the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is REGN5458. In an embodiment, the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is SEA-BCMA.
- the first BCMA antagonist is idecabtagene vicleucel and the second BCMA antagonist is belantamab mafodotin.
- the first BCMA antagonist is ciltacabtagene autoleucel and the second BCMA antagonist is belantamab mafodotin.
- the first BCMA antagonist is teclistamab and the second BCMA antagonist is belantamab mafodotin.
- the first BCMA antagonist is REGN5458 and the second BCMA antagonist is belantamab mafodotin.
- the first BCMA antagonist is SEA-BCMA and the second BCMA antagonist is belantamab mafodotin.
- the first BCMA antagonist is ABBV-383 and the second BCMA antagonist is belantamab mafodotin.
- the first BCMA antagonist is elrantamab and the second BCMA antagonist is belantamab mafodotin.
- the first BCMA antagonist is pavurutumab and the second BCMA antagonist is belantamab mafodotin.
- the first BCMA antagonist is alnuctamab and the second BCMA antagonist is belantamab mafodotin.
- the first BCMA antagonist is MEDI2228 and the second BCMA antagonist is belantamab mafodotin.
- the first BCMA antagonist is CC99712 and the second BCMA antagonist is belantamab mafodotin.
- the first BCMA antagonist is belantamab and the second BCMA antagonist is idecabtagene vicleucel.
- the first BCMA antagonist is belantamab and the second BCMA antagonist is ciltacabtagene autoleucel.
- the first BCMA antagonist is belantamab and the second BCMA antagonist is teclistamab.
- the first BCMA antagonist is belantamab and the second BCMA antagonist is REGN5458.
- the first BCMA antagonist is belantamab and the second BCMA antagonist is SEA- BCMA.
- the first BCMA antagonist is idecabtagene vicleucel and the second BCMA antagonist is belantamab.
- the first BCMA antagonist is ciltacabtagene autoleucel and the second BCMA antagonist is belantamab. In an embodiment, the first BCMA antagonist is teclistamab and the second BCMA antagonist is belantamab. In an embodiment, the first BCMA antagonist is REGN5458 and the second BCMA antagonist is belantamab. In an embodiment, the first BCMA antagonist is SEA-BCMA and the second BCMA antagonist is belantamab. In an embodiment, the first BCMA antagonist is ABBV-383 and the second BCMA antagonist is belantamab. In an embodiment, the first BCMA antagonist is elrantamab and the second BCMA antagonist is belantamab.
- the first BCMA antagonist is pavurutumab and the second BCMA antagonist is belantamab. In an embodiment, the first BCMA antagonist is alnuctamab and the second BCMA antagonist is belantamab. In an embodiment, the first BCMA antagonist is MEDI2228 and the second BCMA antagonist is belantamab. In an embodiment, the first BCMA antagonist is CC99712 and the second BCMA antagonist is belantamab.
- the method further comprises administering a therapeutically effective amount of a third BCMA antagonist to the patient in combination with the second BCMA antagonist, wherein the patient discontinued administration of the first BCMA antagonist prior to beginning administration of the second and third BCMA antagonists and the third BCMA antagonist is not the same as the first and second BCMA antagonists.
- the first BCMA antagonist is an anti-BCMA antibody or antigen binding fragment thereof
- the second BCMA antagonist is belantamab mafodotin
- the third BCMA antagonist is belantamab.
- the first BCMA antagonist is an anti-BCMA antibody-drug conjugate
- the second BCMA antagonist is belantamab mafodotin
- the third BCMA antagonist is belantamab.
- the first BCMA antagonist is a bispecific anti-BCMA antibody or antigen binding fragment thereof
- the second BCMA antagonist is belantamab mafodotin
- the third BCMA antagonist is belantamab.
- the first BCMA antagonist is a BCMA-targeted chimeric antigen receptor T (CAR T)-cell therapy
- the second BCMA antagonist is belantamab mafodotin
- the third BCMA antagonist is belantamab.
- the first BCMA antagonist is idecabtagene vicleucel
- the second BCMA antagonist is belantamab mafodotin
- the third BCMA antagonist is belantamab.
- the first BCMA antagonist is ciltacabtagene autoleucel
- the second BCMA antagonist is belantamab mafodotin
- the third BCMA antagonist is belantamab.
- the first BCMA antagonist is teclistamab
- the second BCMA antagonist is belantamab mafodotin
- the third BCMA antagonist is belantamab.
- the first BCMA antagonist is REGN5458
- the second BCMA antagonist is belantamab mafodotin
- the third BCMA antagonist is belantamab.
- the first BCMA antagonist is SEA-BCMA
- the second BCMA antagonist is belantamab mafodotin
- the third BCMA antagonist is belantamab.
- the first BCMA antagonist is ABBV-383
- the second BCMA antagonist is belantamab mafodotin
- the third BCMA antagonist is belantamab.
- the first BCMA antagonist is elrantamab
- the second BCMA antagonist is belantamab mafodotin
- the third BCMA antagonist is belantamab.
- the first BCMA antagonist is pavurutumab
- the second BCMA antagonist is belantamab mafodotin
- the third BCMA antagonist is belantamab.
- the first BCMA antagonist is alnuctamab
- the second BCMA antagonist is belantamab mafodotin
- the third BCMA antagonist is belantamab.
- the first BCMA antagonist is MEDI2228
- the second BCMA antagonist is belantamab mafodotin
- the third BCMA antagonist is belantamab.
- the first BCMA antagonist is CC99712
- the second BCMA antagonist is belantamab mafodotin
- the third BCMA antagonist is belantamab.
- the first BCMA antagonist is an anti-BCMA antibody-drug conjugate and the second BCMA antagonist is the corresponding unconjugated anti-BCMA antibody.
- the second BCMA antagonist is an anti-BCMA antibody-drug conjugate and the first BCMA antagonist is the corresponding unconjugated anti-BCMA antibody.
- the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is belantamab.
- the first BCMA antagonist is belantamab and the second BCMA antagonist is belantamab mafodotin.
- the second BCMA antagonist, and the third BCMA antagonist are independently administered at least once every 8 weeks ⁇ 3 days, at least once every 6 weeks ⁇ 3 days, at least once every 4 weeks ⁇ 3 days, at least once every 3 weeks ⁇ 3 days, at least once every 2 weeks ⁇ 3 days, at least once every week ⁇ 3 days, once every week ⁇ 3 days to once every 8 weeks ⁇ 3 days, once every week ⁇ 3 days to once every 6 weeks ⁇ 3 days, once every week ⁇ 3 days to once every 4 weeks ⁇ 3 days, once every week ⁇ 3 days to once every 3 weeks ⁇ 3 days, once every week ⁇ 3 days to once every 2 weeks ⁇ 3 days, once every 2 weeks ⁇ 3 days to once every 3 weeks ⁇ 3 days, once every 3 weeks ⁇ 3 days to once every 4 weeks ⁇ 3 days, once every 4 weeks ⁇ 3 days to once every 5 weeks ⁇ 3 days, once every 5 weeks ⁇ 3 days to once every 3 days to once every
- the second BCMA antagonist and the third BCMA antagonist are administered in combination with application of bandage contact lens.
- the second BCMA antagonist, and the third BCMA antagonist, if present, are administered in combination with at least one additional treatment.
- the additional cancer treatment is selected from an anti-CD38 monoclonal antibody, a gamma- secretase inhibitor, a proteasome inhibitor, an immunomodulatory agent, or an anti-PD-1 monoclonal antibody.
- anti-CD38 antibodies useful in the methods described herein include, but are not limited to, isatuximab or isatuximab-irfc (e.g., SARCLISA®) and daratumumab (e.g, DARZALEX®, DARZALEX FASPRO®).
- the anti-CD38 monoclonal antibody is selected from daratumumab or isatuximab.
- Examples of gamma-secretase inhibitors useful in the methods described herein include, but are not limited to, nirogacestat (PF-0308014), crenigacestat (LY3039478), CB-103, tarenflurbil, semagacestat (LY450139), RG-4733, EVP-0962, avagacestat, MK-0752, and BMS- 906024, as well as derivatives and polymorphs thereof.
- proteasome inhibitors useful in the methods described herein include, but are not limited to, bortezomib (e.g., VELCADE®), ixazomib (e.g., NINLARO®), carfilzomib (e.g., KYPROLIS®), oprozomib, and delanzomib.
- the proteasome inhibitor is selected from bortezomib, carfilzomib, or ixazomib.
- the proteasome inhibitor is bortezomib.
- immunomodulatory imide drugs useful in the methods described herein include, but are not limited to, thalidomide (e.g., THALOMID®), lenalidomide (e.g., REVLIMID®), and pomalidomide (e.g., POMALYST®).
- the immunomodulatory agent is selected from thalidomide, lenalidomide, or pomalidomide.
- the immunomodulatory agent is lenalidomide or pomalidomide.
- the immunomodulatory agent is lenalidomide.
- anti-PD-1 monoclonal antibodies useful in the methods described herein include, but are not limited to, pembroluzimab and dostarlimab.
- the anti-PD-1 monoclonal antibody is selected from pembroluzimab or dostarlimab.
- corticosteroids include, but are not limited to, dexamethasone (e.g., DECADRON®, DEXASONE®, DIODEX®, HEXADROL®, MAXIDEX®), prednisone (e.g., DELTASONE®), and methylprednisolone (e.g., MEDROL®).
- dexamethasone e.g., DECADRON®, DEXASONE®, DIODEX®, HEXADROL®, MAXIDEX®
- prednisone e.g., DELTASONE®
- methylprednisolone e.g., MEDROL®
- the additional cancer treatment is selected from lenalidomide, pomalidomide, dexamethasone, or a combination thereof.
- the additional cancer treatments are lenalidomide and dexamethasone.
- the additional cancer treatments are pomalidomide and dexamethasone.
- the additional cancer treatments are bortezomib and dexamethasone.
- the additional cancer treatments are pomalidomide, bortezomib, and dexamethasone.
- the additional cancer treatments are lenalidomide, bortezomib, and dexamethasone.
- the additional cancer treatment is standard of care treatment.
- the second BCMA antagonist, and the third BCMA antagonist, if present, are administered on day 1 of a treatment cycle. In an embodiment, the second BCMA antagonist, and the third BCMA antagonist, if present, are administered on day 1 of a 28-day treatment cycle.
- the additional cancer treatment is lenalidomide at a dose of 10 mg to 25 mg once daily for a period of time. In an embodiment, the additional cancer treatment is lenalidomide at a dose of 10 mg to 25 mg once daily administered on days 1-21 of a 28 day cycle.
- the additional cancer treatment is dexamethasone. In an embodiment, the additional cancer treatment is dexamethasone at a dose of 20 mg to 40 mg once weekly.
- the additional cancer treatment is dexamethasone at a dose of 40 mg once weekly if the patient is less than 75 years old. In an embodiment, the additional cancer treatment is dexamethasone at a dose of 20 mg once weekly if the patient is at least 75 years old. In an embodiment, the additional cancer treatment is dexamethasone at a dose of 40 mg once weekly if the patient has a BMI of at least 18.5. In an embodiment, the additional cancer treatment is dexamethasone at a dose of 20 mg once weekly if the patient has a BMI less than 18.5. In an embodiment, the dexamethasone is administered on days 1, 8, 15, and 22 of a 28 day cycle.
- the additional cancer treatments are lenalidomide at a dose of 10 mg to 25 mg administered once daily on days 1-21 of a 28 day cycle and dexamethasone at a dose of 20 mg to 40 mg administered on days 1, 8, 15, and 22 of a 28 day cycle.
- the additional cancer treatments are lenalidomide at a dose of 10 mg to 25 mg administered once daily on days 1-21 of a 28 day cycle and dexamethasone at a dose of 40 mg administered on days 1, 8, 15, and 22 of a 28 day cycle if the patient is less than 75 years old or has a BMI of at least 18.5.
- the additional cancer treatments are lenalidomide at a dose of 10 mg to 25 mg administered once daily on days 1-21 of a 28 day cycle and dexamethasone at a dose of 20 mg administered on days 1, 8, 15, and 22 of a 28 day cycle if the patient is at least 75 years old or has a BMI of less than 18.5.
- the first BCMA antagonist is discontinued after the patient demonstrates progressive disease.
- an immunoconjugate or antibody-drug conjugate is used in combination with its corresponding unconjugated antibody.
- a corresponding unconjugated antibody refers to the antibody portion of the immunoconjugate or ADC that lacks the cytotoxic payload and optionally any linker portion of the immunoconjugate or ADC.
- the disclosure provides methods of treating a disease or disorder in a patient, the method comprising administering a therapeutically effective amount of a combination comprising an antibody-drug conjugate and the corresponding unconjugated antibody to the patient.
- the disclosure provides methods of reducing toxicity of an antibody-drug conjugate, the method comprising administering to a patient in need thereof a therapeutically effective amount of a combination comprising the antibody-drug conjugate and the corresponding unconjugated antibody to the patient.
- the disclosure provides methods of treating a disease or disorder in a patient previously treated with an antibody-drug conjugate, the method comprising administering a therapeutically effective amount of the corresponding unconjugated antibody to the patient, wherein the patient discontinued administration of the antibody-drug conjugate prior to beginning administration of the corresponding unconjugated antibody.
- the disclosure provides methods of reducing toxicity in a patient previously treated with an antibody-drug conjugate, the method comprising administering a therapeutically effective amount of the corresponding unconjugated antibody to the patient, wherein the patient discontinued administration of the antibody-drug conjugate prior to beginning administration of the corresponding unconjugated antibody.
- the antibody-drug conjugate is selected from gemtuzumab ozogamicin, brentuximab vedotin, ado-trastuzumab emtansine, inotuzumab ozogamicin, polatuzumab vedotin, enfortumab vedotin, fam-trastuzumab deruxtecan, sacituzumab govitecan, belantamab mafodotin, loncastuximab tesirine, tisotumab vedotin, moxetumomab pasudotox, MEDI2228, or CC99712. Diseases and Disorders
- BCMA-inhibiting or blocking therapies in the treatment of a disease or disorder in a patient.
- the disease or disorder is a plasma cell disorder or a B-cell disorder.
- B-cell disorders can be divided into defects of B-cell development/immunoglobulin production (immunodeficiencies) and excessive/uncontrolled proliferation (lymphomas, leukemias).
- B-cell disorder refers to both types of diseases, and methods are provided for treating B- cell disorders.
- the cancer can be a B cell cancer (e.g., leukemias and lymphomas).
- MM Multiple Myeloma
- CLL chronic lymphocytic leukemia
- FL Follicular Lymphoma
- Non-secretory multiple myeloma Smoldering multiple myeloma
- Monoclonal gammopathy of undetermined significance MGUS
- Solitary plasmacytoma Bone, Extramedullary
- Lymphoplasmacytic lymphoma LPL
- Waldenstrom’s Macroglobulinemia Plasma cell leukemia, Primary Amyloidosis (AL), Heavy chain disease, Systemic lupus erythematosus (SLE), POEMS syndrome / osteosclerotic myeloma, Type I and II cryoglobulinemia, Light chain deposition disease, Goodpasture’s syndrome, Idiopathic thrombocytopenic purpura (ITP), Acute glomerulonep
- the disease or disorder can be selected from the group consisting of Multiple Myeloma (MM), Non-Hodgkin’s Lymphoma B- cell leukemia (NHL), Follicular Lymphoma (FL), and Diffuse Large B-Cell Lymphoma (DLBCL).
- MM Multiple Myeloma
- NHL Non-Hodgkin’s Lymphoma B- cell leukemia
- FL Follicular Lymphoma
- the disease can be Multiple Myeloma or Non-Hodgkin’s Lymphoma B-cell leukemia (NHL).
- the disease can be Multiple Myeloma.
- the disease or disorder is a BCMA-expressing cancer.
- the disease or disorder is multiple myeloma (MM).
- the MM is relapsed and/or refractory MM, newly-diagnosed MM, transplant-ineligible MM, or transplant- ineligible newly-diagnosed MM.
- the disease or disorder is multiple myeloma previously treated with at least one, at least two, at least three, or at least four therapeutics to treat the multiple myeloma.
- the disease or disorder is relapsed and/or refractory multiple myeloma previously treated with at least one, at least two, at least three or at least four therapeutics to treat the multiple myeloma.
- the disease or disorder is relapsed and/or refractory multiple myeloma previously treated with at least 3 prior lines of therapy that may include the following: an immunomodulatory drug (ImiD), a proteasome inhibitor (PI) and anti-CD38 treatment (e.g., daratumumab) or combinations thereof. Lines of therapy may be defined by consensus panel of the International Myeloma Workshop (IMWG).
- a patient that had prior lines of treatment may have a cancer that is recurrent, relapsed and/or refractory.
- a cancer can be a primary cancer.
- a cancer can be metastatic cancer.
- a cancer can be chemo-resistant cancer.
- the disease or disorder is an autoimmune disease or disorder.
- the disease or disorder is systemic lupus erythematosus (SLE), idiopathic thrombocytopenic purpura (ITP), rheumatoid arthritis, Type 1 diabetes mellitus, multiple sclerosis, or psoriasis.
- belantamab refers to a B-cell maturation antigen (BCMA)-blocking antibody (“anti-BCMA antibody”) or a functional fragment or functional variant thereof which specifically binds to BCMA and which inhibits the binding of BAFF and/or APRIL to the BCMA receptor, comprising an immunoglobulin heavy chain variable domain (VH) comprising a complementary determining region (CDR) Hl comprising the amino acid sequence of SEQ ID NO 5; a CDRH2 comprising the amino acid sequence of SEQ ID NO: 6; a CDRH3 comprising the amino acid sequence of SEQ ID NO: 7; and an immunoglobulin light chain variable domain (VL) comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO: 8; a CDRL2 comprising the amino acid sequence of SEQ ID NO: 9; and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 10.
- VH immunoglobulin heavy chain variable domain
- CDR complementary determining region
- VL immunoglobulin light chain
- the VH comprises an amino acid sequence of SEQ ID NO: 3.
- the VL comprises an amino acid sequence of SEQ ID NO 4.
- the heavy chain comprises the amino acid sequence of SEQ ID NO 1.
- the light chain comprises the amino acid sequence of SEQ ID NO 2.
- belantamab comprises a VH comprising an amino acid sequence of SEQ ID NO: 3 and a VL comprising an amino acid sequence of SEQ ID NO: 4.
- belantamab comprises the heavy and light chain sequences of SEQ ID NO: 1 and SEQ ID NO: 2, respectively.
- belantamab mafodotin and “belamaf ’ are used interchangeably and refer to an immunoconjugate comprising belantamab conjugated to monomethyl auristatin F (MMAF) via a 6- maleimidocaproyl (MC) linker.
- MMAF monomethyl auristatin F
- MC 6- maleimidocaproyl
- biosimilar refers to a biopharmaceutical or a biologic product that is highly similar to a reference biologic product (e.g., belantamab or belantamab mafodotin) notwithstanding minor differences in clinically inactive components, and for which there are no clinically meaningful differences between the biologic product and the reference product in terms of the safety, purity, and potency of the product (Section 351 (i) of the Public Health Service Act (42 U.S.C. 262(i)).
- a reference biologic product e.g., belantamab or belantamab mafodotin
- biosimilar refers to a biologic product that is highly similar to the reference product (e.g., belantamab or belantamab mafodotin) approved by a regulatory agency (e.g., the Federal Drug Administration (FDA) or the European Medicines Agency (EMA)) based on data from (a) analytical studies demonstrating that the biologic product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; (b) animal studies (including the assessment of toxicity); and/or (c) a clinical study or studies (including the assessment of immunogenicity and pharmacokinetics or pharmacodynamics) that are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which the reference product is approved and intended to be used and for which approval is sought (e.g., that there are no clinically meaningful differences between the biologic product and the reference product in terms of the safety, purity and potency of the product).
- the biosimilar product is an interchangeable product as determined by a regulatory agency (e.g., the Federal Drug Administration (
- the biosimilar may comprise one or more molecular differences, such as post-translational modifications, for example, although not limited to, glycosylation, oxidation, deamidation, and/or truncation which is/are different to the post-translational modifications of the reference medicinal product (e.g., belantamab or belantamab mafodotin) provided that the differences do not result in a significant change in safety and/or efficacy of the medicinal product.
- the reference medicinal product e.g., belantamab or belantamab mafodotin
- the biosimilar may have an identical or different glycosylation pattern to the reference medicinal product (e.g., belantamab or belantamab mafodotin).
- the biosimilar e.g., a biosimilar of belantamab or belantamab mafodotin
- the biosimilar may have a different glycosylation pattern, such as, if the differences address or are intended to address safety concerns associated with the reference medicinal product (e.g., belantamab or belantamab mafodotin).
- biosimilar e.g., a biosimilar of belantamab or belantamab mafodotin
- the reference medicinal product e.g., belantamab or belantamab mafodotin
- the biosimilar e.g., a biosimilar of belantamab or belantamab mafodotin
- the biosimilar may comprise differences in, for example, pharmacokinetic (PK) and/or pharmacodynamic (PD) profiles as compared to the reference medicinal product (e.g., belantamab or belantamab mafodotin) but is still deemed sufficiently similar to the reference medicinal product as to be authorized or considered suitable for authorization.
- PK pharmacokinetic
- PD pharmacodynamic
- the biosimilar e.g., a biosimilar of belantamab or belantamab mafodotin
- the reference medicinal product e.g., belantamab or belantamab mafodotin
- biosimilar is also used synonymously by other national and regional regulatory agencies.
- a drug’s international nonproprietary name (e.g., belantamab or belantamab mafodotin)
- INN international nonproprietary name
- a drug’s INN optionally includes, but is not limited to, glycosylation variants of belantamab or belantamab mafodotin, and biosimilars thereof.
- Embodiment 1 is a method of treating a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) in a patient, the method comprising administering to the patient belantamab at a dose of about 300 mg to about 2000 mg.
- Embodiment 2 is the method of embodiment 1, wherein the dose is about 300 mg, about 900 mg, or about 2000 mg.
- Embodiment 3 is the method of embodiment 1 or 2, wherein the dose is administered at a regular interval for a period of time.
- Embodiment 4 is the method of embodiment 1 or 2, wherein the dose is administered once every week ⁇ 3 days to once every four weeks ⁇ 3 days.
- Embodiment 5 is the method of embodiment 1 or 2, wherein the dose is administered once every two weeks ⁇ 3 days.
- Embodiment 6 is the method of embodiment 1 or 2, wherein the dose is administered once every three weeks ⁇ 3 days.
- Embodiment 7 is the method of embodiment 1 or 2, wherein the dose is administered once every four weeks ⁇ 3 days.
- Embodiment 8 is the method of embodiment 1 or 2, wherein the dose is administered on days 1 and 15 of a 28 day cycle.
- Embodiment 9 is the method of embodiment 1 or 2, wherein the dose is administered on day 1 of a 21 day cycle.
- Embodiment 10 is the method of any one of the preceding embodiments, wherein the patient has been treated with at least one prior line of cancer treatment.
- Embodiment 11 is the method of any one of the preceding embodiments, wherein the patient has been treated with one, two, three, or four prior lines of cancer treatments.
- Embodiment 12 is the method of embodiment 11, wherein the prior lines of cancer treatments include an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
- Embodiment 13 is the method of any one of the preceding embodiments, wherein belantamab is administered through an intravenous infusion or a subcutaneous injection.
- Embodiment 14 is the method of any one of the preceding embodiments, wherein the patient is further receiving at least one additional cancer treatment, such as an anti-CD38 monoclonal antibody, a proteasome inhibitor, an immunomodulatory agent, or an anti-PD-1 monoclonal antibody.
- additional cancer treatment such as an anti-CD38 monoclonal antibody, a proteasome inhibitor, an immunomodulatory agent, or an anti-PD-1 monoclonal antibody.
- Embodiment 15 is the method of embodiment 14, wherein the additional cancer treatment is selected from lenalidomide, dexamethasone, daratumumab, isatuximab, pomalidomide, bortezomib, or a combination thereof, such as lenalidomide and dexamethasone.
- Embodiment 16 is the method of embodiment 15, wherein the additional cancer treatment is lenalidomide at a dose of 10 mg to 25 mg once daily for a period of time.
- Embodiment 17 is the method of embodiment 16, wherein the patient is receiving lenalidomide on days 1-21 of a 28 day cycle.
- Embodiment 18 is the method of any one of embodiments 14 to 17, wherein the additional cancer treatment is dexamethasone.
- Embodiment 19 is the method of embodiment 18, wherein the additional cancer treatment is dexamethasone at a dose of 20 mg to 40 mg once weekly.
- Embodiment 20 is the method of embodiment 19, wherein the patient is receiving dexamethasone on days 1, 8, 15, and 22 of a 28 day cycle.
- Embodiment 21 is the method of embodiment 19, wherein (i) the patient is less than 75 years old and is receiving dexamethasone at a dose of 40 mg once weekly; or (ii) the patient is at least 75 years old and is receiving dexamethasone at a dose of 20 mg once weekly.
- Embodiment 22 is the method of embodiment 19, wherein (i) the patient has a BMI of at least 18.5 and is receiving dexamethasone at a dose of 40 mg once weekly; or (ii) the patient has a BMI less than 18.5 and is receiving dexamethasone at a dose of 20 mg once weekly.
- Embodiment 23 is the method of any one of the preceding embodiments, further comprising discontinuing administration of belantamab and subsequently administering belantamab mafodotin.
- Embodiment 24 is the method of any one of embodiments 1 to 22, further comprising administering belantamab mafodotin and subsequently discontinuing administration of belantamab.
- Embodiment 25 is the method of embodiment 23 or 24, wherein belantamab mafodotin is administered at a dose of 2.5 mg/kg once every three weeks ⁇ 3 days.
- Embodiment 26 is the method of any one of the preceding embodiments, further comprising administering a lead-in dose of belantamab mafodotin prior to beginning administration of belantamab, wherein the lead-in dose of belantamab mafodotin is about 1.4 mg/kg to about 3.4 mg/kg once during a lead-in period.
- Embodiment 27 is the method of embodiment 26, wherein the lead-in dose of belantamab mafodotin is about 1.4 mg/kg to about 1.9 mg/kg once during a lead-in period.
- Embodiment 28 is the method of embodiment 26, wherein the lead-in dose of belantamab mafodotin is about 1.4 mg/kg, about 1.9 mg/kg, about 2.5 mg/kg, or about 3.4 mg/kg once during a lead-in period.
- Embodiment 29 is the method of embodiment 26, wherein the lead-in dose of belantamab mafodotin is about 1.4 mg/kg once during a lead-in period.
- Embodiment 30 is the method of any one of embodiments 26 to 29, wherein the lead- in period is four weeks ⁇ 3 days and belantamab mafodotin is administered on day 1 of the lead- in period.
- Embodiment 31 is the method of any one of embodiments 26 to 30, further comprising administering at least one additional cancer treatment to the patient during the lead-in period, such as an anti-CD38 monoclonal antibody, a proteasome inhibitor, an immunomodulatory agent, or an anti-PD-1 monoclonal antibody.
- at least one additional cancer treatment such as an anti-CD38 monoclonal antibody, a proteasome inhibitor, an immunomodulatory agent, or an anti-PD-1 monoclonal antibody.
- Embodiment 32 is the method of embodiment 31, wherein the additional cancer treatment is selected from lenalidomide, dexamethasone, daratumumab, isatuximab, pomalidomide, bortezomib, or a combination thereof, such as lenalidomide and dexamethasone.
- Embodiment 33 is the method of embodiment 32, wherein the additional cancer treatment is lenalidomide at a dose of 10 mg to 25 mg once daily for a period of time.
- Embodiment 34 is the method of embodiment 33, wherein lenalidomide is administered to the patient on days 1-21 of the lead-in period.
- Embodiment 35 is the method of any one of embodiments 32 to 34, wherein the additional cancer treatment is dexamethasone.
- Embodiment 36 is the method of embodiment 35, wherein the additional cancer treatment is dexamethasone at a dose of 20 mg to 40 mg once weekly.
- Embodiment 37 is the method of embodiment 36, wherein dexamethasone is administered to the patient on days 1, 8, 15, and 22 of the lead-in period.
- Embodiment 38 is the method of embodiment 36, wherein (i) the patient is less than 75 years old and dexamethasone is administered to the patient at a dose of 40 mg once weekly; or (ii) the patient is at least 75 years old and dexamethasone is administered to the patient at a dose of 20 mg once weekly.
- Embodiment 39 is the method of embodiment 36, wherein (i) the patient has a BMI of at least 18.5 and dexamethasone is administered to the patient at a dose of 40 mg once weekly; or (ii) the patient has a BMI less than 18.5 and dexamethasone is administered to the patient at a dose of 20 mg once weekly.
- Embodiment 40 is a method of treating a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) in a patient, the method comprising administering to a patient belantamab mafodotin at a dose of about 1.4 mg/kg to about 3.4 mg/kg once every eight weeks ⁇ 3 days, such as about 1.4 mg/kg to about 1.9 mg/kg once every eight weeks ⁇ 3 days.
- BCMA B-cell maturation antigen
- Embodiment 41 is the method of embodiment 40, wherein the dose is about 1.4 mg/kg, about 1.9 mg/kg, about 2.5 mg/kg, or about 3.4 mg/kg once every eight weeks ⁇ 3 days.
- Embodiment 42 is a method of treating a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) in a patient, the method comprising administering a therapeutically effective amount of a combination comprising a first BCMA antagonist and a second BCMA antagonist to the patient.
- BCMA B-cell maturation antigen
- Embodiment 43 is the method of embodiment 42, wherein the first and second BCMA antagonists are independently selected from the group consisting of an anti-BCMA antibody or antigen binding fragment thereof, an anti-BCMA antibody-drug conjugate, a bispecific anti-BCMA antibody or antigen binding fragment thereof, and a BCMA-targeted chimeric antigen receptor T (CAR T)-cell therapy.
- the first and second BCMA antagonists are independently selected from the group consisting of an anti-BCMA antibody or antigen binding fragment thereof, an anti-BCMA antibody-drug conjugate, a bispecific anti-BCMA antibody or antigen binding fragment thereof, and a BCMA-targeted chimeric antigen receptor T (CAR T)-cell therapy.
- Embodiment 44 is the method of embodiment 42 or 43, wherein the first and second BCMA antagonists are independently selected from the group consisting of idecabtagene vicleucel, ciltacabtagene autoleucel, teclistamab, REGN5458, belantamab mafodotin, belantamab, SEA-BCMA, ABBV-383, elrantamab, pavurutumab, alnuctamab, MEDI2228, and CC99712.
- the first and second BCMA antagonists are independently selected from the group consisting of idecabtagene vicleucel, ciltacabtagene autoleucel, teclistamab, REGN5458, belantamab mafodotin, belantamab, SEA-BCMA, ABBV-383, elrantamab, pavurutumab, alnuctamab, MEDI2228, and CC99712.
- Embodiment 45 is the method of any one of embodiments 42 to 44, wherein the first BCMA antagonist is belantamab mafodotin.
- Embodiment 46 is the method of any one of embodiments 42 to 44, wherein the first BCMA antagonist is belantamab.
- Embodiment 47 is the method of embodiment 42, wherein the first BCMA antagonist is an anti-BCMA antibody-drug conjugate and the second BCMA antagonist is the corresponding unconjugated anti-BCMA antibody.
- Embodiment 48 is the method of embodiment 47, wherein the anti-BCMA antibodydrug conjugate is selected from the group consisting of belantamab mafodotin, MEDI2228, and CC99712.
- Embodiment 49 is the method of embodiment 48, wherein the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is belantamab.
- Embodiment 50 is a method of treating a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) in a patient, the method comprising administering a therapeutically effective amount of a combination comprising belantamab mafodotin and belantamab to the patient.
- BCMA B-cell maturation antigen
- Embodiment 51 is the method of any one of embodiments 42 to 50, further comprising administering at least one additional cancer treatment to the patient, such as an anti- CD38 monoclonal antibody, a proteasome inhibitor, an immunomodulatory agent, or an anti-PD- 1 monoclonal antibody.
- at least one additional cancer treatment such as an anti- CD38 monoclonal antibody, a proteasome inhibitor, an immunomodulatory agent, or an anti-PD- 1 monoclonal antibody.
- Embodiment 52 is the method of embodiment 51 , wherein the additional cancer treatment is selected from lenalidomide, dexamethasone, daratumumab, isatuximab, pomalidomide, bortezomib, or a combination thereof, such as lenalidomide and dexamethasone.
- Embodiment 53 is a kit comprising: (i) a first B-cell maturation antigen (BCMA) antagonist; and (ii) instructions for use in treating a disease or disorder responsive to inhibiting or blocking BCMA when combined with a second BCMA antagonist.
- BCMA B-cell maturation antigen
- Embodiment 54 is a kit comprising: (i) belantamab mafodotin; and (ii) instructions for use in treating a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) when combined with belantamab.
- BCMA B-cell maturation antigen
- Embodiment 55 is a kit comprising: (i) belantamab; and (ii) instructions for use in treating a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) when combined with belantamab mafodotin.
- BCMA B-cell maturation antigen
- Embodiment 56 is a method of treating a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) in a patient previously treated with a first BCMA antagonist, the method comprising administering a therapeutically effective amount of a second BCMA antagonist to the patient, wherein the patient discontinued administration of the first BCMA antagonist prior to beginning administration of the second BCMA antagonist and the second BCMA antagonist is not the same as the first BCMA antagonist.
- BCMA B-cell maturation antigen
- Embodiment 57 is the method of embodiment 56, wherein the first and second BCMA antagonists are independently selected from the group consisting of an anti-BCMA antibody or antigen binding fragment thereof, an anti-BCMA antibody-drug conjugate, a bispecific anti-BCMA antibody or antigen binding fragment thereof, and a BCMA-targeted chimeric antigen receptor T (CAR T)-cell therapy.
- the first and second BCMA antagonists are independently selected from the group consisting of an anti-BCMA antibody or antigen binding fragment thereof, an anti-BCMA antibody-drug conjugate, a bispecific anti-BCMA antibody or antigen binding fragment thereof, and a BCMA-targeted chimeric antigen receptor T (CAR T)-cell therapy.
- Embodiment 58 is the method of embodiment 56 or 57, wherein the first and second BCMA antagonists are independently selected from the group consisting of idecabtagene vicleucel, ciltacabtagene autoleucel, teclistamab, REGN5458, belantamab mafodotin, belantamab, SEA-BCMA, ABBV-383, elrantamab, pavurutumab, alnuctamab, MEDI2228, and CC99712.
- the first and second BCMA antagonists are independently selected from the group consisting of idecabtagene vicleucel, ciltacabtagene autoleucel, teclistamab, REGN5458, belantamab mafodotin, belantamab, SEA-BCMA, ABBV-383, elrantamab, pavurutumab, alnuctamab, MEDI2228, and CC99712.
- Embodiment 59 is the method of any one of embodiments 56 to 58, wherein the first BCMA antagonist is belantamab mafodotin.
- Embodiment 60 is the method of any one of embodiments 56 to 58, wherein the first BCMA antagonist is belantamab.
- Embodiment 61 is the method of any one of embodiments 56 to 58, wherein the second BCMA antagonist is belantamab mafodotin.
- Embodiment 62 is the method of any one of embodiments 56 to 58, wherein the second BCMA antagonist is belantamab.
- Embodiment 63 is the method of embodiment 56, wherein the first BCMA antagonist is an anti-BCMA antibody-drug conjugate and the second BCMA antagonist is the corresponding unconjugated anti-BCMA antibody.
- Embodiment 64 is the method of embodiment 63, wherein the anti-BCMA antibodydrug conjugate is selected from the group consisting of belantamab mafodotin, MEDI2228, and CC99712.
- Embodiment 65 is the method of embodiment 63, wherein the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is belantamab.
- Embodiment 66 is the method of embodiment 56, wherein the second BCMA antagonist is an anti-BCMA antibody-drug conjugate and the first BCMA antagonist is the corresponding unconjugated anti-BCMA antibody.
- Embodiment 67 is the method of embodiment 66, wherein the anti-BCMA antibodydrug conjugate is selected from the group consisting of belantamab mafodotin, MEDI2228, and CC99712.
- Embodiment 68 is the method of embodiment 66, wherein the second BCMA antagonist is belantamab mafodotin and the first BCMA antagonist is belantamab.
- Embodiment 69 is a method of treating a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) in a patient previously treated with belantamab mafodotin, the method comprising administering a therapeutically effective amount of belantamab to the patient, wherein the patient discontinued administration of belantamab mafodotin prior to beginning administration of belantamab.
- BCMA B-cell maturation antigen
- Embodiment 70 is a method of treating a disease or disorder responsive to inhibiting or blocking B-cell maturation antigen (BCMA) in a patient previously treated with belantamab, the method comprising administering a therapeutically effective amount of belantamab mafodotin to the patient, wherein the patient discontinued administration of belantamab prior to beginning administration of belantamab mafodotin.
- BCMA B-cell maturation antigen
- Embodiment 71 is the method of any one of embodiments 56 to 70, further comprising administering at least one additional cancer treatment to the patient, such as an anti- CD38 monoclonal antibody, a proteasome inhibitor, an immunomodulatory agent, or an anti-PD- 1 monoclonal antibody.
- at least one additional cancer treatment such as an anti- CD38 monoclonal antibody, a proteasome inhibitor, an immunomodulatory agent, or an anti-PD- 1 monoclonal antibody.
- Embodiment 72 is the method of embodiment 71, wherein the additional cancer treatment is selected from lenalidomide, dexamethasone, daratumumab, isatuximab, pomalidomide, bortezomib, or a combination thereof, such as lenalidomide and dexamethasone.
- the additional cancer treatment is selected from lenalidomide, dexamethasone, daratumumab, isatuximab, pomalidomide, bortezomib, or a combination thereof, such as lenalidomide and dexamethasone.
- Embodiment 73 is a method of reducing corneal toxicity in a patient previously treated with a first B-cell maturation antigen (BCMA) antagonist, the method comprising administering a therapeutically effective amount of a second BCMA antagonist to the patient, wherein the patient discontinued administration of the first BCMA antagonist prior to beginning administration of the second BCMA antagonist and the second BCMA antagonist is not the same as the first BCMA antagonist.
- BCMA B-cell maturation antigen
- Embodiment 74 is the method of embodiment 73, wherein the first and second BCMA antagonists are independently selected from the group consisting of an anti-BCMA antibody or antigen binding fragment thereof, an anti-BCMA antibody-drug conjugate, a bispecific anti-BCMA antibody or antigen binding fragment thereof, and a BCMA-targeted chimeric antigen receptor T (CAR T)-cell therapy.
- the first and second BCMA antagonists are independently selected from the group consisting of an anti-BCMA antibody or antigen binding fragment thereof, an anti-BCMA antibody-drug conjugate, a bispecific anti-BCMA antibody or antigen binding fragment thereof, and a BCMA-targeted chimeric antigen receptor T (CAR T)-cell therapy.
- Embodiment 75 is the method of embodiment 73 or 74, wherein the first and second BCMA antagonists are independently selected from the group consisting of idecabtagene vicleucel, ciltacabtagene autoleucel, teclistamab, REGN5458, belantamab mafodotin, belantamab, SEA-BCMA, ABBV-383, elrantamab, pavurutumab, alnuctamab, MEDI2228, and CC99712.
- the first and second BCMA antagonists are independently selected from the group consisting of idecabtagene vicleucel, ciltacabtagene autoleucel, teclistamab, REGN5458, belantamab mafodotin, belantamab, SEA-BCMA, ABBV-383, elrantamab, pavurutumab, alnuctamab, MEDI2228, and CC99712.
- Embodiment 76 is the method of any one of embodiments 73 to 75, wherein the first BCMA antagonist is belantamab mafodotin.
- Embodiment 77 is the method of any one of embodiments 73 to 75, wherein the first BCMA antagonist is belantamab.
- Embodiment 78 is the method of any one of embodiments 73 to 75, wherein the second BCMA antagonist is belantamab mafodotin.
- Embodiment 79 is the method of any one of embodiments 73 to 75, wherein the second BCMA antagonist is belantamab.
- Embodiment 80 is the method of embodiment 73, wherein the first BCMA antagonist is an anti-BCMA antibody-drug conjugate and the second BCMA antagonist is the corresponding unconjugated anti-BCMA antibody.
- Embodiment 81 is the method of embodiment 80, wherein the anti-BCMA antibodydrug conjugate is selected from the group consisting of belantamab mafodotin, MEDI2228, and CC99712.
- Embodiment 82 is the method of embodiment 80, wherein the first BCMA antagonist is belantamab mafodotin and the second BCMA antagonist is belantamab.
- Embodiment 83 is the method of embodiment 73, wherein the second BCMA antagonist is an anti-BCMA antibody-drug conjugate and the first BCMA antagonist is the corresponding unconjugated anti-BCMA antibody.
- Embodiment 84 is the method of embodiment 83, wherein the anti-BCMA antibodydrug conjugate is selected from the group consisting of belantamab mafodotin, MEDI2228, and CC99712.
- Embodiment 85 is the method of embodiment 83, wherein the second BCMA antagonist is belantamab mafodotin and the first BCMA antagonist is belantamab.
- Embodiment 86 is a method of reducing corneal toxicity in a patient previously treated with belantamab mafodotin, the method comprising administering a therapeutically effective amount of belantamab to the patient, wherein the patient discontinued administration of belantamab mafodotin prior to beginning administration of belantamab.
- Embodiment 87 is a method of reducing corneal toxicity in a patient previously treated with belantamab, the method comprising administering a therapeutically effective amount of belantamab mafodotin to the patient, wherein the patient discontinued administration of belantamab prior to beginning administration of belantamab mafodotin.
- Embodiment 88 is the method of any one of embodiments 73 to 87, further comprising administering at least one additional cancer treatment to the patient, such as an anti- CD38 monoclonal antibody, a proteasome inhibitor, an immunomodulatory agent, or an anti-PD- 1 monoclonal antibody.
- at least one additional cancer treatment such as an anti- CD38 monoclonal antibody, a proteasome inhibitor, an immunomodulatory agent, or an anti-PD- 1 monoclonal antibody.
- Embodiment 89 is the method of embodiment 88, wherein the additional cancer treatment is selected from lenalidomide, dexamethasone, daratumumab, isatuximab, pomalidomide, bortezomib, or a combination thereof, such as lenalidomide and dexamethasone.
- Embodiment 90 is a method of treating a disease or disorder in a patient, the method comprising administering a therapeutically effective amount of a combination comprising an antibody-drug conjugate and the corresponding unconjugated antibody.
- Embodiment 91 is a method of treating a disease or disorder in a patient previously treated with an antibody-drug conjugate, the method comprising administering a therapeutically effective amount of the corresponding unconjugated antibody to the patient, wherein the patient discontinued administration of the antibody-drug conjugate prior to beginning administration of the corresponding unconjugated antibody.
- Embodiment 92 is the method of embodiment 90 or 91, wherein the antibody-drug conjugate is selected from gemtuzumab ozogamicin, brentuximab vedotin, ado-trastuzumab emtansine, inotuzumab ozogamicin, polatuzumab vedotin, enfortumab vedotin, fam-trastuzumab deruxtecan, 66andomized66 govitecan, belantamab mafodotin, loncastuximab tesirine, tisotumab vedotin, moxetumomab pasudotox, MEDI2228, or CC99712.
- the antibody-drug conjugate is selected from gemtuzumab ozogamicin, brentuximab vedotin, ado-trastuzumab
- Embodiment 93 is the method of any one of embodiments 1 to 52 or 56 to 92, or the kit of any one of embodiments 53 to 55, wherein the disease or disorder is a plasma cell disorder or a B-cell disorder.
- Embodiment 94 is the method any one of embodiments 1 to 52 or 56 to 92, or the kit of any one of embodiments 53 to 55, wherein the disease or disorder is a BCMA-expressing cancer.
- Embodiment 95 is the method any one of embodiments 1 to 52 or 56 to 92, or the kit of any one of embodiments 53 to 55, wherein the disease or disorder is multiple myeloma (MM).
- Embodiment 96 is the method of embodiment 95, wherein the MM is relapsed and/or refractory MM, newly-diagnosed MM, transplant-ineligible MM, or transplant-ineligible newly- diagnosed MM.
- Embodiment 97 is the kit of embodiment 95, wherein the MM is relapsed and/or refractory MM, newly-diagnosed MM, transplant-ineligible MM, or transplant-ineligible newly- diagnosed MM.
- Embodiment 98 is a method of treating cancer in a patient, wherein the patient has a Grade 1 corneal adverse reaction resulting from belantamab mafadotin administration, the method comprising temporarily discontinuing administration of belantamab mafadotin; administering to the patient a therapeutically effective amount of belantamab for a lead-in period; and resuming administration of belantamab mafadotin after the lead-in period.
- Embodiment 99 is a method of treating cancer in a patient, wherein the patient has a Grade 2 or above corneal adverse reaction resulting from belantamab mafodotin administration, the method comprising temporarily discontinuing administration of belantamab mafadotin; administering to the patient a therapeutically effective amount of belantamab I Ifor a lead-in period; and resuming administration of belantamab mafadotin after the lead-in period.
- Example 1 In Vivo Efficacy of Belantamab in the Treatment of Subcutaneous NCI-H929 Human Multiple Myeloma Model in NOD/SCID Mice.
- NCI-H929 tumor cells were maintained in vitro with RPMI1640 medium supplemented with 10% fetal bovine serum and 0.05mM 0-ME at 37°C in an atmosphere of 5% C0 2 in air. Cells in an exponential growth phase were harvested and counted for tumor inoculation. Each mouse was inoculated subcutaneously in the right front flank region with NCI-H929 tumor cells (5x 10 6 ) in 0.1 ml of PBS mixed with matrigel (1: 1) for tumor development. The randomization started when the mean tumor size reached 121 mm 3 . 80 mice were enrolled in the study. All animals were randomly allocated to 8 study groups.
- Randomization was performed based on “Matched distribution” method (Study DirectorTM software, version 3.1.399.19) randomized block design. The date of randomization was denoted as day 0. The treatment was initiated on the same day of randomization (day 0) per study design.
- the survival time was analyzed by Kaplan-Meier method.
- the event of interest was the animal death.
- the survival time was defined as the time from the day of randomization to the day when the tumor volume reached to 2500 mm 3 .
- MST median survival time
- ILS increased in life-span
- the Kaplan-Meier curves was constructed for each group and the log-rank test was used to compare survival curves between groups. All data were analyzed using SPSS 18.0. P ⁇ 0.05 was considered to be statistically significant.
- Results The tumor volume analysis showed that GSK2857916 at 4 mg/kg and GSK2857914 at 8 mg/kg as the single agent or in combination with different dosing schedules (G2-G8) demonstrated significant anti-tumor efficacy in NCLH929 Xenograft model compared with vehicle (Gl).
- GSK2857916 in combination with GSK2857914 (G4 and G6) showed significant improved anti-tumor efficacy compared with the single agent of GSK2857916 (G2).
- the tumor volume growth curves between randomization grouping and study termination are shown in FIG. 1.
- Tumor growth inhibition (TGI) from data collected on day 24 is provided in Table 5.
- GSK2857916 at 4 mg/kg and GSK2857914 at 8 mg/kg as the single agent or in combination with different dosing schedules significantly increased the life-span of mice in NCI-H929 Xenograft model compared with vehicle (Gl).
- GSK2857916 in combination with GSK2857914 (G4 and G6) could further increase the life-span of mice compared with the single agent of GSK2857916 (G2).
- Kaplan-Meier survival curves for all treatment groups as a function of study day are shown in FIG. 2. Median survival day for mice in each group is provided in Table 6.
- Example 2 Phase 1/2 Study to Evaluate the Safety and Efficacy of Belantamab in Multiple Myeloma .
- Part 1 is a Phase 1 open-label study evaluating the safety, tolerability, and clinical activity of escalating doses of single agent belantamab in participants with RRMM who have received at least 3 prior lines of treatment to determine the recommended part 2 dose.
- Belantamab is dosed twice a cycle on Days 1 and 15 of a 28-day cycle, starting at a dose of 300 mg IV.
- Dose escalation is guided by modified toxicity probability interval to 900 mg and then to the maximum dose of 2000 mg according to a dose escalation plan and as directed by a dose escalation committee.
- the exploration of an additional intermediate dose is allowed if suggested by the dose escalation committee and agreed upon by the Medical Monitor and treating investigators.
- the progression from one dose level to another and the recommended Part 2 doses are based on the totality of available data from Part 1 of belantamab treatment; the dose escalation committee takes into consideration, in particular, the safety and tolerability of each dose level, available PK and PD data and preliminary efficacy to recommend two dose levels to further characterize in Part 2.
- Participants are dosed until progressive disease (PD) after which they have the option to receive treatment with single agent belantamab mafodotin (Part IB) at 2.5 mg/kg Q3W.
- Participants who opt to be treated with belantamab mafodotin following the first PD proceed with an end of treatment (EOT) visit before starting belantamab mafodotin treatment, and then continue to be monitored for safety, tolerability and disease response during belantamab mafodotin treatment until the next PD.
- EOT end of treatment
- Participants who opt out of belantamab mafodotin treatment after the first PD terminate the treatment and proceed with the EOT visit and follow-up safety monitoring.
- the belantamab treatment duration is until first PD (followed by optional belantamab mafodotin treatment until second PD), unacceptable toxicity, or any other treatment termination criteria.
- the treatment duration could be up to approximately 8 months.
- the visit frequency is every 2 weeks from Cycle 3 forward. More visits are scheduled in Cycles 1 and 2.
- Part 2 is a 2-arm safety run-in randomized, open-label study evaluating the safety, tolerability, and clinical activity of 1 cycle of belantamab mafodotin-xRd (belantamab mafodotin, treatment x, lenalidomide, and dexamethasone) followed by continuous treatment with belantamab-xRd (belantamab, treatment x, lenalidomide, and dexamethasone) in participants with recurrent MM who have received at least 1 prior line of treatment (2L+).
- belantamab mafodotin-xRd belantamab mafodotin, treatment x, lenalidomide, and dexamethasone
- treatment x includes, but is not limited to, a combination of an anti-CD38 antibody such as daratumumab or isatuximab) and a gamma secretase inhibitor such as nirogacestat. In some cases, treatment x includes, but is not limited to, a proteasome inhibitor such as bortezomib.
- the combination treatment xRd includes lenalidomide (R) and dexamethasone (d).
- the selection of treatment x is based on data from on-going belantamab mafodotin clinical studies and is either a standard of care or an emerging treatment for MM.
- the belantamab doses are based on the totality of available Part 1 data. Two different dose levels of belantamab (Arms A and B) are dosed every 4 weeks. More frequent dosing is used if justified by Part 1 data based on safety, tolerability, PK/PD modelling or other data.
- Part 2 of the study assesses overall safety events and tolerability and corneal adverse events for 10 parti cipants/ Arm after 3 cycles of treatment. Participants are considered evaluable for safety and tolerability if they have completed at least 3 cycles of treatment including one cycle of belantamab mafodotin-xRd followed by 2 cycles of belantamab-xRd. Participants not meeting the definition of evaluable may be replaced if they withdraw for reason other than treatment related adverse event, death or PD. The totality of data from Part 1 and Part 2 are used to determine the belantamab recommended Phase 2 dose(s) to be used in Part 3.
- the treatment duration is until PD, unacceptable toxicity, or any other treatment termination criteria.
- the treatment duration could be up to approximately 15 months.
- the visit frequency is every 4 weeks from Cycle 3 unless data from Part 1 and from on-going belantamab mafodotin clinical trials suggest more frequent dosing with administration of belantamab-xRd. More visits are planned during Cycles 1 and 2.
- Part 3 is a 4-arm Phase 2 randomized, open-label study evaluating the safety and efficacy of continuous belantamab-xRd following treatment with 1 cycle of belantamab mafodotin-xRd in participants with TI-NDMM. Cycle length is 4 weeks. Two different doses of belantamab (Arms A and B) are dosed every 4 weeks. The belantamab dose levels are selected based on the totality of available data from Parts 1 and 2 and may be different to the ones administered in Part 2; the selection process by the dose escalation committee takes into consideration the overall safety and tolerability of the combination, available PK/PD data and evidence of efficacy of the different dose levels.
- belantamab mafodotin and xRd doses are the same in Arms A and B: a single dose of belantamab mafodotin at 1.4 mg/kg administered in combination with treatment x, lenalidomide at 25 or 10 mg once daily (on days 1-21 of the cycle), and dexamethasone at 40 mg once daily (on days 1, 8, 15, and 22 of the cycle) (or 20 mg if age ⁇ 75 years or BMI ⁇ 18.5).
- Part 3 also tests the outcome of: 1) treatment with continuous dosing of belantamab mafodotin-xRd (Arm C), and 2) treatment with a continuous dosing of belantamab-xRd in absence of the belantamab mafodotin-xRd initial dose (Arm D).
- belantamab mafodotin is dosed once every two 28-days cycles (Q8W) at a dose of 1.4 mg/kg in combination with treatment x, lenalidomide at 25 or 10 mg once daily (on days 1-21 of the cycle), and dexamethasone at 40 mg once daily (on days 1, 8, 15, and 22 of the cycle) (or 20 mg if age ⁇ 75 years or BMI ⁇ 18.5).
- belantamab is administered once per 28-day cycle in combination with treatment x, lenalidomide at 25 or 10 mg once daily (on days 1-21 of the cycle), and dexamethasone at 40 mg once daily (on days 1, 8, 15, and 22 of the cycle) (or 20 mg if age ⁇ 75 years or BMI ⁇ 18.5).
- participant A or B or C or D are randomised 1 : 1 : 1 : 1 to either Arm A or B or C or D with the aim to obtain data on 20 evaluable participants per arm. Participants are considered evaluable if they have completed at least 4 cycles of treatment, including one cycle of belantamab mafodotin-xRd followed by 3 cycles of belantamab-xRd. Participants not meeting the definition of evaluable may be replaced if they withdraw for reason other than treatment related adverse event, death or disease progression.
- the xRd doses are the same in all four arms of the study, while the belantamab mafodotin and belantamab doses and dosing frequencies may differ in Arm C and Arm D, respectively, compared to the ones in Arms A and B.
- the study terminates 18 months after last subject first dose. At that time, data collection for all recruited participants who no longer receive study treatment stops and the clinical trial database is closed. If the disease has not progressed at time of study termination, participants who continue benefitting by the treatment as suggested by the investigator are transferred in a post- analysis-continual-treatment study to continue receiving treatment. Under these circumstances, the
- the visit frequency is every 4 weeks starting from Cycle 3, unless data from Parts 1 and 2 and from on-going belantamab mafodotin clinical trials suggest more frequent dosing with belantamab-xRd. More visits are planned during Cycles 1 and 2.
- a standard of care (SoC) treatment or emerging MM treatment is also administered as provided in Table 8.
- the infusion duration may be adjusted to 30-60 mins.
- Premedication e.g., systemic corticosteroids
- Premedication is not required unless deemed medically necessary by the investigator, in which case it should be administered according to institutional recommendations.
- Infusions may be prolonged in the event of an infusion reaction. If multiple participants experience clinically significant infusion reactions, the infusion rate may be slowed for all future administrations of study treatment for all participants. Should this global change in infusion rate be required, it will be communicated to the sites in writing.
- Part 3 Arm C continuous belantamab mafodotin is administered 1.4 mg/kg Q8W, and based on emerging data from ongoing belantamab mafodotin trials, the dose level may be increased to 1.9 mg/kg Q8W unless data supports more frequent administration.
- the initial dose(s) match Parts A and B with the ongoing dose selected based on considerations of data from other studies and clinical experience with belantamab mafodotin.
- Lenalidomide is administered as 25 mg PO daily on days 1-21 of each 28-day cycle, in participants with CLcr of >60 mL/min (by Cockcroft-Gault). The dose of lenalidomide will be reduced to 10 mg daily on Days 1 to 21 in participants with CLcr of 30-60 mL/min. Lenalidomide is administered at a fixed dose level, with no adjustments needed for body weight or BSA.
- lenalidomide On lenalidomide and belantamab/belantamab mafodotin co-administration days, lenalidomide should be administered as close as possible to the end of the 1-2 hours rest period after administration of belantamab/belantamab mafodotin, and on PK days no later than 6 hours after the end of the rest period after administration of belantamab/belantamab mafodotin.
- Dexamethasone will be given at 40 mg (or 20 mg if age ⁇ 75 years or BMI ⁇ 18.5 kg/m 2 ) weekly PO on Days 1, 8, 15 and 22 of each cycle.
- Part 1 Participants who have received at least 3 prior lines of anti-myeloma treatments, and have already received an immunomodulating agent, a proteasome inhibitor, and an anti-CD38 mAb (unless contraindicated or unavailable). Lines of therapy are defined by consensus panel of the International Myeloma Workshop.
- Part 2 Participants who meet all of the following: (1) have undergone autologous stem cell transplant (ASCT) or are considered transplant ineligible; (2) have been previously treated with at least one prior line of MM therapy; (3) have documented disease progression during or after their most recent therapy.
- ASCT autologous stem cell transplant
- Part 3 Participants who meet both of the following: (1) NDMM with a requirement for treatment as documented per IMWG criteria; and (2) not considered a candidate for high dose chemotherapy with ASCT due to: (a) Age 65 years; or (b) age 18-65 years with presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT or who refuse high-dose chemotherapy with ASCT as an initial treatment.
- [00392] 4. Eastern cooperative oncology group-performance status (ECOG-PS) of 0-2. [00393] 5. Measurable disease defined as at least ONE of the following: (a) serum M-protein concentration 0.5 g/dL ( ⁇ 5 g/L); (b) urine M-protein excretion -'200 mg/24 hours ( '0.2 g/24 hours); or (c) serum free light chain (FLC) assay: involved FLC level ⁇ 10 mg/dL ( ' 100 mg/L) and an abnormal serum FLC ratio ( ⁇ 0.26 or >1.65).
- FLC serum free light chain
- Laboratory results obtained during screening should be used to determine eligibility criteria. In situations where laboratory results are outside the permitted range, the investigator may re-test the participant and the subsequent within range screening result may be used to confirm eligibility.
- Grade ⁇ 1 at the time of screening except for alopecia any grade
- neuropathy Grade ⁇ 2
- endocrinopathy managed with replacement therapy any grade
- Participant is exhibiting signs of meningeal or central nervous system involvement with MM.
- Evidence of cardiovascular risk including any of the following: (a) Evidence of current clinically significant untreated arrhythmias, including, but not limited to, clinically significant ECG abnormalities such as 2nd degree (Mobiz Type II) or 3rd degree AV block; (b) QTcF interval >450 msec (QT interval corrected for heart rate according to Fridericia’s formula), and/or hypokalemia, and/or family history of long QT syndrome (for Part 1); (c) History of MI, acute coronary syndromes (including unstable angina), coronary angioplasty, stenting or bypass grafting, all within three months of screening; (d) Class III or IV heart failure as defined by the NYHA functional classification system; (e) Uncontrolled hypertension.
- ECG abnormalities such as 2nd degree (Mobiz Type II) or 3rd degree AV block
- Part 1 and 2 Refractory to belantamab mafodotin (confirmed PD as per IMWG criteria while on belantamab mafodotin therapy or within 60 days of completing that treatment). Prior belantamab mafodotin is allowed if it was discontinued due to toxicity which subsequently resolved. Note: Prior treatment with other Anti-BCMA directed agents is allowed.
- Part 1 and 2 Refractoriness to prior standard anti-myeloma therapies including lenalidomide is allowed for other mAbs within 30 days or systemic anti-myeloma therapy within 14 days of first dose of study drug.
- Focal palliative radiation is permitted prior to enrolment, provided it occurred at least 2 weeks prior to the first dose of study intervention, that the participant has recovered from radiation-related toxicities, and that the participant did not require corticosteroids for radiation- induced AEs.
- [00427] 25 Has received transfusion of blood products (including platelets or red blood cells) or administration of colony stimulating factors (including G-CSF, GMCSF, recombinant erythropoietin) or any thrombopoietin receptor agonists within 2 weeks before the first dose of study drug.
- blood products including platelets or red blood cells
- colony stimulating factors including G-CSF, GMCSF, recombinant erythropoietin
- any thrombopoietin receptor agonists within 2 weeks before the first dose of study drug.
- live vaccines include, but are not limited to the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, BCG, and typhoid vaccine.
- Seasonal influenza and COVID-19 vaccines for injection are not live or attenuated virus vaccines and are allowed; however, intranasal influenza vaccines (for example, FluMist) are live attenuated vaccines and are not allowed.
- Lenalidomide capsules should be swallowed whole with water; the capsules should not be opened, broken, or chewed.
- Lenalidomide should be taken orally at approximately the same time each day.
- Lenalidomide capsules contain lactose. The risk-benefit of should be evaluated in participants with lactose intolerance.
- Participants will abstain from ingesting caffeine- or xanthine- containing products (e.g., coffee, tea, cola drinks, and chocolate) for 24 hours before clinic visits on days scheduled for periodic PK and pharmacodynamic sample collection throughout the study.
- caffeine- or xanthine- containing products e.g., coffee, tea, cola drinks, and chocolate
- Dose modifications may be made for individual participants, based on safety findings for that participant. After Cycle 1, participants may have their belantamab or belantamab mafodotin dose reduced or delayed due to toxicities, including corneal events/toxicity. [00439] If a dose is delayed, the participant should wait for the next scheduled dose to resume treatment. In individual cases, where in the judgment of the investigator waiting a full cycle to resume treatment after delay (skipping dose) related to toxicity which has resolved would be detrimental to the participant’s health, the investigator should contact the Medical Monitor to discuss an earlier re-start. An earlier re-start may be considered only for participants who have recovered from toxicity to at most Grade 1.
- Dosing delays are permitted in the case of medical/surgical events or for logistical reasons not related to study therapy (e.g., elective surgery, unrelated medical events, participant vacation, and/or holidays, but not for participants’ decision to delay treatment).
- the reason for any dose delay must be documented in the participant’s eCRF and clinic record and discussed with the Medical Monitor.
- Part 1 the decision to proceed to the next dose level of belantamab (either an increase or a decrease) will be made by the DEC based on safety, tolerability, and preliminary PK data obtained in participants at the prior dose level.
- mice Female severe combined immunodeficient (SCID) mice were nine weeks old with a body weight range of 15.6 to 23.8 grams on Day 1 of the study.
- H929 human plasmacytoma cell line was obtained from the American Type Culture Collection (ATCC). The cells were maintained as exponentially growing suspension cultures in RPMI 1640 medium supplemented with 20% fetal bovine serum, 2 mM glutamine, 50 pM mercaptoethanol, 100 units/mL sodium penicillin G, 100 pg/mL streptomycin sulfate, and 25 pg/mL gentamicin.
- the tumor cells were cultured in tissue culture flasks in a humidified incubator at 37 °C, in an atmosphere of 5% CO2 and 95% air.
- Example 4 Evaluation of soluble BCMA (sBCMA) levels in relapsed/refractory multiple myeloma (RRMM) patients treated with belantamab mafodotin
- Soluble BCMA (sBCMA) levels were analyzed as an exploratory endpoint in patients enrolled in a phase III open-label randomized clinical trial evaluating the safety and efficacy of single agent belantamab mafodotin compared to a combination of pomalidomide dexamethasone in participants with RRMM (DREAMM-3 study; NCT04162210).
- sBCMA Soluble BCMA
- Serum samples were obtained from patients in both study arms at the following timepoints relative to belantamab mafodotin infusion: pre-dose, at end of infusion, 2 hours postinfusion, 24 hours post-infusion, 4 days post- infusion, and 8-15 days post- infusion.
- sBCMA levels in cell supernatants were measured using a validated electrochemiluminescent immunoassay.
- sBCMA levels are impacted by treatment with belantamab mafodotin.
- Analysis of sBCMA levels in patients treated with belantamab mafodotin versus pom/dex demonstrated a difference in sBCMA levels between the two treatment arms with sBCMA levels being impacted specifically by belantamab mafodotin treatment compared to pom/dex treatment.
- progression free survival (PFS) of patients in the highest quartile (Q4) of baseline sBCMA levels was the lowest in both treatment arms, indicating a worse response to treatment.
- Belantamab mafodotin binds sBCMA in patient samples.
- sBCMA levels were measured at the end of infusion (EOI) of belantamab mafodotin in participants in the belantamab mafodotin treatment arm.
- EOI end of infusion
- Patient samples were obtained within 30 minutes following the end of infusion of belantamab mafodotin and sBCMA levels in the samples were measured. Based on sBCMA levels detected at EOI, it was determined that belantamab mafodotin substantially bound all sBCMA in the periphery at a dose level of 2.5 mg/kg. See FIG.
- sBCMA is immediately bound following belantamab mafodotin infusion, but sBCMA levels rebound 24 hours later.
- sBCMA levels were detected to be increasing in participants treated with belantamab mafodotin at 24 hours post-end of infusion (EOI) of belantamab mafodotin. While a linear decrease in sBCMA levels was observed, an exponential increase in sBCMA levels was observed 24 hours later suggesting that sBCMA rebound is non-linear with baseline level of sBCMA and follows a different pattern than the decrease of sBCMA levels (FIG. 6).
- sBCMA levels observed at 24 hours post-EOI is not due solely to dissociation of sBCMA from belantamab mafodotin because the half-life of sBCMA is approximately 24 hours suggesting that the majority of the increase in sBCMA levels is due to fresh shedding from tumor cells.
- patients with progressive disease (PD) had the highest baseline sBCMA levels, but there was a large overlap observed in baseline sBCMA levels between responders and nonresponders (FIG. 7A).
- Example 5 In Vivo Efficacy of Belantamab and Belantamab Mafodotin in the Treatment of Human Multiple Myeloma Xenograft Model in NOG Mice
- MM.1 S-Luc cancer cells were maintained in vitro with RMPI1640 medium supplemented with 10% fetal bovine serum and 1% sodium pyruvate + 1% L-glutamine + 1% penicillin-streptomycin at 37°C in an atmosphere of 5% CO2. The cells in exponential growth phase were harvested and quantitated by cell counter before tumor inoculation.
- Tumor inoculation Each mouse was inoculated intravenously via tail vein with MM.1S-Luc tumor cells (1 x 10 7 ) in 0.1 mL PBS for tumor development. Mice were imaged 7 days after tumor cell inoculation and randomly allocated to seven study groups.
- mice were dosed by intraperitoneal (ip) administration in the amount and at the frequency and duration shown in Table 11.
- Tumor monitoring Tumor growth was imaged twice per week by bioluminescent imaging. At 15 minutes prior to imaging, mice were injected subcutaneously with D-Luciferin (PerkinElmer, Catalog Number 122799) at 150 mg/kg. Mice were imaged on a PerkinElmer IVIS Lumina Series III in vivo imaging system.
- GSK2857916 in combination with GSK2857914 (Groups 3 and 4) and GSK2857916 in combination with nirogacestat (Group 5) significantly prolonged animals’ survival (Median Survival Day 54.5, 58.00, and 53.50, respectively), compared with vehicle control group (Median Survival Day 25.00).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La divulgation concerne des méthodes de traitement d'une maladie ou d'un trouble sensible à l'inhibition ou au blocage de l'antigène de maturation des lymphocytes B (BCMA) par l'administration d'un ou de plusieurs antagonistes BCMA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263430249P | 2022-12-05 | 2022-12-05 | |
US63/430,249 | 2022-12-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024121711A1 true WO2024121711A1 (fr) | 2024-06-13 |
Family
ID=89221982
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2023/062182 WO2024121711A1 (fr) | 2022-12-05 | 2023-12-04 | Méthodes de traitement au moyen d'antagonistes d'antigène de maturation des lymphocytes b |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024121711A1 (fr) |
Citations (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
WO1993021232A1 (fr) | 1992-04-10 | 1993-10-28 | Research Development Foundation | IMMUNOTOXINES DIRIGEES CONTRE DES ANTIGENES DE SURFACE APPARENTEES A c-erbB-2(HER-2/neu) |
EP1391213A1 (fr) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions et méthodes pour le traitement du cancer en utilisant un conjugué d'un anticorps contre le CD44 avec un maytansinoide et des agents chimiothérapeutiques |
US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
WO2012163805A1 (fr) | 2011-05-27 | 2012-12-06 | Glaxo Group Limited | Protéines de liaison à bcma (cd269/tnfrsf17) |
WO2013072406A1 (fr) | 2011-11-15 | 2013-05-23 | Amgen Research (Munich) Gmbh | Molécules de liaison pour bcma et cd3 |
WO2013154760A1 (fr) | 2012-04-11 | 2013-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Récepteurs antigéniques chimériques ciblant un antigène de maturation des lymphocytes b |
WO2014068079A1 (fr) | 2012-11-01 | 2014-05-08 | Max-Delbrück-Centrum für Molekulare Medizin | Anticorps qui se lie à cd269 (bcma) pouvant être utilisé dans le traitement de maladies des cellules plasmatiques comme le myélome multiple et les maladies auto-immunes |
WO2014089335A2 (fr) | 2012-12-07 | 2014-06-12 | Amgen Inc. | Protéines de liaison à l'antigène bcma |
WO2014122144A1 (fr) | 2013-02-05 | 2014-08-14 | Engmab Ag | Anticorps bispécifiques anti-cd3ɛ et bcma |
WO2014140248A1 (fr) | 2013-03-15 | 2014-09-18 | Amgen Research (Munich) Gmbh | Molécules liantes pour bcma et cd3 |
WO2015052536A1 (fr) | 2013-10-10 | 2015-04-16 | Ucl Business Plc | Molécule |
WO2015158671A1 (fr) | 2014-04-14 | 2015-10-22 | Cellectis | Récepteurs antigéniques chimériques spécifiques de bcma (cd269), utiles dans l'immunothérapie du cancer |
WO2015166649A1 (fr) | 2014-04-28 | 2015-11-05 | 株式会社ブリヂストン | Pneu à carcasse diagonale et son procédé de fabrication |
WO2016014565A2 (fr) | 2014-07-21 | 2016-01-28 | Novartis Ag | Traitement du cancer au moyen d'un récepteur d'antigène chimérique anti-bcma humanisé |
WO2016014789A2 (fr) | 2014-07-24 | 2016-01-28 | Bluebird Bio, Inc. | Récepteurs de l'antigène chimérique bcma |
WO2016020332A1 (fr) | 2014-08-04 | 2016-02-11 | Engmab Ag | Anticorps bispécifiques anti cd3epsilon et bcma |
WO2016079177A1 (fr) | 2014-11-20 | 2016-05-26 | Engmab Ag | Anticorps bispécifiques anti-cd3epsilon et bcma |
WO2016090327A2 (fr) | 2014-12-05 | 2016-06-09 | Memorial Sloan-Kettering Cancer Center | Anticorps ciblant l'antigène de maturation des lymphocytes b et procédés d'utilisation |
WO2016090320A1 (fr) | 2014-12-05 | 2016-06-09 | Memorial Sloan-Kettering Cancer Center | Récepteurs antigéniques chimériques ciblant l'antigène de maturation des cellules b et leurs utilisations |
WO2017021450A1 (fr) | 2015-08-03 | 2017-02-09 | Engmab Ag | Anticorps monoclonaux dirigés contre bcma |
WO2017051068A1 (fr) | 2015-09-22 | 2017-03-30 | Nokia Technologies Oy | Photodétecteur à canal conducteur fabriqué à partir d'un matériau bidimensionnel et son procédé de fabrication |
US20170165373A1 (en) | 2012-12-07 | 2017-06-15 | Amgen Inc. | Bcma antigen binding proteins |
WO2018201051A1 (fr) | 2017-04-28 | 2018-11-01 | Novartis Ag | Agent ciblant le bcma et polythérapie incluant un inhibiteur de gamma-sécrétase |
WO2021024133A2 (fr) | 2019-08-06 | 2021-02-11 | Glaxosmithkline Intellectual Property Development Limited | Compositions biopharmaceutiques et procédés associés |
US20220168417A1 (en) * | 2019-04-10 | 2022-06-02 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy with an anti bcma antibody and a gamma secretase inhibitor |
-
2023
- 2023-12-04 WO PCT/IB2023/062182 patent/WO2024121711A1/fr unknown
Patent Citations (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
WO1993021232A1 (fr) | 1992-04-10 | 1993-10-28 | Research Development Foundation | IMMUNOTOXINES DIRIGEES CONTRE DES ANTIGENES DE SURFACE APPARENTEES A c-erbB-2(HER-2/neu) |
US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
EP1391213A1 (fr) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions et méthodes pour le traitement du cancer en utilisant un conjugué d'un anticorps contre le CD44 avec un maytansinoide et des agents chimiothérapeutiques |
US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
WO2012163805A1 (fr) | 2011-05-27 | 2012-12-06 | Glaxo Group Limited | Protéines de liaison à bcma (cd269/tnfrsf17) |
WO2013072406A1 (fr) | 2011-11-15 | 2013-05-23 | Amgen Research (Munich) Gmbh | Molécules de liaison pour bcma et cd3 |
WO2013072415A1 (fr) | 2011-11-15 | 2013-05-23 | Amgen Research (Munich) Gmbh | Molécules de liaison pour bcma et cd3 |
WO2013154760A1 (fr) | 2012-04-11 | 2013-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Récepteurs antigéniques chimériques ciblant un antigène de maturation des lymphocytes b |
WO2014068079A1 (fr) | 2012-11-01 | 2014-05-08 | Max-Delbrück-Centrum für Molekulare Medizin | Anticorps qui se lie à cd269 (bcma) pouvant être utilisé dans le traitement de maladies des cellules plasmatiques comme le myélome multiple et les maladies auto-immunes |
WO2014089335A2 (fr) | 2012-12-07 | 2014-06-12 | Amgen Inc. | Protéines de liaison à l'antigène bcma |
US20170165373A1 (en) | 2012-12-07 | 2017-06-15 | Amgen Inc. | Bcma antigen binding proteins |
WO2014122144A1 (fr) | 2013-02-05 | 2014-08-14 | Engmab Ag | Anticorps bispécifiques anti-cd3ɛ et bcma |
WO2014122143A1 (fr) | 2013-02-05 | 2014-08-14 | Engmab Ag | Procédé de sélection d'anticorps anti-bcma |
WO2014140248A1 (fr) | 2013-03-15 | 2014-09-18 | Amgen Research (Munich) Gmbh | Molécules liantes pour bcma et cd3 |
WO2015052536A1 (fr) | 2013-10-10 | 2015-04-16 | Ucl Business Plc | Molécule |
WO2015158671A1 (fr) | 2014-04-14 | 2015-10-22 | Cellectis | Récepteurs antigéniques chimériques spécifiques de bcma (cd269), utiles dans l'immunothérapie du cancer |
WO2015166649A1 (fr) | 2014-04-28 | 2015-11-05 | 株式会社ブリヂストン | Pneu à carcasse diagonale et son procédé de fabrication |
WO2016014565A2 (fr) | 2014-07-21 | 2016-01-28 | Novartis Ag | Traitement du cancer au moyen d'un récepteur d'antigène chimérique anti-bcma humanisé |
WO2016014789A2 (fr) | 2014-07-24 | 2016-01-28 | Bluebird Bio, Inc. | Récepteurs de l'antigène chimérique bcma |
WO2016020332A1 (fr) | 2014-08-04 | 2016-02-11 | Engmab Ag | Anticorps bispécifiques anti cd3epsilon et bcma |
WO2016079177A1 (fr) | 2014-11-20 | 2016-05-26 | Engmab Ag | Anticorps bispécifiques anti-cd3epsilon et bcma |
WO2016090327A2 (fr) | 2014-12-05 | 2016-06-09 | Memorial Sloan-Kettering Cancer Center | Anticorps ciblant l'antigène de maturation des lymphocytes b et procédés d'utilisation |
WO2016090320A1 (fr) | 2014-12-05 | 2016-06-09 | Memorial Sloan-Kettering Cancer Center | Récepteurs antigéniques chimériques ciblant l'antigène de maturation des cellules b et leurs utilisations |
WO2017021450A1 (fr) | 2015-08-03 | 2017-02-09 | Engmab Ag | Anticorps monoclonaux dirigés contre bcma |
WO2017051068A1 (fr) | 2015-09-22 | 2017-03-30 | Nokia Technologies Oy | Photodétecteur à canal conducteur fabriqué à partir d'un matériau bidimensionnel et son procédé de fabrication |
WO2018201051A1 (fr) | 2017-04-28 | 2018-11-01 | Novartis Ag | Agent ciblant le bcma et polythérapie incluant un inhibiteur de gamma-sécrétase |
US20220168417A1 (en) * | 2019-04-10 | 2022-06-02 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy with an anti bcma antibody and a gamma secretase inhibitor |
WO2021024133A2 (fr) | 2019-08-06 | 2021-02-11 | Glaxosmithkline Intellectual Property Development Limited | Compositions biopharmaceutiques et procédés associés |
Non-Patent Citations (36)
Title |
---|
"GenBank", Database accession no. Q02223.2 |
ADAMS GREGORY P ET AL: "Monoclonal antibody therapy of cancer", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP US, NEW YORK, vol. 23, no. 9, 1 September 2005 (2005-09-01), pages 1147 - 1157, XP002456710, ISSN: 1087-0156, DOI: 10.1038/NBT1137 * |
ALHALLAK ET AL., CANCERS, vol. 13, 2021, pages 2853 |
BECK A. ET AL., NATURE REV. DRUG DISC., vol. 16, 2017, pages 315 - 337 |
BO YU ET AL: "BCMA-targeted immunotherapy for multiple myeloma", JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 13, no. 1, 17 September 2020 (2020-09-17), XP055735685, DOI: 10.1186/s13045-020-00962-7 * |
CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 877 - 883 |
FU ZHIWEN ET AL: "Antibody drug conjugate: the "biological missile" for targeted cancer therapy", SIGNAL TRANSDUCTION AND TARGETED THERAPY, vol. 7, no. 1, 1 December 2022 (2022-12-01), XP093049353, ISSN: 2095-9907, DOI: 10.1038/s41392-022-00947-7 * |
GARRIDO PANIAGUA SARA ET AL: "Secondary effects after belantamab treatment: A new anti-B-cell maturation antigen monoclonal antibody for multiple myeloma", EJHAEM, vol. 2, no. 3, 7 August 2021 (2021-08-07), pages 646 - 647, XP093126419, ISSN: 2688-6146, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1002/jha2.205> DOI: 10.1002/jha2.205 * |
HARTLEY-BROWN MONIQUE ET AL: "Monoclonal Antibodies in Myeloma : Optimizing Targeted Therapy", CANCER JOURNAL, vol. 27, no. 3, 1 May 2021 (2021-05-01), US, pages 222 - 230, XP055962840, ISSN: 1528-9117, Retrieved from the Internet <URL:http://dx.doi.org/10.1097/PPO.0000000000000521> DOI: 10.1097/PPO.0000000000000521 * |
HINMAN ET AL., CANCER RES., vol. 53, 1993, pages 3336 - 3342 |
HOLLIGERHUDSON, NATURE BIOTECHNOLOGY, vol. 23, no. 9, 2005, pages 1137 - 1146 |
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1987, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF |
KLEBER MARTINA ET AL: "BCMA in Multiple Myeloma-A Promising Key to Therapy", JOURNAL OF CLINICAL MEDICINE, vol. 10, no. 18, 1 January 2021 (2021-01-01), CH, pages 4088, XP093126491, ISSN: 2077-0383, DOI: 10.3390/jcm10184088 * |
KUMAR SPAIVA BANDERSON KC ET AL.: "International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma", LANCET ONCOL, vol. 17, no. 8, 2016, pages e328 - 46, XP029663519, DOI: 10.1016/S1470-2045(16)30206-6 |
LAMBERT, J., CURR. OPINION IN PHARMACOLOGY, vol. 5, 2005, pages 543 - 549 |
LIU ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 8618 - 8623 |
LODE ET AL., CANCER RES., vol. 58, 1998, pages 2928 |
MANDLER ET AL., BIOCONJUGATE CHEM, vol. 13, 2002, pages 786 - 791 |
MANDLER ET AL., BIOORGANIC & MED. CHEM. LETTERS, vol. 10, 2000, pages 1025 - 1028 |
MANDLER ET AL., J. NAT. CANCER INST., vol. 92, no. 19, 2000, pages 1573 - 1581 |
MARKHAM ANTHONY: "Belantamab Mafodotin: First Approval", DRUGS, vol. 80, no. 15, 16 October 2020 (2020-10-16), NZ, pages 1607 - 1613, XP055975324, ISSN: 0012-6667, Retrieved from the Internet <URL:https://link.springer.com/article/10.1007/s40265-020-01404-x/fulltext.html> DOI: 10.1007/s40265-020-01404-x * |
MONTES DE OCA ROCIO ET AL: "Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo", MOLECULAR CANCER THERAPEUTICS, vol. 20, no. 10, 12 July 2021 (2021-07-12), US, pages 1941 - 1955, XP093072531, ISSN: 1535-7163, Retrieved from the Internet <URL:https://aacrjournals.org/mct/article-pdf/20/10/1941/3198522/1941.pdf> DOI: 10.1158/1535-7163.MCT-21-0035 * |
MORÈ SONIA ET AL: "Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment", PHARMACEUTICALS, vol. 16, no. 11, 1 November 2023 (2023-11-01), CH, pages 1628, XP093126317, ISSN: 1424-8247, DOI: 10.3390/ph16111628 * |
NICULESCU-DUVAZSPRINGER, ADV. DRUG DELIV. REV., vol. 26, 1997, pages 151 - 172 |
PAUL G. RICHARDSON: "P-212: DREAMM-5 platform trial: Belantamab mafodotin (belamaf; GSK2857916) in combination with five different novel agents in patients with relapsed/refractory multiple myeloma (RRMM)", CLINICAL LYMPHOMA MYELOMA AND LEUKEMIA, vol. 21, 1 October 2021 (2021-10-01), NL, pages S156, XP093153308, ISSN: 2152-2650, Retrieved from the Internet <URL:https://dx.doi.org/10.1016/S2152-2650(21)02339-9> DOI: 10.1016/S2152-2650(21)02339-9 * |
PAYNE, G., CANCER CELL, vol. 3, 2003, pages 207 - 212 |
PILLARISETTI ET AL., BLOOD ADVANCES, vol. 4, 2020, pages 4538 - 49 |
ROCIO MONTES DE OCA ET AL: "Combinations of belantamab mafodotin with lenalidomide, pomalidomide, bortezomib and/or dexamethasone synergize in vitro and potentiate in vivo anti-tumor activity in multiple myeloma", INTERNET CITATION, 10 September 2021 (2021-09-10), XP002808898, Retrieved from the Internet <URL:https://web.archive.org/web/20210910200818/https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/e4d0a915-9e92-4811-b030-404086c877d7/e4d0a915-9e92-4811-b030-404086c877d7_viewable_rendition__v.pdf?medcommid=REF--ALL-002878> [retrieved on 20230320] * |
ROCIO MONTES DE OCA ET AL: "The anti-BCMA Antibody-Drug Conjugate Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-Mediated Anti- Tumor Responses, and in Combination with an OX40 Agonist Potentiates in vivo Activity", BLOOD. BLOOD CANCER J. CANCER IMMUNOL RES, 16 June 2019 (2019-06-16), pages 3128 - 3837, XP055735690, Retrieved from the Internet <URL:https://www.adcreview.com/wp-content/uploads/2019/07/ICD-EHA-2019-poster_-03-June_For-upload-Final-1.pdf> [retrieved on 20201001] * |
ROWLAND ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 21, 1986, pages 183 - 87 |
RYAN MAUREEN C ET AL: "Antibody targeting of B-cell maturation antigen on malignant plasma cells", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 6, no. 11, 1 November 2007 (2007-11-01), pages 3009 - 3018, XP002581270, ISSN: 1535-7163 * |
SYRIGOSEPENETOS, ANTICANCER RESEARCH, vol. 19, 1999, pages 605 - 614 |
TRUDEL SUZANNE ET AL: "Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial", THE LANCET ONCOLOGY, vol. 19, no. 12, 1 December 2018 (2018-12-01), AMSTERDAM, NL, pages 1641 - 1653, XP093125559, ISSN: 1470-2045, DOI: 10.1016/S1470-2045(18)30576-X * |
TSUCHIKAMAAN, PROTEIN AND CELL, vol. 9, 2018, pages 33 - 46 |
TZOGANI KYRIAKI ET AL: "EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma", THE ONCOLOGIST, vol. 26, no. 1, 23 November 2020 (2020-11-23), pages 70 - 76, XP093125542, ISSN: 1083-7159, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1002/onco.13592> DOI: 10.1002/onco.13592 * |
VAN EPPS ET AL., CANCER RES, vol. 78, no. 3833, 2018 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11052081B2 (en) | Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) | |
US11180559B2 (en) | Subcutaneous anti-HLA-DR monoclonal antibody for treatment of hematologic malignancies | |
RU2758234C2 (ru) | ЛЕЧЕНИЕ ТРИЖДЫ НЕГАТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ХАРАКТЕРИЗУЮЩЕГОСЯ ЭКСПРЕССИЕЙ Trop-2, С ПОМОЩЬЮ САЦИТУЗУМАБА ГОВИТЕКАНА И ИНГИБИТОРА Rad51 | |
US20230218776A1 (en) | Anti-ntb-a antibodies and related compositions and methods | |
US20180271996A1 (en) | Combination therapies of her2-targeted antibody-drug conjugates | |
CN113924318A (zh) | 具有抗BCMA抗体和gamma分泌酶抑制剂的联合疗法 | |
AU2018269173A1 (en) | Anti-FOLR1 immunoconjugates and anti-PD-1 antibody combinations | |
CA3101790A1 (fr) | Regimes posologiques d'immunoconjugue anti-cd37 | |
EP3548088A1 (fr) | Thérapie pour le cancer urothélial métastatique avec le conjugué anticorps-médicament, sacituzumab govitécan (immu-132) | |
WO2018183366A1 (fr) | Polythérapies d'anticorps csf-1r ou csf-1 et thérapie reposant sur des lymphocytes t | |
WO2024121711A1 (fr) | Méthodes de traitement au moyen d'antagonistes d'antigène de maturation des lymphocytes b | |
US20230226206A1 (en) | Methods for the use of a b7-h3 antibody-drug conjugate alone or in combination | |
CN111655725A (zh) | 用于治疗癌症的组合产品 | |
WO2023159176A1 (fr) | Polythérapie contre les troubles des lymphocytes b | |
US20240180892A1 (en) | Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (immu-132) | |
WO2023144702A1 (fr) | Polythérapie contre le cancer | |
US20230190949A1 (en) | Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates | |
WO2017034906A1 (fr) | Anticorps monoclonal anti-hla-dr à administrer par voie sous-cutanée pour le traitement de tumeurs malignes hématologiques | |
CA3169661A1 (fr) | Conjugues medicament-anticorps anti-cd30 et leur utilisation pour le traitement d'un lymphome non hodgkinien | |
JP2024521667A (ja) | 抗-cd205抗体及び免疫チェックポイント・インヒビターを含む組み合わせ医薬 | |
EA044092B1 (ru) | Анти-ntb-a антитела и терапевтические композиции, их содержащие |